Phthalazinone-based modulators for treatment of disease

Abstract

The present disclosure provides compounds of Formula (I), (II), (III), (IV), (V) or (VI) and pharmaceutical compositions for killing or inhibiting cancer cell proliferation. Further, the compounds of formula (I), (II), (III), (IV), (V), or (VI) and pharmaceutical compositions may be used in methods of inhibiting cancer cell proliferation.

Description

[0001] Cross-references

[0002] This application claims the benefit of U.S. Provisional Application Serial No. 63 / 426,670, filed November 18, 2022, which is incorporated herein by reference in its entirety. Background Art

[0003] In 2020, an estimated 19.3 million new cancer cases were diagnosed worldwide. This number is projected to rise to 30.2 million by 2040. In 2022, an estimated 1.9 million new cancer cases and 609,360 cancer deaths were diagnosed in the United States. Although medical advances have improved cancer survival rates, certain patient populations and specific cancers still require further research. Consequently, there is an unmet need for new and more effective treatments for cancer patients. Summary of the Invention

[0004] In some aspects, the present disclosure provides a compound represented by the structure of Formula (I):

[0005]

[0006] or a pharmaceutically acceptable salt thereof, wherein:

[0007] R 1 Selected from (i) and (ii):

[0008] (i) C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10 )C(O)R 10 、-N(R 10 )C(O)OR 10 、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R 10 、-S(O)2N(R 10 )2, -NO2, =S, =O and -CN; and

[0009] (ii) optionally substituted C 3-10 Saturated carbocyclic rings and optionally substituted 3- to 10-membered heterocyclic rings, wherein the optional substituents are independently selected from:

[0010] Halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10 )C(O)R 10 、-N(R 10 )C(O)OR 10 、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R 10 、-S(O)2N(R 10 )2, -NO2, =S, =O and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10 )C(O)R 10 、-N(R 10 )C(O)OR 10 、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R 10 、-S(O)2N(R 10 )2-NO2, =S, =O and -CN;

[0011] R 2 is selected from hydrogen, optionally substituted C 3-10Saturated carbocyclic rings and optionally substituted 3- to 10-membered heterocyclic rings, wherein the optional substituents are independently selected from:

[0012] Halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 、-OC(O)R 11 、-OC(O)N(R 11 )2、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 、-N(R 11 )C(O)OR 11 、-N(R 11 )C(O)N(R 11 )2、-N(R 11 )S(O)2(R 11 ),-S(O)R 11 、-S(O)2R 11 、-S(O)2N(R 11 )2, -NO2, =S, =O and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 、-OC(O)R 11 、-OC(O)N(R 11 )2、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 、-N(R 11 )C(O)OR 11 、-N(R 11 )C(O)N(R 11 )2、-N(R 11 )S(O)2(R 11 ),-S(O)R 11 、-S(O)2R 11 、-S(O)2N(R 11 )2, -NO2, =S, =O and -CN;

[0013] where R 1 and R 2 At least one of the following is selected from optionally substituted C 3-10carbocyclic rings and optionally substituted 3- to 10-membered heterocyclic rings;

[0014] R 3 independently selected at each occurrence from:

[0015] Halogen, -OR 12 、-SR 12 、-N(R 12 )2、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )2、-C(O)N(R 12 )2、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )2、-N(R 12 )S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 、-S(O)2N(R 12 )2, -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 12 、-SR 12 、-N(R 12 )2、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )2、-C(O)N(R 12 )2、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )2、-N(R 12 )S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 、-S(O)2N(R 12 )2, -NO2, =S, =O and -CN;

[0016] is a 3- to 10-membered heterocyclylene group optionally substituted with one or more substituents independently selected from:

[0017] Halogen, -OR 13 、-SR 13 、-N(R 13 )2、-C(O)R 13 、-C(O)OR 13 、-OC(O)R 13 、-OC(O)N(R 13 )2、-C(O)N(R 13 )2、-N(R 13 )C(O)R 13 、-N(R 13 )C(O)OR 13 、-N(R 13 )C(O)N(R 13 )2、-N(R 13 )S(O)2(R 13 ),-S(O)R 13 、-S(O)2R 13 、-S(O)2N(R 13 )2, -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 13 、-SR 13 、-N(R 13 )2、-C(O)R 13 、-C(O)OR 13 、-OC(O)R 13 、-OC(O)N(R 13 )2、-C(O)N(R 13 )2、-N(R 13 )C(O)R 13 、-N(R 13 )C(O)OR 13 、-N(R 13 )C(O)N(R 13 )2、-N(R 13 )S(O)2(R 13 ),-S(O)R 13 、-S(O)2R 13 、-S(O)2N(R 13 )2, -NO2, =S, =O and -CN;

[0018] A is selected from optionally substituted C 3-10 carbocyclylene and optionally substituted 3- to 10-membered heterocyclylene, wherein the optional substituents are independently selected from:

[0019] Halogen, -OR 14 、-SR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 、-OC(O)R 14 、-OC(O)N(R 14 )2、-C(O)N(R 14 )2、-N(R 14 )C(O)R 14 、-N(R 14 )C(O)OR 14 、-N(R 14 )C(O)N(R 14 )2、-N(R 14 )S(O)2(R 14 ),-S(O)R 14 、-S(O)2R 14 、-S(O)2N(R 14 )2, -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 14 、-SR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 、-OC(O)R 14 、-OC(O)N(R 14 )2、-C(O)N(R 14 )2、-N(R 14 )C(O)R 14 、-N(R 14 )C(O)OR 14 、-N(R 14 )C(O)N(R 14 )2、-N(R 14 )S(O)2(R 14 ),-S(O)R 14 、-S(O)2R 14 、-S(O)2N(R 14 )2, -NO2, =S, =O and -CN;

[0020] wherein when A is a 5-membered heteroaryl, the 5-membered heteroaryl contains one or more heteroatoms selected from O, S and N, and there are no more than two N atoms in the ring;

[0021] R 10 、R 11、R 12 、R 13 and R 14 is independently selected at each occurrence from (iii), (iv) and (v):

[0022] (iii) hydrogen;

[0023] (iv) C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, and -CN; and

[0024] (v) C optionally substituted with one or more substituents independently selected from the following 3-10 Carbocyclic rings and 3- to 10-membered heterocyclic rings: halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 haloalkyl, -NH2, -NO2, =O, and -CN; and

[0025] n is selected from 0, 1, 2, 3 and 4.

[0026] In another aspect, the present disclosure provides a compound represented by the structure of formula (II):

[0027]

[0028] or a pharmaceutically acceptable salt thereof, wherein:

[0029] X 1 Selected from N and C(R 8 );

[0030] R 4 is independently selected at each occurrence from (a), (b), and (c):

[0031] (a) Halogen, -OR 20 、-SR 20 、-N(R 20 )2、-C(O)R 20 、-C(O)OR 20 、-OC(O)R 20 、-OC(O)N(R 20)2、-C(O)N(R 20 )2、-N(R 20 )C(O)R 20 、-N(R 20 )C(O)OR 20 、-N(R 20 )C(O)N(R 20 )2、-N(R 20 )S(O)2(R 20 ),-S(O)R 20 、-S(O)2R 20 、-S(O)2N(R 20 )2, -NO2 and -CN;

[0032] (b) C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 20 、-SR 20 、-N(R 20 )2、-C(O)R 20 、-C(O)OR 20 、-OC(O)R 20 、-OC(O)N(R 20 )2、-C(O)N(R 20 )2、-N(R 20 )C(O)R 20 、-N(R 20 )C(O)OR 20 、-N(R 20 )C(O)N(R 20 )2、-N(R 20 )S(O)2(R 20 ),-S(O)R 20 、-S(O)2R 20 、-S(O)2N(R 20 )2, -NO2, =S, =O and -CN; and

[0033] (c)C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 20 、-SR 20 、-N(R 20 )2、-C(O)R 20 、-C(O)OR 20 、-OC(O)R 20 、-OC(O)N(R 20 )2、-C(O)N(R 20 )2、-N(R 20)C(O)R 20 、-N(R 20 )C(O)OR 20 、-N(R 20 )C(O)N(R 20 )2、-N(R 20 )S(O)2(R 20 ),-S(O)R 20 、-S(O)2R 20 、-S(O)2N(R 20 )2, -NO2, =S, =O and -CN;

[0034] R 5 is C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 21 、-SR 21 、-N(R 21 )2、-C(O)R 21 、-C(O)OR 21 、-OC(O)R 21 、-OC(O)N(R 21 )2、-C(O)N(R 21 )2、-N(R 21 )C(O)R 21 、-N(R 21 )C(O)OR 21 、-N(R 21 )C(O)N(R 21 )2、-N(R 21 )S(O)2(R 21 ),-S(O)R 21 、-S(O)2R 21 、-S(O)2N(R 21 )2, -NO2, =S, =O and -CN;

[0035] R 6 independently selected at each occurrence from:

[0036] Halogen, -OR 22 、-SR 22 、-N(R 22 )2、-C(O)R 22 、-C(O)OR 22 、-OC(O)R 22 、-OC(O)N(R 22 )2、-C(O)N(R 22 )2、-N(R 22 )C(O)R 22 、-N(R22 )C(O)OR 22 、-N(R 22 )C(O)N(R 22 )2、-N(R 22 )S(O)2(R 22 ),-S(O)R 22 、-S(O)2R 22 、-S(O)2N(R 21 )2, -NO2, =S, =O and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: Halogen -OR 22 、-SR 22 、-N(R 22 )2、-C(O)R 22 、-C(O)OR 22 、-OC(O)R 22 、-OC(O)N(R 22 )2、-C(O)N(R 22 )2、-N(R 22 )C(O)R 22 、-N(R 22 )C(O)OR 22 、-N(R 22 )C(O)N(R 22 )2、-N(R 22 )S(O)2(R 22 ),-S(O)R 22 、-S(O)2R 22 、-S(O)2N(R 21 )2, -NO2, =S, =O and -CN;

[0037] Ring B is selected from C 3-10 Carbocyclylene and 3- to 10-membered heterocyclylene;

[0038] R 7 independently selected at each occurrence from:

[0039] Hydrogen, halogen, -OR 23 、-SR 23 、-N(R 23 )2、-C(O)R 23 、-OC(O)R 23 、-OC(O)N(R 23 )2、-C(O)N(R 23 )2、-N(R 23 )C(O)R 23 、-N(R 23 )C(O)OR 23、-N(R 23 )C(O)N(R 23 )2、-N(R 12 )S(O)2(R 23 ),-S(O)R 23 、-S(O)2R 23 、-S(O)2N(R 23 )2, -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 23 、-SR 23 、-N(R 23 )2、-C(O)R 23 、-C(O)OR 23 、-OC(O)R 23 、-OC(O)N(R 23 )2、-C(O)N(R 23 )2、-N(R 23 )C(O)R 23 、-N(R 23 )C(O)OR 23 、-N(R 23 )C(O)N(R 23 )2、-N(R 23 )S(O)2(R 23 ),-S(O)R 23 、-S(O)2R 23 、-S(O)2N(R 23 )2, -NO2, =S, =O and -CN;

[0040] R 8 、R 20 、R 21 、R 22 and R 23 is independently selected at each occurrence from (d), (e) and (f):

[0041] (d) hydrogen;

[0042] (e) C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC1-6 Haloalkyl, -NH2, -NO2, =O, and -CN; and

[0043] (f) C optionally substituted with one or more substituents independently selected from the following 3-10 Carbocyclic rings and 3- to 10-membered heterocyclic rings: halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN;

[0044] x is selected from 0, 1, 2, 3 and 4;

[0045] y is selected from 0, 1, 2, 3 and 4;

[0046] z is selected from 0, 1, 2, 3, 4 and 5; and

[0047] At least one of x or y is selected from 1, 2, 3 and 4.

[0048] In another aspect, the present disclosure provides a compound represented by the structure of formula (III):

[0049]

[0050] or a pharmaceutically acceptable salt thereof, wherein:

[0051] X 1 Selected from N and C(R 35 );

[0052] R 31 is independently selected at each occurrence from (I), (II) and (III):

[0053] (I) halogen, -OR 40 、-SR 40 、-N(R 40 )2、-C(O)R 40 、-C(O)OR 40 、-OC(O)R 40 、-OC(O)N(R 40 )2、-C(O)N(R 40 )2、-N(R 40 )C(O)R 40 、-N(R 40 )C(O)OR 40 、-N(R 40 )C(O)N(R 40 )2、-N(R 40 )S(O)2(R 40 ),-S(O)R 40 、-S(O)2R 40、-S(O)2N(R 40 )2, -NO2 and -CN;

[0054] (II) C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 40 、-SR 40 、-N(R 40 )2、-C(O)R 40 、-C(O)OR 40 、-OC(O)R 40 、-OC(O)N(R 40 )2、-C(O)N(R 40 )2、-N(R 40 )C(O)R 40 、-N(R 40 )C(O)OR 40 、-N(R 40 )C(O)N(R 40 )2、-N(R 40 )S(O)2(R 40 ),-S(O)R 40 、-S(O)2R 40 、-S(O)2N(R 40 )2, -NO2, =S, =O and -CN; and

[0055] (III)C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 40 、-SR 40 、-N(R 40 )2、-C(O)R 40 、-C(O)OR 40 、-OC(O)R 40 、-OC(O)N(R 40 )2、-C(O)N(R 40 )2、-N(R 40 )C(O)R 40 、-N(R 40 )C(O)OR 40 、-N(R 40 )C(O)N(R 40 )2、-N(R 40 )S(O)2(R 40 ),-S(O)R 40 、-S(O)2R 40 、-S(O)2N(R 40 )2, -NO2, =S, =O and -CN;

[0056] R 32 independently selected at each occurrence from:

[0057] Halogen, -OR 41 、-SR 41 、-N(R 41 )2、-C(O)R 41 、-C(O)OR 41 、-OC(O)R 41 、-OC(O)N(R 41 )2、-C(O)N(R 41 )2、-N(R 41 )C(O)R 41 、-N(R 41 )C(O)OR 41 、-N(R 41 )C(O)N(R 41 )2、-N(R 41 )S(O)2(R 41 ),-S(O)R 41 、-S(O)2R 41 、-S(O)2N(R 41 )2, -NO2, =S, =O and -CN; and

[0058] C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 41 、-SR 41 、-N(R 41 )2、-C(O)R 41 、-C(O)OR 41 、-OC(O)R 41 、-OC(O)N(R 41 )2、-C(O)N(R 41 )2、-N(R 41 )C(O)R 41 、-N(R 41 )C(O)OR 41 、-N(R 41 )C(O)N(R 41 )2、-N(R 41 )S(O)2(R 41 ),-S(O)R 41 、-S(O)2R 41 、-S(O)2N(R 41 )2, -NO2, =S, =O and -CN; and

[0059] R 33independently selected at each occurrence from:

[0060] Halogen, -OR 42 、-SR 42 、-N(R 42 )2、-C(O)OR 42 、-OC(O)R 42 、-OC(O)N(R 42 )2、-C(O)N(R 42 )2、-N(R 42 )C(O)R 42 、-N(R 42 )C(O)OR 42 、-N(R 42 )C(O)N(R 42 )2、-N(R 42 )S(O)2(R 42 ),-S(O)R 42 、-S(O)2R 42 and -S(O)2N(R 42 )2; and

[0061] C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 42 、-SR 42 、-N(R 42 )2、-C(O)R 42 、-C(O)OR 42 、-OC(O)R 42 、-OC(O)N(R 42 )2、-C(O)N(R 42 )2、-N(R 42 )C(O)R 42 、-N(R 42 )C(O)OR 42 、-N(R 42 )C(O)N(R 42 )2、-N(R 42 )S(O)2(R 42 ),-S(O)R 42 、-S(O)2R 42 、-S(O)2N(R 42 )2, -NO2, =S and -CN;

[0062] When an R 33 is methyl, each additional R 33 are all independently selected from (IV), (V) and (VI):

[0063] (IV) Halogen, -OR 42 、-SR 42 、-N(R 42 )2、-C(O)R 42 、-C(O)OR 42 、-OC(O)R 42 、-OC(O)N(R 42 )2、-C(O)N(R 42 )2、-N(R 42 )C(O)R 42 、-N(R 42 )C(O)OR 42 、-N(R 42 )C(O)N(R 42 )2、-N(R 42 )S(O)2(R 42 ),-S(O)R 42 、-S(O)2R 42 、-S(O)2N(R 42 )2, -NO2 and -CN;

[0064] (V) C1 alkyl substituted by one or more substituents independently selected from the group consisting of halogen, -OR 42 、-SR 42 、-N(R 42 )2、-C(O)R 42 、-C(O)OR 42 、-OC(O)R 42 、-OC(O)N(R 42 )2、-C(O)N(R 42 )2、-N(R 42 )C(O)R 42 、-N(R 42 )C(O)OR 42 、-N(R 42 )C(O)N(R 42 )2、-N(R 42 )S(O)2(R 42 ),-S(O)R 42 、-S(O)2R 42 、-S(O)2N(R 42 )2, -NO2, =S, =O and -CN; and

[0065] (VI) C optionally substituted by one or more substituents independently selected from the following 2-6 Alkyl: halogen, -OR 42 、-SR 42 、-N(R 42 )2、-C(O)R42 、-C(O)OR 42 、-OC(O)R 42 、-OC(O)N(R 42 )2、-C(O)N(R 42 )2、-N(R 42 )C(O)R 42 、-N(R 42 )C(O)OR 42 、-N(R 42 )C(O)N(R 42 )2、-N(R 42 )S(O)2(R 42 ),-S(O)R 42 、-S(O)2R 42 、-S(O)2N(R 42 )2, -NO2, =S, =O and -CN; or

[0066] Two R on adjacent atoms 33 Can form C together 3-8 a carbocyclic ring or a 3- to 8-membered heterocyclic ring, each of which is optionally substituted with one or more substituents independently selected from the following:

[0067] Halogen, -OR 42 、-SR 42 、-N(R 42 )2、-C(O)R 42 、-C(O)OR 42 、-OC(O)R 42 、-OC(O)N(R 42 )2、-C(O)N(R 42 )2、-N(R 42 )C(O)R 42 、-N(R 42 )C(O)OR 42 、-N(R 42 )C(O)N(R 42 )2、-N(R 42 )S(O)2(R 42 ),-S(O)R 42 、-S(O)2R 42 、-S(O)2N(R 42 )2, -NO2, =O and -CN; and

[0068] C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 42 、-SR 42 、-N(R 42)2、-C(O)R 42 、-C(O)OR 42 、-OC(O)R 42 、-OC(O)N(R 42 )2、-C(O)N(R 42 )2、-N(R 42 )C(O)R 42 、-N(R 42 )C(O)OR 42 、-N(R 42 )C(O)N(R 42 )2、-N(R 42 )S(O)2(R 42 ),-S(O)R 42 、-S(O)2R 42 、-S(O)2N(R 42 )2, -NO2, =S, =O and -CN;

[0069] R 34 Selected from C 1-6 Alkyl and C 2-6 alkenyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 43 、-SR 43 、-N(R 43 )2、-C(O)R 43 、-C(O)OR 43 、-OC(O)R 43 、-OC(O)N(R 43 )2、-C(O)N(R 43 )2、-N(R 43 )C(O)R 43 、-N(R 43 )C(O)OR 43 、-N(R 43 )C(O)N(R 43 )2、-N(R 43 )S(O)2(R 43 ),-S(O)R 43 、-S(O)2R 43 、-S(O)2N(R 43 )2, -NO2, =S, =O and -CN;

[0070] Ring B is selected from C 3-6 Carbocyclylene and 4- to 6-membered heterocyclylene;

[0071] R 35 、R 40 、R 41 、R 42and R 43 is independently selected at each occurrence from (VII), (VIII) and (IX):

[0072] (VII) hydrogen;

[0073] (VII) C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, and -CN; and

[0074] (IX) C optionally substituted by one or more substituents independently selected from the following 3-10 Carbocyclic rings and 3- to 10-membered heterocyclic rings: halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN;

[0075] x is selected from 0, 1, 2, 3 and 4;

[0076] y is selected from the group consisting of 0, 1, 2, 3, and 4; and

[0077] z is selected from 2, 3, 4 and 5.

[0078] In another aspect, the present disclosure provides a compound represented by the structure of formula (IV):

[0079]

[0080] or a pharmaceutically acceptable salt, wherein:

[0081] Each X 1 All selected from C(R 50 ) and N, and at least one X 1 It is N;

[0082] R 50 independently selected at each occurrence from:

[0083] Hydrogen, halogen, -OR 60 、-SR 60 、-N(R 60 )2、-C(O)R 60、-C(O)OR 60 、-OC(O)R 60 、-OC(O)N(R 60 )2、-C(O)N(R 60 )2、-N(R 60 )C(O)R 60 、-N(R 60 )C(O)OR 60 、-N(R 60 )C(O)N(R 60 )2、-N(R 60 )S(O)2(R 60 ),-S(O)R 60 、-S(O)2R 60 、-S(O)2N(R 60 )2, -NO2 and -CN; and

[0084] C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 60 、-SR 60 、-N(R 60 )2、-C(O)R 60 、-C(O)OR 60 、-OC(O)R 60 、-OC(O)N(R 60 )2、-C(O)N(R 60 )2、-N(R 60 )C(O)R 60 、-N(R 60 )C(O)OR 60 、-N(R 60 )C(O)N(R 60 )2、-N(R 60 )S(O)2(R 60 ),-S(O)R 60 、-S(O)2R 60 、-S(O)2N(R 60 )2, -NO2, =S, =O and -CN;

[0085] R 51 Independently selected from:

[0086] C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 61 、-SR 61 、-N(R 61 )2、-C(O)R 61 、-C(O)OR61 、-OC(O)R 61 、-OC(O)N(R 61 )2、-C(O)N(R 61 )2、-N(R 61 )C(O)R 61 、-N(R 61 )C(O)OR 61 、-N(R 61 )C(O)N(R 61 )2、-N(R 61 )S(O)2(R 61 ),-S(O)R 61 、-S(O)2R 61 、-S(O)2N(R 61 )2, -NO2, =S, =O and -CN; and

[0087] C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 61 、-SR 61 、-N(R 61 )2、-C(O)R 61 、-C(O)OR 61 、-OC(O)R 61 、-OC(O)N(R 61 )2、-C(O)N(R 61 )2、-N(R 61 )C(O)R 61 、-N(R 61 )C(O)OR 61 、-N(R 61 )C(O)N(R 61 )2、-N(R 61 )S(O)2(R 61 ),-S(O)R 61 、-S(O)2R 61 、-S(O)2N(R 61 )2, -NO2, =S, =O and -CN;

[0088] is a 3- to 12-membered heterocyclylene group optionally substituted with one or more substituents independently selected from:

[0089] Halogen, -OR 62 、-SR 62 、-N(R 62 )2、-C(O)R 62 、-C(O)OR 62、-OC(O)R 62 、-OC(O)N(R 62 )2、-C(O)N(R 62 )2、-N(R 62 )C(O)R 62 、-N(R 62 )C(O)OR 62 、-N(R 62 )C(O)N(R 62 )2、-N(R 62 )S(O)2(R 62 ),-S(O)R 62 、-S(O)2R 62 、-S(O)2N(R 62 )2, -NO2 and -CN;

[0090] C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 62 、-SR 62 、-N(R 62 )2、-C(O)R 62 、-C(O)OR 62 、-OC(O)R 62 、-OC(O)N(R 62 )2、-C(O)N(R 62 )2、-N(R 62 )C(O)R 62 、-N(R 62 )C(O)OR 62 、-N(R 62 )C(O)N(R 62 )2、-N(R 62 )S(O)2(R 62 ),-S(O)R 62 、-S(O)2R 62 、-S(O)2N(R 62 )2, -NO2, =S, =O and -CN; and

[0091] Ring B is selected from C 3-10 carbocyclic ring and 3- to 10-membered heterocyclic ring, any of which is optionally substituted with one or more substituents independently selected from:

[0092] Halogen, -OR 63 、-SR 63 、-N(R 63 )2、-C(O)R 63 、-C(O)OR 63 、-OC(O)R 63、-OC(O)N(R 63 )2、-C(O)N(R 63 )2、-N(R 63 )C(O)R 63 、-N(R 63 )C(O)OR 63 、-N(R 63 )C(O)N(R 63 )2、-N(R 63 )S(O)2(R 63 ),-S(O)R 63 、-S(O)2R 63 、-S(O)2N(R 63 )2, -NO2 and -CN; and

[0093] C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 63 、-SR 63 、-N(R 63 )2、-C(O)R 63 、-C(O)OR 63 、-OC(O)R 63 、-OC(O)N(R 63 )2、-C(O)N(R 63 )2、-N(R 63 )C(O)R 63 、-N(R 63 )C(O)OR 63 、-N(R 63 )C(O)N(R 63 )2、-N(R 63 )S(O)2(R 63 ),-S(O)R 63 、-S(O)2R 63 、-S(O)2N(R 63 )2, -NO2, =S, =O and -CN;

[0094] R 60 、R 61 、R 62 and R 63 independently selected at each occurrence from:

[0095] hydrogen;

[0096] C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, and -CN; and

[0097] C optionally substituted with one or more substituents independently selected from the following 3-10 Carbocyclic rings and 3- to 10-membered heterocyclic rings: halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN.

[0098] In some aspects, the present disclosure provides a method for killing cancer cells or inhibiting the proliferation of cancer cells, the method comprising contacting the cells with a compound represented by the structure of Formula (V):

[0099]

[0100] or a pharmaceutically acceptable salt, wherein:

[0101] Each X 1 Selected from C(R 100 ) and N;

[0102] R 100 independently selected at each occurrence from:

[0103] Hydrogen, halogen, -OR 102 、-SR 102 、-N(R 102 )2、-C(O)R 102 、-C(O)OR 102 、-OC(O)R 102 、-OC(O)N(R 102 )2、-C(O)N(R 102 )2、-N(R 102 )C(O)R 102 、-N(R 102 )C(O)OR 102 、-N(R 102 )C(O)N(R 102 )2、-N(R 102 )S(O)2(R 102 ),-S(O)R 102 、-S(O)2R 102 、-S(O)2N(R 102)2, -NO2 and -CN;

[0104] C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 102 、-SR 102 、-N(R 102 )2、-C(O)R 102 、-C(O)OR 102 、-OC(O)R 102 、-OC(O)N(R 102 )2、-C(O)N(R 102 )2、-N(R 102 )C(O)R 102 、-N(R 102 )C(O)OR 102 、-N(R 102 )C(O)N(R 102 )2、-N(R 102 )S(O)2(R 102 ),-S(O)R 102 、-S(O)2R 102 、-S(O)2N(R 102 )2, -NO2, =S, =O and -CN; and

[0105] C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 102 、-SR 102 、-N(R 102 )2、-C(O)R 102 、-C(O)OR 102 、-OC(O)R 102 、-OC(O)N(R 102 )2、-C(O)N(R 102 )2、-N(R 102 )C(O)R 102 、-N(R 102 )C(O)OR 102 、-N(R 102 )C(O)N(R 102 )2、-N(R 102 )S(O)2(R 102 ),-S(O)R 102 、-S(O)2R 102 、-S(O)2N(R 102 )2, -NO2, =S, =O and -CN;

[0106] R101 Independently selected from:

[0107] C 1-6 Alkyl and C 2-6 alkenyl, any of which is optionally substituted with one or more substituents independently selected from halogen, -OR 103 、-SR 103 、-N(R 103 )2、-C(O)R 103 、-C(O)OR 103 、-OC(O)R 103 、-OC(O)N(R 103 )2、-C(O)N(R 103 )2、-N(R 103 )C(O)R 103 、-N(R 103 )C(O)OR 103 、-N(R 103 )C(O)N(R 103 )2、-N(R 103 )S(O)2(R 103 ),-S(O)R 103 、-S(O)2R 103 、-S(O)2N(R 103 )2, -NO2, =S, =O and -CN; and

[0108] C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 103 、-SR 103 、-N(R 103 )2、-C(O)R 103 、-C(O)OR 103 、-OC(O)R 103 、-OC(O)N(R 103 )2、-C(O)N(R 103 )2、-N(R 103 )C(O)R 103 、-N(R 103 )C(O)OR 103 、-N(R 103 )C(O)N(R 103 )2、-N(R 103 )S(O)2(R 103 ),-S(O)R 103 、-S(O)2R 103 、-S(O)2N(R 103 )2, -NO2, =S, =O and -CN;

[0109] is a 3- to 12-membered heterocyclylene group optionally substituted with one or more substituents independently selected from:

[0110] Halogen, -OR 104 、-SR 104 、-N(R 104 )2、-C(O)R 104 、-C(O)OR 104 、-OC(O)R 104 、-OC(O)N(R 104 )2、-C(O)N(R 104 )2、-N(R 104 )C(O)R 104 、-N(R 104 )C(O)OR 104 、-N(R 104 )C(O)N(R 104 )2、-N(R 104 )S(O)2(R 104 ),-S(O)R 104 、-S(O)2R 104 、-S(O)2N(R 104 )2, -NO2 and -CN;

[0111] C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 104 、-SR 104 、-N(R 104 )2、-C(O)R 104 、-C(O)OR 104 、-OC(O)R 104 、-OC(O)N(R 104 )2、-C(O)N(R 104 )2、-N(R 104 )C(O)R 104 、-N(R 104 )C(O)OR 104 、-N(R 104 )C(O)N(R 104 )2、-N(R 104 )S(O)2(R 104 ),-S(O)R 104 、-S(O)2R 104 、-S(O)2N(R 104 )2, -NO2, =S, =O and -CN; and

[0112] C3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 104 、-SR 104 、-N(R 104 )2、-C(O)R 104 、-C(O)OR 104 、-OC(O)R 104 、-OC(O)N(R 104 )2、-C(O)N(R 104 )2、-N(R 104 )C(O)R 104 、-N(R 104 )C(O)OR 104 、-N(R 104 )C(O)N(R 104 )2、-N(R 104 )S(O)2(R 104 ),-S(O)R 104 、-S(O)2R 104 、-S(O)2N(R 104 )2, -NO2, =S, =O and -CN;

[0113] Ring B is selected from C 3-12 carbocyclic ring and 3- to 12-membered heterocyclic ring, any of which is optionally substituted with one or more substituents independently selected from:

[0114] Halogen, -OR 105 、-SR 105 、-N(R 105 )2、-C(O)R 105 、-C(O)OR 105 、-OC(O)R 105 、-OC(O)N(R 105 )2、-C(O)N(R 105 )2、-N(R 105 )C(O)R 105 、-N(R 105 )C(O)OR 105 、-N(R 105 )C(O)N(R 105 )2、-N(R 105 )S(O)2(R 105 ),-S(O)R 105 、-S(O)2R 105 、-S(O)2N(R 105 )2, -NO2 and -CN;

[0115] C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 105 、-SR 105 、-N(R 105 )2、-C(O)R 105 、-C(O)OR 105 、-OC(O)R 105 、-OC(O)N(R 105 )2、-C(O)N(R 105 )2、-N(R 105 )C(O)R 105 、-N(R 105 )C(O)OR 105 、-N(R 105 )C(O)N(R 105 )2、-N(R 105 )S(O)2(R 105 ),-S(O)R 105 、-S(O)2R 105 、-S(O)2N(R 105 )2, -NO2, =S, =O and -CN; and

[0116] C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 105 、-SR 105 、-N(R 105 )2、-C(O)R 105 、-C(O)OR 105 、-OC(O)R 105 、-OC(O)N(R 105 )2、-C(O)N(R 105 )2、-N(R 105 )C(O)R 105 、-N(R 105 )C(O)OR 105 、-N(R 105 )C(O)N(R 105 )2、-N(R 105 )S(O)2(R 105 ),-S(O)R 105 、-S(O)2R 105 、-S(O)2N(R 105 )2, -NO2, =S, =O and -CN;

[0117] R 102 、R 103 、R 104and R 105 independently selected at each occurrence from:

[0118] hydrogen;

[0119] C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, and -CN; and

[0120] C optionally substituted with one or more substituents independently selected from the following 3-10 Carbocyclic rings and 3- to 10-membered heterocyclic rings: halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN.

[0121] Incorporation by reference

[0122] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. If any publication, patent, or patent application incorporated by reference contradicts the disclosure contained in this specification, the present specification is intended to supersede and / or take precedence over any such contradictory material. DETAILED DESCRIPTION

[0123] Although preferred embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that these embodiments are provided by way of example only. Many variations, modifications, and substitutions will occur to those skilled in the art without departing from the present invention. It should be understood that various alternatives to the embodiments of the present invention described herein may be employed in practicing the present invention. The following claims are intended to define the scope of the present invention and are intended to encompass methods and structures within the scope of these claims and their equivalents.

[0124] definition

[0125] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All patents and publications mentioned herein are incorporated by reference.

[0126] As used in this specification and claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

[0127] "Alkyl" refers to a linear or branched hydrocarbon chain monovalent radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, and preferably having from 1 to 12 carbon atoms (i.e., C1-C 12 Alkyl). The alkyl group is attached to the rest of the molecule by a single bond. In certain embodiments, the alkyl group contains 1 to 12 carbon atoms (i.e., C1-C 12 In certain embodiments, the alkyl group comprises 1 to 8 carbon atoms (i.e., C1-C8 alkyl). In other embodiments, the alkyl group comprises 1 to 5 carbon atoms (i.e., C1-C5 alkyl). In other embodiments, the alkyl group comprises 1 to 4 carbon atoms (i.e., C1-C4 alkyl). In other embodiments, the alkyl group comprises 1 to 3 carbon atoms (i.e., C1-C3 alkyl). In other embodiments, the alkyl group comprises 1 to 2 carbon atoms (i.e., C1-C2 alkyl). In other embodiments, the alkyl group comprises 1 carbon atom (i.e., C1 alkyl). In other embodiments, the alkyl group comprises 5 to 15 carbon atoms (i.e., C5-C 15 In some embodiments, the alkyl group may be a C5-C8 alkyl group. In other ...

[0128] "Alkenyl" refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one carbon-carbon double bond, and preferably having 2 to 12 carbon atoms (i.e., C2-C 12 In some embodiments, the alkenyl group contains 2 to 8 carbon atoms (i.e., C2-C8 alkenyl). In some embodiments, the alkenyl group contains 2 to 6 carbon atoms (i.e., C2-C6 alkenyl). In other embodiments, the alkenyl group contains 2 to 4 carbon atoms (i.e., C2-C4 alkenyl). The alkenyl group is attached to the rest of the molecule by a single bond, for example, ethenyl (i.e., vinyl), prop-1-enyl (i.e., allyl), but-1-enyl, pent-1-enyl, pent-1,4-dienyl, and the like.

[0129] "Alkynyl" refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one carbon-carbon triple bond, and preferably having from 2 to 12 carbon atoms (i.e., C2-C 12 In some embodiments, the alkynyl group contains 2 to 8 carbon atoms (i.e., C2-C8 alkynyl). In other embodiments, the alkynyl group contains 2 to 6 carbon atoms (i.e., C2-C6 alkynyl). In other embodiments, the alkynyl group contains 2 to 4 carbon atoms (i.e., C2-C4 alkynyl). The alkynyl group is attached to the rest of the molecule by a single bond, for example, ethynyl, propynyl, butynyl, pentynyl, hexynyl, etc.

[0130] "Alkylene" refers to a straight divalent hydrocarbon chain that connects the rest of the molecule to a radical group, consisting only of carbon and hydrogen, does not contain unsaturation, and preferably has 1 to 12 carbon atoms, for example, methylene, ethylene, propylene, butylene, etc. The alkylene chain is attached to the rest of the molecule by a single bond and is attached to the radical group by a single bond. The attachment point of the alkylene chain to the rest of the molecule and to the radical group are respectively through the terminal carbon. The alkylene chain can be optionally substituted with one or more substituents, such as those described herein. In certain embodiments, the alkylene group comprises 1 to 10 carbon atoms (i.e., C1-C 10 In certain embodiments, the alkylene group comprises 1 to 8 carbon atoms (i.e., C1-C8 alkylene). In other embodiments, the alkylene group comprises 1 to 5 carbon atoms (i.e., C1-C5 alkylene). In other embodiments, the alkylene group comprises 1 to 4 carbon atoms (i.e., C1-C4 alkylene). In other embodiments, the alkylene group comprises 1 to 3 carbon atoms (i.e., C1-C3 alkylene). In other embodiments, the alkylene group comprises 1 to 2 carbon atoms (i.e., C1-C2 alkylene). In other embodiments, the alkylene group comprises 1 carbon atom (i.e., C1 alkylene). In other embodiments, the alkylene group comprises 5 to 8 carbon atoms (i.e., C5-C8 alkylene). In other embodiments, the alkylene group comprises 2 to 5 carbon atoms (i.e., C2-C5 alkylene). In other embodiments, the alkylene group comprises 3 to 5 carbon atoms (i.e., C3-C5 alkylene).

[0131] "Alkenylene" refers to a straight divalent hydrocarbon chain that connects the remainder of the molecule to a radical group, consisting only of carbon and hydrogen, contains at least one carbon-carbon double bond, and preferably has 2 to 12 carbon atoms. The alkenylene chain is attached to the remainder of the molecule and to the radical group via a single bond. The attachment point of the alkenylene chain to the remainder of the molecule and to the radical group are respectively through the terminal carbon. The alkenylene chain can optionally be substituted with one or more substituents, such as those described herein. In certain embodiments, the alkenylene group comprises 2 to 10 carbon atoms (i.e., C2-C10 In certain embodiments, the alkenylene group comprises 2 to 8 carbon atoms (i.e., C2-C8 alkenylene). In other embodiments, the alkenylene group comprises 2 to 5 carbon atoms (i.e., C2-C5 alkenylene). In other embodiments, the alkenylene group comprises 2 to 4 carbon atoms (i.e., C2-C4 alkenylene). In other embodiments, the alkenylene group comprises 2 to 3 carbon atoms (i.e., C2-C3 alkenylene). In other embodiments, the alkenylene group comprises 2 carbon atoms (i.e., C2 alkenylene). In other embodiments, the alkenylene group comprises 5 to 8 carbon atoms (i.e., C5-C8 alkenylene). In other embodiments, the alkenylene group comprises 3 to 5 carbon atoms (i.e., C3-C5 alkenylene).

[0132] "Alkynylidene" refers to a straight divalent hydrocarbon chain that connects the rest of the molecule to a radical group, consisting only of carbon and hydrogen, contains at least one carbon-carbon triple bond, and preferably has 2 to 12 carbon atoms. The alkynylene chain is attached to the rest of the molecule by a single bond and to the radical group by a single bond. The attachment point of the alkynylene chain to the rest of the molecule and to the radical group is respectively through a terminal carbon. The alkynylene chain can be optionally substituted with one or more substituents, such as those described herein. In certain embodiments, the alkynylene group comprises 2 to 10 carbon atoms (i.e., C2-C 10 In certain embodiments, the alkynylene group comprises 2 to 8 carbon atoms (i.e., C2-C8 alkynylene). In other embodiments, the alkynylene group comprises 2 to 5 carbon atoms (i.e., C2-C5 alkynylene). In other embodiments, the alkynylene group comprises 2 to 4 carbon atoms (i.e., C2-C4 alkynylene). In other embodiments, the alkynylene group comprises 2 to 3 carbon atoms (i.e., C2-C3 alkynylene). In other embodiments, the alkynylene group comprises 2 carbon atoms (i.e., C2 alkylene). In other embodiments, the alkynylene group comprises 5 to 8 carbon atoms (i.e., C5-C8 alkynylene). In other embodiments, the alkynylene group comprises 3 to 5 carbon atoms (i.e., C3-C5 alkynylene).

[0133] The term "C x-y " when used in combination with a chemical moiety such as alkyl, alkenyl, or alkynyl is intended to include groups containing x to y carbons in the chain. For example, the term "C 1-6 "Alkyl" refers to a substituted or unsubstituted saturated hydrocarbon group containing 1 to 6 carbon atoms, including straight-chain alkyl groups and branched-chain alkyl groups. The term -C x-y Alkylene- refers to a substituted or unsubstituted alkylene chain containing from x to y carbon atoms. For example, -C 1-6 Alkylene- may be selected from methylene, ethylene, propylene, butylene, pentylene and hexylene, any of which are optionally substituted.

[0134] The term "Cx-y Alkenyl" and "C x-y "Alkynyl" refers to an unsaturated aliphatic group analogous in length and possible substitution to the alkyl groups described above, but containing at least one double or triple bond, respectively. The term -C x-y Alkenylene- refers to a substituted or unsubstituted alkenylene chain containing from x to y carbon atoms. For example, -C 2-6 Alkenylene- may be selected from ethenylene, propenylene, butenylene, pentenylene and hexenylene, any of which are optionally substituted. The alkenylene chain may have one double bond or more than one double bond in the alkenylene chain. The term -C x-y Alkyne- refers to a substituted or unsubstituted alkynylene chain containing from x to y carbon atoms. For example, -C 2-6 Alkynylene- can be selected from ethynylene, propynylene, butynylene, pentynylene and hexynylene, any of which are optionally substituted. The alkynylene chain can have one triple bond or more than one triple bond in the alkynylene chain.

[0135] As used herein, the term "carbocycle" refers to a saturated, unsaturated, or aromatic ring in which each atom of the ring is carbon. Carbocycles include 3- to 10-membered monocycles and 6- to 12-membered bicyclic rings. Each ring of a bicyclic carbocycle can be selected from saturated, unsaturated, and aromatic rings. Bicyclic carbocycles can be fused, bridged, or spirocyclic ring systems. In some embodiments, the carbocycle is an aryl group. In some embodiments, the carbocycle is a cycloalkyl group. In some embodiments, the carbocycle is a cycloalkenyl group. In exemplary embodiments, an aromatic ring such as a phenyl group can be fused to a saturated or unsaturated ring such as cyclohexane, cyclopentane, or cyclohexene. The definition of carbocycle includes any combination of saturated, unsaturated, and aromatic bicyclic rings, as permitted by the valence states. Exemplary carbocycles include cyclopentyl, cyclohexyl, cyclohexenyl, adamantyl, phenyl, indanyl, and naphthyl. The carbocycle can optionally be substituted with one or more substituents, such as those described herein.

[0136] "Cycloalkyl" refers to a stable, fully saturated monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, including fused or bridged ring systems, and preferably having from 3 to 12 carbon atoms (i.e., C 3-12 In certain embodiments, the cycloalkyl group contains 3 to 10 carbon atoms (i.e., C 3-10 In other embodiments, the cycloalkyl group contains 5 to 7 carbon atoms (i.e., C 5-7Cycloalkyl). The cycloalkyl group may be attached to the rest of the molecule by a single bond. Examples of monocyclic cycloalkyl groups include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyl radicals include, for example, adamantyl, norbornyl (i.e., bicyclo[2.2.1]heptyl), norbornenyl, decahydronaphthyl, 7,7-dimethylbicyclo[2.2.1]heptyl, and the like. The cycloalkyl group may be optionally substituted with one or more substituents, such as those described herein.

[0137] "Cycloalkenyl" refers to a stable, unsaturated, non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, including fused or bridged ring systems, preferably having 3 to 12 carbon atoms and containing at least one double bond (i.e., C 3-12 In certain embodiments, the cycloalkenyl group contains 3 to 10 carbon atoms (ie, C 3-10 In other embodiments, the cycloalkenyl group contains 5 to 7 carbon atoms (i.e., C 5-7 Cycloalkenyl). The cycloalkenyl group can be attached to the rest of the molecule by a single bond. Examples of monocyclic cycloalkenyl groups include, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl. The cycloalkenyl group can be optionally substituted with one or more substituents, such as those described herein.

[0138] The term "carbocyclylene" refers to a bivalent ring that connects the rest of the molecule to a radical group and consists only of carbon and hydrogen atoms. The carbocyclylene is attached to the rest of the molecule and to the radical group via a single bond. The attachment point of the carbocyclylene to the rest of the molecule and to the radical group are each through any two carbon atoms. Carbocyclylene includes arylene and cycloalkylene. Thus, the term distinguishes carbocyclylene from heterocyclylene, in which the bivalent ring contains at least one atom that is different from a carbon atom. Heterocyclylene is attached to the rest of the molecule and to the radical group via a single bond. The attachment point of the heterocyclylene to the rest of the molecule and to the radical group are each through any two atoms that the valence allows. Heterocyclylene includes heteroarylene and heterocycloalkylene. Carbocyclylene and heterocyclylene can each optionally be substituted with one or more substituents, such as those described herein.

[0139] "Aryl" refers to a free radical derived from an aromatic monocyclic or polycyclic hydrocarbon ring system by removing hydrogen atoms from ring carbon atoms. The aromatic monocyclic or polycyclic hydrocarbon ring system contains only hydrogen and carbon and contains 5 to 18 carbon atoms, wherein at least one of the rings in the ring system is aromatic, that is, it contains a cyclic delocalized (4n+2)π-electron system that conforms to Hückel theory. Ring systems from which aryl groups are derived include, but are not limited to, groups such as benzene, fluorene, indane, indene, tetralin and naphthalene. The aryl group may optionally be substituted with one or more substituents, such as those described herein.

[0140] “C x-y Carbocycle is intended to include groups containing x to y carbon atoms in the ring. For example, the term "C 3-6 A "carbocycle" can be a saturated, unsaturated, or aromatic ring system containing from 3 to 6 carbon atoms, any of which is optionally substituted as provided herein.

[0141] As used herein, the term "heterocycle" refers to a saturated, unsaturated, non-aromatic, or aromatic ring containing one or more heteroatoms. Exemplary heteroatoms include N, O, Si, P, B, and S atoms. Heterocycles include 3- to 10-membered monocycles and 6- to 12-membered bicyclic rings. Each ring of a bicyclic heterocycle can be selected from a saturated, unsaturated, or aromatic ring. In some embodiments, the heterocycle contains at least one heteroatom selected from oxygen, nitrogen, sulfur, or any combination thereof. In some embodiments, the heterocycle contains at least one heteroatom selected from oxygen, nitrogen, or any combination thereof. In some embodiments, the heterocycle contains at least one heteroatom selected from oxygen, sulfur, or any combination thereof. In some embodiments, the heterocycle contains at least one heteroatom selected from nitrogen, sulfur, or any combination thereof. The heterocycle can be attached to the rest of the molecule by any atom permitted by the valence state of the heterocycle, such as a carbon or nitrogen atom of the heterocycle. In some embodiments, the heterocycle is a heteroaryl. In some embodiments, the heterocycle is a heterocycloalkyl. Exemplary heterocycles include pyrrolidinyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, piperidinyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, thienyl, oxazolyl, thiazolyl, morpholinyl, indazolyl, indolyl and quinolyl. Heterocycle can be optionally substituted by one or more substituents, such as those described herein. Bicyclic heterocycle can be fused, bridged or spirocyclic system. In exemplary embodiments, heterocycle such as pyridyl can be fused to saturated or unsaturated ring, such as cyclohexane, cyclopentane or cyclohexene. Heterocycle can be optionally substituted by one or more substituents, such as those described herein.

[0142] "Heterocycloalkyl" refers to a stable 3- to 12-membered non-aromatic ring radical containing 2 to 12 carbon atoms and at least one heteroatom, wherein each heteroatom can be selected from N, O, Si, P, B, and S atoms. In some embodiments, the heterocycloalkyl group contains at least one heteroatom selected from oxygen, nitrogen, sulfur, or any combination thereof. In some embodiments, the heterocycloalkyl group contains at least one heteroatom selected from oxygen, nitrogen, or any combination thereof. In some embodiments, the heterocycloalkyl group contains at least one heteroatom selected from oxygen, sulfur, or any combination thereof. In some embodiments, the heterocycloalkyl group contains at least one heteroatom selected from nitrogen, sulfur, or any combination thereof. The heterocycloalkyl group can be selected from monocyclic or bicyclic and fused or bridged ring systems. The heteroatoms in the heterocycloalkyl group are optionally oxidized. One or more nitrogen atoms, if present, are optionally quaternized. The heterocycloalkyl group is partially or fully saturated. The heterocycloalkyl group is attached to the remainder of the molecule through any atom permitted by the valence state of the heterocycloalkyl group, such as any carbon or nitrogen atom of the heterocycloalkyl group. Examples of heterocycloalkyl include, but are not limited to, dioxolane, thienyl[1,3]dithianyl, decahydroisoquinolinyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuranyl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. Heterocycloalkyl may be optionally substituted with one or more substituents, such as those described herein.

[0143] The term "heteroaryl" refers to a radical derived from a 5- to 12-membered aromatic ring whose ring structure contains at least one heteroatom, preferably 1 to 4 heteroatoms. In some embodiments, the heteroaryl group contains at least one heteroatom selected from oxygen, nitrogen, sulfur, or any combination thereof. In some embodiments, the heteroaryl group contains at least one heteroatom selected from oxygen, nitrogen, or any combination thereof. In some embodiments, the heteroaryl group contains at least one heteroatom selected from oxygen, sulfur, or any combination thereof. In some embodiments, the heteroaryl group contains at least one heteroatom selected from nitrogen, sulfur, or any combination thereof. The one or more heteroatoms in the heteroaryl radical may optionally be oxidized. The one or more nitrogen atoms, if present, may be optionally quaternized. The heteroaryl group may be attached to the remainder of the molecule through any atom permitted by the valence state of the heteroaryl group, such as a carbon or nitrogen atom of the heteroaryl group.

[0144] As used herein, heteroaryl ring can be selected from monocyclic or polycyclic (bicyclic and fused or bridged) system ring, wherein at least one of the rings in the ring system is aromatic, that is, it comprises a cyclic delocalized (4n+2) π-electron system that conforms to Huckel theory. Heteroaryl comprises an aromatic monocyclic structure, preferably a 5- to 6-membered ring, and its ring structure comprises at least one heteroatom, preferably 1 to 4 heteroatoms, more preferably one or two heteroatoms. Heteroaryl groups include, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine. Heteroaryl can optionally be substituted by one or more substituents, such as those described herein. Heteroaryl also includes a polycyclic system with two or more rings, wherein two or more atoms are shared by two adjacent rings, and wherein at least one of the rings is heteroaromatic, for example, and other rings can be aromatic or non-aromatic carbocyclic or heterocyclic rings.

[0145] "X-membered heterocycle" refers to the number of atoms in the ring, i.e., X. For example, a 5-membered heteroaryl ring or a 5-membered aromatic heterocycle has 5 atoms in the ring, such as triazole, oxazole, thiophene, and the like.

[0146] "Alkoxy" refers to a radical bonded through an oxygen atom of the formula -O-alkyl, where alkyl is an alkyl chain as defined above.

[0147] "Halo" or "halogen" refers to halogen substituents such as bromo, chloro, fluoro and iodo substituents.

[0148] As used herein, the term "haloalkyl" or "haloalkane" refers to an alkyl radical as defined above that is substituted with one or more halogen radicals, for example, trifluoromethyl, dichloromethyl, bromomethyl, 2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl, etc. In some embodiments, the alkyl portion of the fluoroalkyl radical is optionally further substituted. Examples of halogen-substituted alkanes ("haloalkanes") include halogenated methanes (e.g., chloromethane, bromomethane, fluoromethane, iodomethane), dihalogenated methanes and trihalogenated methanes (e.g., chloroform, bromomethane, trifluoromethane, iodomethane), 1-haloethane, 2-haloethane, 1,2-dihaloethane, 1-halopropane, 2-halopropane, 3-halopropane, 1,2-dihalopropane, 1,3-dihalopropane, 2,3-dihalopropane, 1,2,3-trihalopropane, and any other suitable combination of an alkane (or substituted alkane) and a halogen (e.g., Cl, Br, F, and I). When an alkyl group is substituted with more than one halogen radical, each halogen can be independently selected, for example, 1-chloro, 2-fluoroethane.

[0149] The term "substituted" refers to a moiety having a substituent that replaces one or more carbons or replaceable heteroatoms of a compound, such as hydrogen on NH or NH2. It should be understood that "substituted" or "substituted by..." includes implicit conditions: such substitution complies with the allowed valence of the substituted atom and the substituent, and the substitution produces a stable compound, i.e., a compound that does not spontaneously undergo transformations such as rearrangement, cyclization, elimination, etc. In certain embodiments, substituted refers to a moiety having a substituent that replaces two hydrogen atoms on the same carbon atom, such as replacing two hydrogen atoms on a single carbon with an oxo, imino, or thio group. As used herein, the term "substituted" is intended to include all permissible substituents of an organic compound. In broad terms, permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of an organic compound. For appropriate organic compounds, the permissible substituents may be one or more and may be the same or different.

[0150] In some embodiments, the substituents may include any of the substituents described herein, for example, halogen, hydroxy, oxo (=O), thio (=S), cyano (-CN), nitro (-NO2), imino (=NH), oxime (=N-OH), hydrazine (=N-NH2), -R b -OR a 、-R b -OC(O)-R a 、-R b -OC(O)-OR a 、-R b -OC(O)-N(R a )2. -R b -N(R a )2. -R b -C(O)R a 、-R b -C(O)OR a 、-R b -C(O)N(R a )2. -R b -OR c -C(O)N(R a )2. -R b -N(R a )C(O)OR a 、-R b -N(R a )C(O)R a 、-R b -N(R a )S(O) t R a (where t is 1 or 2), -R b-S(O) t R a (where t is 1 or 2), -R b -S(O) t OR a (where t is 1 or 2) and -R b -S(O) t N(R a )2 (wherein t is 1 or 2); and alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl and heteroarylalkyl, any of which may be optionally substituted with alkyl, alkenyl, alkynyl, halogen, haloalkyl, haloalkenyl, haloalkynyl, oxo (=O), thioxo (=S), cyano (-CN), nitro (-NO2), imino (=NH), oxime (=N-OH), hydrazine (=N-NH2), -R b -OR a 、-R b -OC(O)-R a 、-R b -OC(O)-OR a 、-R b -OC(O)-N(R a )2. -R b -N(R a )2. -R b -C(O)R a 、-R b -C(O)OR a 、-R b -C(O)N(R a )2. -R b -OR c -C(O)N(R a )2. -R b -N(R a )C(O)OR a 、-R b -N(R a )C(O)R a 、-R b -N(R a )S(O) t R a (where t is 1 or 2), -R b -S(O) t R a (where t is 1 or 2), -R b -S(O) t OR a (where t is 1 or 2) and -R b -S(O) t N(Ra )2 (where t is 1 or 2); where each R a are independently selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl, wherein each R a It may be optionally substituted by the following, as valence permits: alkyl, alkenyl, alkynyl, halogen, haloalkyl, haloalkenyl, haloalkynyl, oxo (=O), thio (=S), cyano (-CN), nitro (-NO2), imino (=NH), oxime (=N-OH), hydrazine (=N-NH2), -R b -OR a 、-R b -OC(O)-R a 、-R b -OC(O)-OR a 、-R b -OC(O)-N(R a )2. -R b -N(R a )2. -R b -C(O)R a 、-R b -C(O)OR a 、-R b -C(O)N(R a )2. -R b -OR c -C(O)N(R a )2. -R b -N(R a )C(O)OR a 、-R b -N(R a )C(O)R a 、-R b -N(R a )S(O) t R a (where t is 1 or 2), -R b -S(O) t R a (where t is 1 or 2), -R b -S(O) t OR a (where t is 1 or 2) and -R b -S(O) t N(R a )2 (where t is 1 or 2); and wherein each R b are independently selected from a bond or a straight or branched alkylene, alkenylene or alkynylene chain, and each R cis a straight or branched alkylene, alkenylene or alkynylene chain. It will be understood by those skilled in the art that the substituents may themselves be substituted, if appropriate.

[0151] The term "salt" or "pharmaceutically acceptable salt" refers to salts derived from various organic and inorganic counterions well known in the art. Pharmaceutically acceptable acid addition salts can be formed with inorganic and organic acids. Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.

[0152] The phrase "pharmaceutically acceptable" is used herein to refer to those compounds, materials, compositions and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications, and commensurate with a reasonable benefit / risk ratio.

[0153] As used herein, the phrase "pharmaceutically acceptable excipient" or "pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.

[0154] The terms "subject," "individual," and "patient" are used interchangeably and refer to humans, as well as non-human mammals (e.g., non-human primates, canines, equines, felines, porcines, bovines, ungulates, lagomorphs, etc.). In various embodiments, a subject can be a human (e.g., an adult male, an adult female, an adolescent male, an adolescent female, a male child, a female child) who is receiving care from a physician or other healthcare provider as an outpatient in a hospital or other clinical setting. In certain embodiments, a subject may not be receiving care or prescriptions from a physician or other healthcare provider.

[0155] As used herein, the phrase "a subject in need thereof" refers to a subject suffering from or at risk for a pathology to be treated prophylactically or therapeutically with a compound or salt described herein, as described below.

[0156] The terms "administer, administered, administrators, and administering" are defined as providing a composition to a subject by a route known in the art, including but not limited to intravenous, intraarterial, oral, parenteral, buccal, topical, transdermal, rectal, intramuscular, subcutaneous, intraosseous, transmucosal, or intraperitoneal administration. In certain embodiments, an oral route of administration of the composition may be used. The terms "administer, administered, administrators, and administering" a compound should be understood to mean providing a compound of the invention or a prodrug of a compound of the invention to an individual in need thereof.

[0157] As used herein, "treatment (treatment / treating)" refers to a method for obtaining a beneficial or desired result (including but not limited to therapeutic benefit and / or preventive benefit) related to a disease, disorder or medical condition. In certain embodiments, treatment (treatment / treating) includes administering a compound or composition disclosed herein to a subject. Therapeutic benefit can include eradicating or improving the underlying condition being treated. In addition, therapeutic benefit can also be achieved by eradicating or improving one or more physiological symptoms associated with the underlying condition, such as observing improvement in the subject, although the subject may still be troubled by the underlying condition. In certain embodiments, for preventive benefit, the composition is applied to a subject at risk of a specific disease, or to a subject reporting one or more physiological symptoms of a disease, even if a diagnosis may not yet be made to the disease. Treatment can include, for example, alleviating, delaying or alleviating the severity of one or more symptoms of a disease or condition, or can include reducing the frequency of symptoms of a patient experiencing a disease, defect, disorder or adverse condition, etc. Treatment can be used herein to refer to a method for treating or improving a certain level of a disease or condition, and a series of results for this purpose can be considered, including but not limited to preventing the condition completely.

[0158] In certain embodiments, the terms "prevent" or "preventing" in relation to a disease or condition may refer to a compound reducing the occurrence of the disease or condition in a treated sample relative to an untreated control sample, or delaying the onset or lessening the severity of one or more symptoms of the disease or condition relative to an untreated control sample.

[0159] As used herein, the term "therapeutic effect" includes therapeutic benefits and / or prophylactic benefits as described above. A prophylactic effect includes delaying or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, stopping or reversing the progression of a disease or condition, or any combination thereof.

[0160] Compound

[0161] A compound of formula (I).

[0162] In some aspects, the present disclosure provides a compound represented by the structure of Formula (I):

[0163]

[0164] or a pharmaceutically acceptable salt thereof, wherein:

[0165] R 1 Selected from (i) and (ii):

[0166] (i) C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10 )C(O)R 10 、-N(R 10 )C(O)OR 10 、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R 10 、-S(O)2N(R 10 )2, -NO2, =S, =O and -CN; and

[0167] (ii) optionally substituted C 3-10 Saturated carbocyclic rings and optionally substituted 3- to 10-membered heterocyclic rings, wherein the optional substituents are independently selected from:

[0168] Halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R10 )C(O)R 10 、-N(R 10 )C(O)OR 10 、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R 10 、-S(O)2N(R 10 )2, -NO2, =S, =O and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10 )C(O)R 10 、-N(R 10 )C(O)OR 10 、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R 10 、-S(O)2N(R 10 )2, -NO2, =S, =O and -CN;

[0169] R 2 is selected from hydrogen, optionally substituted C 3-10 Saturated carbocyclic rings and optionally substituted 3- to 10-membered heterocyclic rings, wherein the optional substituents are independently selected from:

[0170] Halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 、-OC(O)R 11 、-OC(O)N(R 11 )2、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11、-N(R 11 )C(O)OR 11 、-N(R 11 )C(O)N(R 11 )2、-N(R 11 )S(O)2(R 11 ),-S(O)R 11 、-S(O)2R 11 、-S(O)2N(R 11 )2, -NO2, =S, =O and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 、-OC(O)R 11 、-OC(O)N(R 11 )2、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 、-N(R 11 )C(O)OR 11 、-N(R 11 )C(O)N(R 11 )2、-N(R 11 )S(O)2(R 11 ),-S(O)R 11 、-S(O)2R 11 、-S(O)2N(R 11 )2, -NO2, =S, =O and -CN;

[0171] where R 1 and R 2 At least one of the optionally substituted C 3-10 carbocyclic rings and optionally substituted 3- to 10-membered heterocyclic rings;

[0172] R 3 independently selected at each occurrence from:

[0173] Halogen, -OR 12 、-SR 12 、-N(R 12 )2、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )2、-C(O)N(R 12 )2、-N(R12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )2、-N(R 12 )S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 、-S(O)2N(R 12 )2, -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 12 、-SR 12 、-N(R 12 )2、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )2、-C(O)N(R 12 )2、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )2、-N(R 12 )S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 、-S(O)2N(R 12 )2, -NO2, =S, =O and -CN;

[0174] is a 3- to 10-membered heterocyclylene group optionally substituted with one or more substituents independently selected from:

[0175] Halogen, -OR 13 、-SR 13 、-N(R 13 )2、-C(O)R 13 、-C(O)OR 13 、-OC(O)R 13 、-OC(O)N(R 13 )2、-C(O)N(R 13 )2、-N(R 13 )C(O)R 13 、-N(R 13 )C(O)OR13 、-N(R 13 )C(O)N(R 13 )2、-N(R 13 )S(O)2(R 13 ),-S(O)R 13 、-S(O)2R 13 、-S(O)2N(R 13 )2, -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 13 、-SR 13 、-N(R 13 )2、-C(O)R 13 、-C(O)OR 13 、-OC(O)R 13 、-OC(O)N(R 13 )2、-C(O)N(R 13 )2、-N(R 13 )C(O)R 13 、-N(R 13 )C(O)OR 13 、-N(R 13 )C(O)N(R 13 )2、-N(R 13 )S(O)2(R 13 ),-S(O)R 13 、-S(O)2R 13 、-S(O)2N(R 13 )2, -NO2, =S, =O and -CN;

[0176] A is selected from optionally substituted C 3-10 carbocyclylene and optionally substituted 3- to 10-membered heterocyclylene, wherein the optional substituents are independently selected from:

[0177] Halogen, -OR 14 、-SR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 、-OC(O)R 14 、-OC(O)N(R 14 )2、-C(O)N(R 14 )2、-N(R 14 )C(O)R 14 、-N(R 14 )C(O)OR 14 、-N(R 14 )C(O)N(R14 )2、-N(R 14 )S(O)2(R 14 ),-S(O)R 14 、-S(O)2R 14 、-S(O)2N(R 14 )2, -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 14 、-SR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 、-OC(O)R 14 、-OC(O)N(R 14 )2、-C(O)N(R 14 )2、-N(R 14 )C(O)R 14 、-N(R 14 )C(O)OR 14 、-N(R 14 )C(O)N(R 14 )2、-N(R 14 )S(O)2(R 14 ),-S(O)R 14 、-S(O)2R 14 、-S(O)2N(R 14 )2, -NO2, =S, =O and -CN;

[0178] wherein when A is a 5-membered heteroaryl, the 5-membered heteroaryl contains one or more heteroatoms selected from O, S and N, and there are not more than two N atoms in the ring;

[0179] R 10 、R 11 、R 12 、R 13 and R 14 is independently selected at each occurrence from (iii), (iv) and (v):

[0180] (iii) hydrogen;

[0181] (iv) C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein each C 3-10The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, and -CN; and

[0182] (v) C optionally substituted with one or more substituents independently selected from the following 3-10 Carbocyclic rings and 3- to 10-membered heterocyclic rings: halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 haloalkyl, -NH2, -NO2, =O, and -CN; and

[0183] n is selected from 0, 1, 2, 3 and 4.

[0184] In some embodiments, for the compound or salt of Formula (I), n is selected from 0, 1, 2, and 3. In some embodiments, n is selected from 0, 1, and 2. In some aspects, n is selected from 1, 2, 3, and 4. In some embodiments, n is selected from 1, 2, and 3. In some embodiments, n is selected from 2, 3, and 4. In some embodiments, n is selected from 1 and 2. In some embodiments, n is selected from 0 and 1. In some embodiments, n is 4. In some embodiments, n is 3. In some embodiments, n is 2. In some embodiments, n is 1. In some embodiments, n is 0.

[0185] In some embodiments, for the compound or salt of formula (I), n is selected from 1, and the compound of formula (I) is selected from formula (Ia), (Ib), (Ic), and (Id):

[0186] In some embodiments, for the compound or salt of formula (I), the compound of formula (I) is selected from formula (Ia):

[0187] In some embodiments, the compounds or salts of the present disclosure are represented by Formula (Ia) or a pharmaceutically acceptable salt thereof: where R 1 、R 2 、R 3 , A and As defined in formula (I).

[0188] In some embodiments, the compounds or salts of the present disclosure are represented by Formula (Ib) or a pharmaceutically acceptable salt thereof: where R 1 、R 2 、R 3 , A and As defined in formula (I).

[0189] In some embodiments, the compounds or salts of the present disclosure are represented by Formula (Ic) or a pharmaceutically acceptable salt thereof: where R 1 、R 2 、R 3 , A and As defined in formula (I).

[0190] In some embodiments, the compounds or salts of the present disclosure are represented by Formula (Id) or a pharmaceutically acceptable salt thereof: where R 1 、R 2 、R 3 , A and As defined in formula (I).

[0191] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 1 is selected from C optionally substituted by one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10 )C(O)R 10 、-N(R 10 )C(O)OR 10 、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R 10 、-S(O)2N(R 10 )2, -NO2, =S, =O and -CN. In some embodiments, R 1 is selected from C optionally substituted by one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 10 、-N(R 10 )2、-C(O)R 10 , -NO2, =S, =O and -CN.

[0192] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 1 is selected from C optionally substituted by one or more substituents independently selected from 1-3 Alkyl: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10 )C(O)R 10 、-N(R 10 )C(O)OR 10 、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R 10 、-S(O)2N(R 10 )2, -NO2, =S, =O and -CN. In some embodiments, R 1 is selected from C optionally substituted by one or more substituents independently selected from 1-3 Alkyl: halogen, -OR 10 、-N(R 10 )2、-C(O)R 10 , -NO2, =S, =O and -CN.

[0193] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 1 is selected from methyl, ethyl, propyl and isopropyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10 )C(O)R 10、-N(R 10 )C(O)OR 10 、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R 10 、-S(O)2N(R 10 )2, -NO2, =S, =O and -CN. In some embodiments, R 1 is selected from methyl, ethyl, propyl and isopropyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 10 、-N(R 10 )2、-C(O)R 10 , -NO2, =S, =O and -CN. In some embodiments, R 1 is selected from optionally substituted methyl and optionally substituted ethyl.

[0194] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 1 Selected from optionally substituted C 3-10 saturated carbocyclic ring and optionally substituted 3- to 10-membered heterocyclic ring. In some embodiments, R 1 Selected from optionally substituted C 3-10 Saturated carbocyclic and optionally substituted 3- to 10-membered heterocyclic rings, wherein the optional substituents are independently selected from: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10 )C(O)R 10 、-N(R 10 )C(O)OR 10 、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R 10 、-S(O)2N(R 10)2, -NO2, =S, =O and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10 )C(O)R 10 、-N(R 10 )C(O)OR 10 、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R 10 、-S(O)2N(R 10 )2, -NO2, =S, =O and -CN. In some embodiments, R 1 Selected from optionally substituted C 3-10 Saturated carbocyclic and optionally substituted 3- to 10-membered heterocyclic rings, wherein the optional substituents are independently selected from: halogen, -OR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 , -NO2, =S, =O and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 , -NO2, =S, =O and -CN.

[0195] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 1 Selected from optionally substituted C 3-10 Saturated carbocyclic and optionally substituted 3- to 10-membered heterocyclic rings, wherein the optional substituents are independently selected from: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10 )C(O)R 10 、-N(R 10 )C(O)OR 10 、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R 10 、-S(O)2N(R 10 )2, -NO2, =S, =O and -CN. In some embodiments, R 1 Selected from optionally substituted C 3-10 Saturated carbocyclic and optionally substituted 3- to 10-membered heterocyclic rings, wherein the optional substituents are independently selected from: halogen, -OR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 , -NO2, =S, =O and -CN.

[0196] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 1 Selected from optionally substituted C 3-10 Saturated carbocyclic and optionally substituted 3- to 10-membered heterocyclic rings, wherein the optional substituents are independently selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10 )C(O)R 10 、-N(R 10 )C(O)OR 10 、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R10 、-S(O)2R 10 、-S(O)2N(R 10 )2, -NO2, =S, =O and -CN. In some embodiments, R 1 Selected from optionally substituted C 3-10 Saturated carbocyclic and optionally substituted 3- to 10-membered heterocyclic rings, wherein the optional substituents are independently selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 , -NO2, =S, =O and -CN.

[0197] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 1 Selected from optionally substituted C 3-6 saturated carbocyclic ring and optionally substituted 3- to 6-membered heterocyclic ring. In some embodiments, R 1 Selected from optionally substituted C 3-6 Saturated carbocyclic and optionally substituted 3- to 6-membered heterocyclic rings, wherein the optional substituents are independently selected from: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10 )C(O)R 10 、-N(R 10 )C(O)OR 10 、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R 10 、-S(O)2N(R 10 )2, -NO2, =S, =O and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10 )C(O)R 10 、-N(R 10 )C(O)OR 10 、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R 10 、-S(O)2N(R 10 )2, -NO2, =S, =O and -CN. In some embodiments, R 1 Selected from optionally substituted C 3-6 Saturated carbocyclic and optionally substituted 3- to 6-membered heterocyclic rings, wherein the optional substituents are independently selected from: halogen, -OR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 , -NO2, =S, =O and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 , -NO2, =S, =O and -CN.

[0198] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 1 Selected from optionally substituted C 3-6 Saturated carbocyclic and optionally substituted 3- to 6-membered heterocyclic rings, wherein the optional substituents are independently selected from: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10 )C(O)R 10 、-N(R10 )C(O)OR 10 、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R 10 、-S(O)2N(R 10 )2, -NO2, =S, =O and -CN. In some embodiments, R 1 Selected from optionally substituted C 3-6 Saturated carbocyclic and optionally substituted 3- to 6-membered heterocyclic rings, wherein the optional substituents are independently selected from: halogen, -OR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 , -NO2, =S, =O and -CN.

[0199] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 1 Selected from optionally substituted C 3-6 Saturated carbocyclic and optionally substituted 3- to 6-membered heterocyclic rings, wherein the optional substituents are independently selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10 )C(O)R 10 、-N(R 10 )C(O)OR 10 、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R 10 、-S(O)2N(R 10 )2, -NO2, =S, =O and -CN. In some embodiments, R 1 Selected from optionally substituted C 3-6Saturated carbocyclic and optionally substituted 3- to 6-membered heterocyclic rings, wherein the optional substituents are independently selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 , -NO2, =S, =O and -CN.

[0200] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 1 Selected from optionally substituted C 3-10 In some embodiments, R 1 The optionally substituted C 3-10 The saturated carbocycle is selected from the group consisting of an optionally substituted C3 saturated carbocycle, an optionally substituted C4 saturated carbocycle, an optionally substituted C5 saturated carbocycle, an optionally substituted C6 saturated carbocycle, an optionally substituted C7 saturated carbocycle, an optionally substituted C8 saturated carbocycle, an optionally substituted C9 saturated carbocycle and an optionally substituted C 10 In some embodiments, R 1 The optionally substituted C 3-10 The saturated carbocyclic ring is selected from the group consisting of: optionally substituted C 3-4 Saturated carbocyclic ring, optionally substituted C 3-5 Saturated carbocyclic ring, optionally substituted C 3-6 Saturated carbocyclic ring, optionally substituted C 3-7 Saturated carbocyclic ring, optionally substituted C 3-8 Saturated carbocyclic and optionally substituted C 3-9 Saturated carbocyclic ring.

[0201] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 1 Selected from optionally substituted C 3-10 Saturated carbocyclic ring, wherein the optional substituents are independently selected from: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10 )C(O)R 10 、-N(R 10 )C(O)OR 10、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R 10 、-S(O)2N(R 10 )2, -NO2, =S, =O and -CN. In some embodiments, R 1 Selected from optionally substituted C 3-10 Saturated carbocyclic ring, wherein the optional substituents are independently selected from: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 , -NO2, =S, =O and -CN.

[0202] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 1 Selected from optionally substituted C 3-10 Saturated carbocyclic ring, wherein the optional substituents are independently selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10 )C(O)R 10 、-N(R 10 )C(O)OR 10 、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R 10 、-S(O)2N(R 10 )2, -NO2, =S, =O and -CN. In some embodiments, R 1 Selected from optionally substituted C 3-10 Saturated carbocyclic ring, wherein the optional substituents are independently selected from C optionally substituted with one or more substituents independently selected from1-6 Alkyl: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 , -NO2, =S, =O and -CN.

[0203] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 1 Selected from optionally substituted C 3-6 Saturated carbocyclic ring, wherein the optional substituents are independently selected from: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10 )C(O)R 10 、-N(R 10 )C(O)OR 10 、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R 10 、-S(O)2N(R 10 )2, -NO2, =S, =O and -CN. In some embodiments, R 1 Selected from optionally substituted C 3-6 Saturated carbocyclic ring, wherein the optional substituents are independently selected from halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 , -NO2, =S, =O and -CN.

[0204] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 1 Selected from optionally substituted C 3-6 Saturated carbocyclic ring, wherein the optional substituents are independently selected from C optionally substituted with one or more substituents independently selected from 1-6Alkyl: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10 )C(O)R 10 、-N(R 10 )C(O)OR 10 、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R 10 、-S(O)2N(R 10 )2, -NO2, =S, =O and -CN. In some embodiments, R 1 Selected from optionally substituted C 3-6 Saturated carbocyclic ring, wherein the optional substituents are independently selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 , -NO2, =S, =O and -CN.

[0205] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 1 is selected from optionally substituted cyclopropyl, optionally substituted cyclobutyl, optionally substituted cyclopentyl and optionally substituted cyclohexyl, wherein the optional substituents are independently selected from: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10 )C(O)R 10 、-N(R 10 )C(O)OR 10、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R 10 、-S(O)2N(R 10 )2, -NO2, =S, =O and -CN. In some embodiments, R 1 Selected from optionally substituted C 3-6 Saturated carbocyclic ring, wherein the optional substituents are independently selected from halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 , -NO2, =S, =O and -CN.

[0206] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 1 is selected from optionally substituted cyclopropyl, optionally substituted cyclobutyl, optionally substituted cyclopentyl and optionally substituted cyclohexyl, wherein the optional substituents are independently selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10 )C(O)R 10 、-N(R 10 )C(O)OR 10 、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R 10 、-S(O)2N(R 10 )2, -NO2, =S, =O and -CN. In some embodiments, R 1is selected from optionally substituted cyclopropyl, optionally substituted cyclobutyl, optionally substituted cyclopentyl and optionally substituted cyclohexyl, wherein the optional substituents are independently selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 , -NO2, =S, =O and -CN.

[0207] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 1 is cyclopropyl optionally substituted with one or more substituents independently selected from halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10 )C(O)R 10 、-N(R 10 )C(O)OR 10 、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R 10 、-S(O)2N(R 10 )2, -NO2, =S, =O and -CN. In some embodiments, R 1 is cyclopropyl optionally substituted with one or more substituents independently selected from halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 , -NO2, =S, =O and -CN. In some embodiments, R 1 It is cyclopropyl.

[0208] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 1is cyclopropyl optionally substituted with one or more substituents independently selected from halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10 )C(O)R 10 、-N(R 10 )C(O)OR 10 、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R 10 、-S(O)2N(R 10 )2, -NO2, =S, =O and -CN. In some embodiments, R 1 is cyclopropyl optionally substituted with one or more substituents independently selected from halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 , -NO2, =S, =O and -CN. In some embodiments, R 1 It is cyclopropyl.

[0209] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 1 is selected from an optionally substituted 3- to 10-membered heterocycle. 1 The optionally substituted 3- to 10-membered heterocycle is selected from the group consisting of an optionally substituted 3-membered heterocycle, an optionally substituted 4-membered heterocycle, an optionally substituted 5-membered heterocycle, an optionally substituted 6-membered heterocycle, an optionally substituted 7-membered heterocycle, an optionally substituted 8-membered heterocycle, an optionally substituted 9-membered heterocycle, and an optionally substituted 10-membered heterocycle. 1 The optionally substituted 3- to 10-membered heterocycle is selected from the group consisting of an optionally substituted 3- to 4-membered heterocycle, an optionally substituted 3- to 5-membered heterocycle, an optionally substituted 3- to 6-membered heterocycle, an optionally substituted 3- to 7-membered heterocycle, an optionally substituted 3- to 8-membered heterocycle, and an optionally substituted 3- to 9-membered heterocycle.

[0210] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 1 is selected from optionally substituted 3- to 10-membered heterocycles, wherein the optional substituents are independently selected from: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10 )C(O)R 10 、-N(R 10 )C(O)OR 10 、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R 10 、-S(O)2N(R 10 )2, -NO2, =S, =O and -CN. In some embodiments, R 1 is selected from optionally substituted 3- to 10-membered heterocycles, wherein the optional substituents are independently selected from halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 , -NO2, =S, =O and -CN.

[0211] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 1 is selected from an optionally substituted 3- to 10-membered heterocycle, wherein the optional substituents are independently selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10)C(O)R 10 、-N(R 10 )C(O)OR 10 、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R 10 、-S(O)2N(R 10 )2, -NO2, =S, =O and -CN. In some embodiments, R 1 is selected from an optionally substituted 3- to 10-membered heterocycle, wherein the optional substituents are independently selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 , -NO2, =S, =O and -CN.

[0212] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 1 is selected from optionally substituted 3- to 6-membered heterocycles, wherein the optional substituents are independently selected from: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10 )C(O)R 10 、-N(R 10 )C(O)OR 10 、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R 10 、-S(O)2N(R 10 )2, -NO2, =S, =O and -CN. In some embodiments, R 1is selected from an optionally substituted 3- to 6-membered heterocycle, wherein the optional substituents are independently selected from halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 , -NO2, =S, =O and -CN.

[0213] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 1 is selected from an optionally substituted 3- to 6-membered heterocyclic ring, wherein the optional substituents are independently selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10 )C(O)R 10 、-N(R 10 )C(O)OR 10 、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R 10 、-S(O)2N(R 10 )2, -NO2, =S, =O and -CN. In some embodiments, R 1 is selected from an optionally substituted 3- to 6-membered heterocyclic ring, wherein the optional substituents are independently selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 , -NO2, =S, =O and -CN.

[0214] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 1is selected from an optionally substituted 4- to 6-membered saturated heterocyclic ring, wherein the optional substituents are independently selected from: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10 )C(O)R 10 、-N(R 10 )C(O)OR 10 、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R 10 、-S(O)2N(R 10 )2, -NO2, =S, =O and -CN. In some embodiments, R 1 is selected from an optionally substituted 4- to 6-membered saturated heterocyclic ring, wherein the optional substituents are independently selected from halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 , -NO2, =S, =O and -CN.

[0215] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 1 is selected from an optionally substituted 4- to 6-membered saturated heterocyclic ring, wherein the optional substituents are independently selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10 )C(O)R 10 、-N(R 10 )C(O)OR 10、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R 10 、-S(O)2N(R 10 )2, -NO2, =S, =O and -CN. In some embodiments, R 1 is selected from an optionally substituted 4- to 6-membered saturated heterocyclic ring, wherein the optional substituents are independently selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 , -NO2, =S, =O and -CN.

[0216] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 1 Selected from optionally substituted azirdidinyl, optionally substituted oxiranyl, optionally substituted azetidinyl, optionally substituted diazetidinyl and optionally substituted oxetanyl, wherein the optional substituents are independently selected from halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10 )C(O)R 10 、-N(R 10 )C(O)OR 10 、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R 10 、-S(O)2N(R 10 )2, -NO2, =S, =O and -CN. In some embodiments, R 1is selected from optionally substituted aziridine, optionally substituted oxirane, optionally substituted azetidinyl, optionally substituted diazetidinyl and optionally substituted oxetanyl, wherein the optional substituents are independently selected from halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 , -NO2, =S, =O and -CN.

[0217] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 1 is selected from optionally substituted optionally substituted aziridine, optionally substituted oxirane, optionally substituted azetidinyl, optionally substituted diazetidinyl and optionally substituted oxetanyl, wherein the optional substituents are independently selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10 )C(O)R 10 、-N(R 10 )C(O)OR 10 、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R 10 、-S(O)2N(R 10 )2, -NO2, =S, =O and -CN. In some embodiments, R 1 is selected from optionally substituted aziridine, optionally substituted oxirane, optionally substituted azetidinyl, optionally substituted diazetidinyl and optionally substituted oxetanyl, wherein the optional substituents are independently selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 10 、-SR 10 、-N(R 10)2、-C(O)R 10 、-C(O)OR 10 , -NO2, =S, =O and -CN.

[0218] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 1 is an optionally substituted oxetane, wherein the optional substituents are independently selected from: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10 )C(O)R 10 、-N(R 10 )C(O)OR 10 、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R 10 、-S(O)2N(R 10 )2, -NO2, =S, =O and -CN. In some embodiments, R 1 is an optionally substituted oxetane, wherein the optional substituents are independently selected from halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 , -NO2, =S, =O and -CN.

[0219] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 1 is an optionally substituted oxetanyl group, wherein the optional substituents are independently selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 、-OC(O)R10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10 )C(O)R 10 、-N(R 10 )C(O)OR 10 、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R 10 、-S(O)2N(R 10 )2, -NO2, =S, =O and -CN. In some embodiments, R 1 is an optionally substituted oxetanyl group, wherein the optional substituents are independently selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 , -NO2, =S, =O and -CN.

[0220] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 2 It's hydrogen.

[0221] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 2 is an optionally substituted C 3-10 Saturated carbocyclic and optionally substituted 3- to 10-membered heterocyclic rings, wherein the optional substituents are independently selected from: halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 、-OC(O)R 11 、-OC(O)N(R 11 )2、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 、-N(R 11 )C(O)OR 11 、-N(R 11 )C(O)N(R11 )2、-N(R 11 )S(O)2(R 11 ),-S(O)R 11 、-S(O)2R 11 、-S(O)2N(R 11 )2, -NO2, =S, =O and -CN. In some embodiments, R 2 is an optionally substituted C 3-10 Saturated carbocyclic and optionally substituted 3- to 10-membered heterocyclic rings, wherein the optional substituents are independently selected from: halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 -NO2, =S, =O and -CN.

[0222] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 2 is an optionally substituted C 3-10 Saturated carbocyclic and optionally substituted 3- to 10-membered heterocyclic rings, wherein the optional substituents are independently selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 、-OC(O)R 11 、-OC(O)N(R 11 )2、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 、-N(R 11 )C(O)OR 11 、-N(R 11 )C(O)N(R 11 )2、-N(R 11 )S(O)2(R 11 ),-S(O)R 11 、-S(O)2R 11 、-S(O)2N(R 11 )2, -NO2, =S, =O and -CN. In some embodiments, R 2 is an optionally substituted C 3-10Saturated carbocyclic and optionally substituted 3- to 10-membered heterocyclic rings, wherein the optional substituents are independently selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 , -NO2, =S, =O and -CN.

[0223] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 2 is an optionally substituted C 3-6 Saturated carbocyclic and optionally substituted 3- to 6-membered heterocyclic rings, wherein the optional substituents are independently selected from: halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 、-OC(O)R 11 、-OC(O)N(R 11 )2、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 、-N(R 11 )C(O)OR 11 、-N(R 11 )C(O)N(R 11 )2、-N(R 11 )S(O)2(R 11 ),-S(O)R 11 、-S(O)2R 11 、-S(O)2N(R 11 )2, -NO2, =S, =O and -CN. In some embodiments, R 2 is an optionally substituted C 3-6 Saturated carbocyclic and optionally substituted 3- to 6-membered heterocyclic rings, wherein the optional substituents are independently selected from: halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 , -NO2, =S, =O and -CN.

[0224] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 2is an optionally substituted C 3-6 Saturated carbocyclic and optionally substituted 3- to 10-membered heterocyclic rings, wherein the optional substituents are independently selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 、-OC(O)R 11 、-OC(O)N(R 11 )2、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 、-N(R 11 )C(O)OR 11 、-N(R 11 )C(O)N(R 11 )2、-N(R 11 )S(O)2(R 11 ),-S(O)R 11 、-S(O)2R 11 、-S(O)2N(R 11 )2, -NO2, =S, =O and -CN. In some embodiments, R 2 is an optionally substituted C 3-6 Saturated carbocyclic and optionally substituted 3- to 6-membered heterocyclic rings, wherein the optional substituents are independently selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 -NO2, =S, =O and -CN.

[0225] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 2 Selected from optionally substituted C 3-10 In some embodiments, R 2 The optionally substituted C 3-10 The saturated carbocycle is selected from the group consisting of an optionally substituted C3 saturated carbocycle, an optionally substituted C4 saturated carbocycle, an optionally substituted C5 saturated carbocycle, an optionally substituted C6 saturated carbocycle, an optionally substituted C7 saturated carbocycle, an optionally substituted C8 saturated carbocycle, an optionally substituted C9 saturated carbocycle and an optionally substituted C 10In some embodiments, R 2 The optionally substituted C 3-10 The saturated carbocyclic ring is selected from the group consisting of: optionally substituted C 3-4 Saturated carbocyclic ring, optionally substituted C 3-5 Saturated carbocyclic ring, optionally substituted C 3-6 Saturated carbocyclic ring, optionally substituted C 3-7 Saturated carbocyclic ring, optionally substituted C 3-8 Saturated carbocyclic and optionally substituted C 3-9 Saturated carbocyclic ring.

[0226] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 2 is an optionally substituted C 3-10 Saturated carbocyclic ring, wherein the optional substituents are independently selected from: halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 、-OC(O)R 11 、-OC(O)N(R 11 )2、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 、-N(R 11 )C(O)OR 11 、-N(R 11 )C(O)N(R 11 )2、-N(R 11 )S(O)2(R 11 ),-S(O)R 11 、-S(O)2R 11 、-S(O)2N(R 11 )2, -NO2, =S, =O and -CN. In some embodiments, R 2 is an optionally substituted C 3-10 Saturated carbocyclic ring, wherein the optional substituents are independently selected from: halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 , -NO2, =S, =O and -CN.

[0227] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 2 is an optionally substituted C3-10 Saturated carbocyclic ring, wherein the optional substituents are independently selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 、-OC(O)R 11 、-OC(O)N(R 11 )2、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 、-N(R 11 )C(O)OR 11 、-N(R 11 )C(O)N(R 11 )2、-N(R 11 )S(O)2(R 11 ),-S(O)R 11 、-S(O)2R 11 、-S(O)2N(R 11 )2, -NO2, =S, =O and -CN. In some embodiments, R 2 is an optionally substituted C 3-10 Saturated carbocyclic ring, wherein the optional substituents are independently selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 -NO2, =S, =O and -CN.

[0228] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 2 is an optionally substituted C 3-6 Saturated carbocyclic ring, wherein the optional substituents are independently selected from: halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 、-OC(O)R 11 、-OC(O)N(R 11 )2、-C(O)N(R 11 )2、-N(R 11)C(O)R 11 、-N(R 11 )C(O)OR 11 、-N(R 11 )C(O)N(R 11 )2、-N(R 11 )S(O)2(R 11 ),-S(O)R 11 、-S(O)2R 11 、-S(O)2N(R 11 )2, -NO2, =S, =O and -CN. In some embodiments, R 2 is an optionally substituted C 3-6 Saturated carbocyclic ring, wherein the optional substituents are independently selected from: halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 -NO2, =S, =O and -CN.

[0229] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 2 is an optionally substituted C 3-6 Saturated carbocyclic ring, wherein the optional substituents are independently selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 、-OC(O)R 11 、-OC(O)N(R 11 )2、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 、-N(R 11 )C(O)OR 11 、-N(R 11 )C(O)N(R 11 )2、-N(R 11 )S(O)2(R 11 ),-S(O)R 11 、-S(O)2R 11 、-S(O)2N(R 11 )2, -NO2, =S, =O and -CN. In some embodiments, R 2 is an optionally substituted C3-6 Saturated carbocyclic ring, wherein the optional substituents are independently selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 -NO2, =S, =O and -CN.

[0230] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 2 is optionally substituted cyclopropyl, optionally substituted cyclobutyl, optionally substituted cyclopentyl and optionally substituted cyclohexyl, wherein the optional substituents are independently selected from: halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 、-OC(O)R 11 、-OC(O)N(R 11 )2、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 、-N(R 11 )C(O)OR 11 、-N(R 11 )C(O)N(R 11 )2、-N(R 11 )S(O)2(R 11 ),-S(O)R 11 、-S(O)2R 11 、-S(O)2N(R 11 )2, -NO2, =S, =O and -CN. In some embodiments, R 2 is optionally substituted cyclopropyl, optionally substituted cyclobutyl, optionally substituted cyclopentyl and optionally substituted cyclohexyl, wherein the optional substituents are independently selected from: halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 , -NO2, =S, =O and -CN.

[0231] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 2is optionally substituted cyclopropyl, optionally substituted cyclobutyl, optionally substituted cyclopentyl and optionally substituted cyclohexyl, wherein the optional substituents are independently selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 、-OC(O)R 11 、-OC(O)N(R 11 )2、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 、-N(R 11 )C(O)OR 11 、-N(R 11 )C(O)N(R 11 )2、-N(R 11 )S(O)2(R 11 ),-S(O)R 11 、-S(O)2R 11 、-S(O)2N(R 11 )2, -NO2, =S, =O and -CN. In some embodiments, R 2 is optionally substituted cyclopropyl, optionally substituted cyclobutyl, optionally substituted cyclopentyl and optionally substituted cyclohexyl, wherein the optional substituents are independently selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 -NO2, =S, =O and -CN.

[0232] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 2 is cyclopropyl optionally substituted with one or more substituents independently selected from halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 、-OC(O)R 11 、-OC(O)N(R 11 )2、-C(O)N(R 11)2、-N(R 11 )C(O)R 11 、-N(R 11 )C(O)OR 11 、-N(R 11 )C(O)N(R 11 )2、-N(R 11 )S(O)2(R 11 ),-S(O)R 11 、-S(O)2R 11 、-S(O)2N(R 11 )2, -NO2, =S, =O and -CN. In some embodiments, R 2 is cyclopropyl optionally substituted with one or more substituents independently selected from halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 -NO2, =S, =O and -CN. In some embodiments, R 2 It is cyclopropyl.

[0233] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 2 is optionally independently selected from C 1-6 The cyclopropyl group is substituted with one or more alkyl substituents, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 、-OC(O)R 11 、-OC(O)N(R 11 )2、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 、-N(R 11 )C(O)OR 11 、-N(R 11 )C(O)N(R 11 )2、-N(R 11 )S(O)2(R 11 ),-S(O)R 11 、-S(O)2R 11 、-S(O)2N(R 11)2, -NO2, =S, =O and -CN. In some embodiments, R 2 is optionally independently selected from C 1-6 The cyclopropyl group is substituted with one or more alkyl substituents, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 -NO2, =S, =O and -CN. In some embodiments, R 2 It is cyclopropyl.

[0234] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 2 is selected from an optionally substituted 3- to 10-membered heterocycle. 2 The optionally substituted 3- to 10-membered heterocycle is selected from the group consisting of an optionally substituted 3-membered heterocycle, an optionally substituted 4-membered heterocycle, an optionally substituted 5-membered heterocycle, an optionally substituted 6-membered heterocycle, an optionally substituted 7-membered heterocycle, an optionally substituted 8-membered heterocycle, an optionally substituted 9-membered heterocycle, and an optionally substituted 10-membered heterocycle. 2 The optionally substituted 3- to 10-membered heterocycle is selected from the group consisting of an optionally substituted 3- to 4-membered heterocycle, an optionally substituted 3- to 5-membered heterocycle, an optionally substituted 3- to 6-membered heterocycle, an optionally substituted 3- to 7-membered heterocycle, an optionally substituted 3- to 8-membered heterocycle, and an optionally substituted 3- to 9-membered heterocycle.

[0235] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 2 is an optionally substituted 3- to 10-membered heterocyclic ring, wherein the optional substituents are independently selected from: halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 、-OC(O)R 11 、-OC(O)N(R 11 )2、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 、-N(R 11 )C(O)OR 11 、-N(R 11 )C(O)N(R 11)2、-N(R 11 )S(O)2(R 11 ),-S(O)R 11 、-S(O)2R 11 、-S(O)2N(R 11 )2, -NO2, =S, =O and -CN. In some embodiments, R 2 is an optionally substituted 3- to 10-membered heterocyclic ring, wherein the optional substituents are independently selected from: halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 , -NO2, =S, =O and -CN.

[0236] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 2 is an optionally substituted 3- to 10-membered heterocyclic ring, wherein the optional substituents are independently selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 、-OC(O)R 11 、-OC(O)N(R 11 )2、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 、-N(R 11 )C(O)OR 11 、-N(R 11 )C(O)N(R 11 )2、-N(R 11 )S(O)2(R 11 ),-S(O)R 11 、-S(O)2R 11 、-S(O)2N(R 11 )2, -NO2, =S, =O and -CN. In some embodiments, R 2 is an optionally substituted 3- to 10-membered heterocyclic ring, wherein the optional substituents are independently selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 11 、-SR 11 、-N(R 11)2、-C(O)R 11 、-C(O)OR 11 -NO2, =S, =O and -CN.

[0237] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 2 is an optionally substituted 3- to 6-membered heterocyclic ring, wherein the optional substituents are independently selected from: halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 、-OC(O)R 11 、-OC(O)N(R 11 )2、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 、-N(R 11 )C(O)OR 11 、-N(R 11 )C(O)N(R 11 )2、-N(R 11 )S(O)2(R 11 ),-S(O)R 11 、-S(O)2R 11 、-S(O)2N(R 11 )2, -NO2, =S, =O and -CN. In some embodiments, R 2 is a 3- to 6-membered heterocyclic ring, wherein the optional substituents are independently selected from: halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 -NO2, =S, =O and -CN.

[0238] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 2 is an optionally substituted 3- to 6-membered heterocyclic ring, wherein the optional substituents are independently selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 、-OC(O)R11 、-OC(O)N(R 11 )2、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 、-N(R 11 )C(O)OR 11 、-N(R 11 )C(O)N(R 11 )2、-N(R 11 )S(O)2(R 11 ),-S(O)R 11 、-S(O)2R 11 、-S(O)2N(R 11 )2, -NO2, =S, =O and -CN. In some embodiments, R 2 is an optionally substituted 3- to 6-membered heterocyclic ring, wherein the optional substituents are independently selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 -NO2, =S, =O and -CN.

[0239] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 1 Selected from C 1-3 Alkyl, C 1-3 haloalkyl, optionally substituted saturated C 3-6 carbocyclic and optionally substituted 3- to 6-membered heterocyclic rings; and R 2 is selected from hydrogen, optionally substituted C 3-6 saturated carbocyclic and optionally substituted 3- to 6-membered heterocyclic rings; wherein R 1 and R 2 At least one of the following is selected from optionally substituted C 3-6 saturated carbocyclic ring and optionally substituted 3- to 6-membered heterocyclic ring. In some embodiments, R 1 It is C 1-3 Alkyl, and R 2 Selected from optionally substituted C 3-6 saturated carbocyclic ring and optionally substituted 3- to 6-membered heterocyclic ring. In some embodiments, R 1 It is C 1-3 haloalkyl, and R 2 Selected from optionally substituted C 3-6 saturated carbocyclic ring and optionally substituted 3- to 6-membered heterocyclic ring. In some embodiments, R1 is an optionally substituted saturated C 3-6 carbon ring, and R 2 is selected from hydrogen, optionally substituted C 3-6 saturated carbocyclic ring and optionally substituted 3- to 6-membered heterocyclic ring. In some embodiments, R 1 is an optionally substituted 3- to 6-membered heterocyclic ring, and R 2 is selected from hydrogen, optionally substituted C 3-6 saturated carbocyclic rings and optionally substituted 3- to 6-membered heterocyclic rings.

[0240] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 1 Selected from C 1-3 Alkyl, C 1-3 haloalkyl, optionally substituted saturated C 3-6 carbocyclic and optionally substituted 3- to 6-membered heterocyclic rings; and R 2 is selected from hydrogen, optionally substituted C 3-6 saturated carbocyclic and optionally substituted 3- to 6-membered heterocyclic rings; wherein R 1 and R 2 At least one of the following is selected from optionally substituted C 3-6 saturated carbocyclic ring and optionally substituted 3- to 6-membered heterocyclic ring. In some embodiments, R 1 Selected from optionally substituted saturated C 3-6 carbocyclic and optionally substituted 3- to 6-membered heterocyclic rings; and R 2 In some embodiments, R 1 Selected from C 1-3 Alkyl, C 1-3 haloalkyl, optionally substituted saturated C 3-6 carbocyclic and optionally substituted 3- to 6-membered heterocyclic rings; and R 2 is an optionally substituted C 3-6 In some embodiments, R 1 Selected from C 1-3 Alkyl, C 1-3 haloalkyl, optionally substituted saturated C 3-6 carbocyclic and optionally substituted 3- to 6-membered heterocyclic rings; and R 2 is an optionally substituted 3- to 6-membered heterocyclic ring.

[0241] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 1 is an optionally substituted saturated C 3-6 carbocyclic or optionally substituted saturated 3- to 6-membered heterocyclic ring; and R 2 is selected from hydrogen, optionally substituted C 3-6saturated carbocyclic ring and optionally substituted saturated 3- to 6-membered heterocyclic ring. 1 is an optionally substituted saturated C 3-4 carbocyclic or optionally substituted saturated 3- to 4-membered heterocyclic ring; and R 2 selected from hydrogen, optionally substituted saturated C 3-6 In some embodiments, R 1 is an optionally substituted C 3-4 cycloalkyl or optionally substituted 3- to 4-membered heterocycloalkyl; and R 2 It's hydrogen.

[0242] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 2 is an optionally substituted C 3-6 saturated carbocyclic ring and optionally substituted 3- to 6-membered heterocyclic ring; and R 1 Selected from C 1-3 Alkyl, C 1-3 haloalkyl, optionally substituted saturated C 3-6 In some embodiments, R 2 is an optionally substituted saturated C 3-4 carbocyclic or optionally substituted saturated 3- to 4-membered heterocyclic ring; and R 1 Selected from C 1-3 Alkyl, C 1-3 haloalkyl, optionally substituted saturated C 3-6 carbocyclic rings and optionally substituted 3- to 6-membered heterocyclic rings.

[0243] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 1 Selected from methyl, ethyl, In some embodiments, R 1 Selected from In some embodiments, R 1 Selected from methyl and ethyl.

[0244] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 2 is hydrogen or In some embodiments, R 2 In some embodiments, R 2 yes

[0245] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 1 and R 2 At least one selected from In some embodiments, R 1 and R 2 At least one selected from In some embodiments, R 1 and R 2 At least one selected from

[0246] In some embodiments, for compounds or salts of Formula (I), (Ia), (Ib), (Ic), or (Id), A is selected from optionally substituted C 3-10 In some embodiments, the optionally substituted C 3-10 The saturated carbocyclylene group is selected from the group consisting of an optionally substituted C3 saturated carbocyclylene group, an optionally substituted C4 saturated carbocyclylene group, an optionally substituted C5 saturated carbocyclylene group, an optionally substituted C6 saturated carbocyclylene group, an optionally substituted C7 saturated carbocyclylene group, an optionally substituted C8 saturated carbocyclylene group, an optionally substituted C9 saturated carbocyclylene group and an optionally substituted C 10 In some embodiments, the optionally substituted C 3-10 The saturated carbocyclylene group is selected from the group consisting of: optionally substituted C 3-4 Saturated carbocyclylene, optionally substituted C 3-5 Saturated carbocyclylene, optionally substituted C 3-6 Saturated carbocyclylene, optionally substituted C 3-7 Saturated carbocyclylene, optionally substituted C 3-8 Saturated carbocyclyl and optionally substituted C 3-9 Saturated carbocyclylene.

[0247] In some embodiments, for compounds or salts of Formula (I), (Ia), (Ib), (Ic), or (Id), A is optionally substituted C 3-10 Carbocyclylene, wherein the optional substituents are independently selected from: halogen, -OR 14 、-SR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 、-OC(O)R 14 、-OC(O)N(R 14 )2、-C(O)N(R 14 )2、-N(R 14 )C(O)R 14 、-N(R14 )C(O)OR 14 、-N(R 14 )C(O)N(R 14 )2、-N(R 14 )S(O)2(R 14 ),-S(O)R 14 、-S(O)2R 14 、-S(O)2N(R 14 )2, -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 14 、-SR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 、-OC(O)R 14 、-OC(O)N(R 14 )2、-C(O)N(R 14 )2、-N(R 14 )C(O)R 14 、-N(R 14 )C(O)OR 14 、-N(R 14 )C(O)N(R 14 )2、-N(R 14 )S(O)2(R 14 ),-S(O)R 14 、-S(O)2R 14 、-S(O)2N(R 14 )2, -NO2, =S, =O and -CN. In some embodiments, A is optionally substituted C 3-10 Carbocyclylene, wherein the optional substituents are independently selected from: halogen, -OR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 , -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 , -NO2 and -CN.

[0248] In some embodiments, for compounds or salts of Formula (I), (Ia), (Ib), (Ic), or (Id), A is optionally substituted C 3-6Carbocyclylene, wherein the optional substituents are independently selected from: halogen, -OR 14 、-SR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 、-OC(O)R 14 、-OC(O)N(R 14 )2、-C(O)N(R 14 )2、-N(R 14 )C(O)R 14 、-N(R 14 )C(O)OR 14 、-N(R 14 )C(O)N(R 14 )2、-N(R 14 )S(O)2(R 14 ),-S(O)R 14 、-S(O)2R 14 、-S(O)2N(R 14 )2, -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 14 、-SR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 、-OC(O)R 14 、-OC(O)N(R 14 )2、-C(O)N(R 14 )2、-N(R 14 )C(O)R 14 、-N(R 14 )C(O)OR 14 、-N(R 14 )C(O)N(R 14 )2、-N(R 14 )S(O)2(R 14 ),-S(O)R 14 、-S(O)2R 14 、-S(O)2N(R 14 )2, -NO2, =S, =O and -CN. In some embodiments, A is optionally substituted C 3-6 Carbocyclylene, wherein the optional substituents are independently selected from: halogen, -OR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14, -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 , -NO2 and -CN.

[0249] In some embodiments, for compounds or salts of Formula (I), (Ia), (Ib), (Ic), or (Id), A is optionally substituted phenylene, wherein the optional substituents are independently selected from: halogen, -OR 14 、-SR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 、-OC(O)R 14 、-OC(O)N(R 14 )2、-C(O)N(R 14 )2、-N(R 14 )C(O)R 14 、-N(R 14 )C(O)OR 14 、-N(R 14 )C(O)N(R 14 )2、-N(R 14 )S(O)2(R 14 ),-S(O)R 14 、-S(O)2R 14 、-S(O)2N(R 14 )2, -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 14 、-SR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 、-OC(O)R 14 、-OC(O)N(R 14 )2、-C(O)N(R 14 )2、-N(R 14 )C(O)R 14 、-N(R 14 )C(O)OR 14 、-N(R 14 )C(O)N(R 14 )2、-N(R 14 )S(O)2(R 14),-S(O)R 14 、-S(O)2R 14 、-S(O)2N(R 14 )2, -NO2, =S, =O and -CN. In some embodiments, A is optionally substituted phenylene, wherein the optional substituents are independently selected from: halogen, -OR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 , -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 , -NO2 and -CN.

[0250] In some embodiments, for compounds or salts of Formula (I), (Ia), (Ib), (Ic), or (Id), A is optionally substituted phenylene, wherein the optional substituents are independently selected from: halogen, -OR 14 、-SR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 、-OC(O)R 14 、-OC(O)N(R 14 )2、-C(O)N(R 14 )2、-N(R 14 )C(O)R 14 、-N(R 14 )C(O)OR 14 、-N(R 14 )C(O)N(R 14 )2、-N(R 14 )S(O)2(R 14 ),-S(O)R 14 、-S(O)2R 14 、-S(O)2N(R 14 )2, -NO2 and -CN. In some embodiments, A is optionally substituted phenylene, wherein the optional substituents are independently selected from: halogen, -OR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 , -NO2 and -CN.

[0251] In some embodiments, for compounds or salts of Formula (I), (Ia), (Ib), (Ic), or (Id), A is optionally substituted phenylene, wherein the optional substituents are independently selected from: C optionally substituted with one or more substituents independently selected from: 1-6 Alkyl: halogen, -OR 14 、-SR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 、-OC(O)R 14 、-OC(O)N(R 14 )2、-C(O)N(R 14 )2、-N(R 14 )C(O)R 14 、-N(R 14 )C(O)OR 14 、-N(R 14 )C(O)N(R 14 )2、-N(R 14 )S(O)2(R 14 ),-S(O)R 14 、-S(O)2R 14 、-S(O)2N(R 14 )2, -NO2, =S, =O and -CN. In some embodiments, A is optionally substituted phenylene, wherein the optional substituents are independently selected from: C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 , -NO2 and -CN.

[0252] In some embodiments, for a compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), Selected from:

[0253] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 1 Selected from optionally substituted C 3-10 Carbocyclic and optionally substituted 3- to 10-membered heterocyclic rings; R 2 is selected from hydrogen; and A is selected from

[0254] In some embodiments, for a compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), Selected from:

[0255] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), A is selected from an optionally substituted 3- to 10-membered heterocyclylene, wherein when A is a 5-membered heteroaryl, the 5-membered heteroaryl contains one or more heteroatoms selected from O, S, and N, and there are no more than two N atoms in the ring. In some embodiments, the optionally substituted 3- to 10-membered heterocyclylene of A is selected from an optionally substituted 3-membered heterocyclylene, an optionally substituted 4-membered heterocyclylene, an optionally substituted 5-membered heterocyclylene, an optionally substituted 6-membered heterocyclylene, an optionally substituted 7-membered heterocyclylene, an optionally substituted 8-membered heterocyclylene, an optionally substituted 9-membered heterocyclylene, and an optionally substituted 10-membered heterocyclylene. In some embodiments, the optionally substituted 3- to 10-membered heterocyclylene of A is selected from an optionally substituted 3- to 4-membered heterocyclylene, an optionally substituted 3- to 5-membered heterocyclylene, an optionally substituted 3- to 6-membered heterocyclylene, an optionally substituted 3- to 7-membered heterocyclylene, an optionally substituted 3- to 8-membered heterocyclylene, and an optionally substituted 3- to 9-membered heterocyclylene.

[0256] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), A is an optionally substituted 3- to 10-membered heterocyclylene, wherein the optional substituents are independently selected from: halogen, -OR 14 、-SR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 、-OC(O)R 14 、-OC(O)N(R 14 )2、-C(O)N(R 14 )2、-N(R 14 )C(O)R 14 、-N(R 14 )C(O)OR 14 、-N(R 14 )C(O)N(R 14 )2、-N(R 14 )S(O)2(R 14 ),-S(O)R 14 、-S(O)2R 14 、-S(O)2N(R 14)2, -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 14 、-SR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 、-OC(O)R 14 、-OC(O)N(R 14 )2、-C(O)N(R 14 )2、-N(R 14 )C(O)R 14 、-N(R 14 )C(O)OR 14 、-N(R 14 )C(O)N(R 14 )2、-N(R 14 )S(O)2(R 14 ),-S(O)R 14 、-S(O)2R 14 、-S(O)2N(R 14 )2, -NO2, =S, =O and -CN. In some embodiments, A is an optionally substituted 3- to 10-membered heterocyclylene, wherein the optional substituents are independently selected from: halogen, -OR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 , -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 , -NO2 and -CN.

[0257] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), A is an optionally substituted 3- to 6-membered heterocyclylene, wherein the optional substituents are independently selected from: halogen, -OR 14 、-SR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 、-OC(O)R 14 、-OC(O)N(R 14 )2、-C(O)N(R 14 )2、-N(R14 )C(O)R 14 、-N(R 14 )C(O)OR 14 、-N(R 14 )C(O)N(R 14 )2、-N(R 14 )S(O)2(R 14 ),-S(O)R 14 、-S(O)2R 14 、-S(O)2N(R 14 )2, -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 14 、-SR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 、-OC(O)R 14 、-OC(O)N(R 14 )2、-C(O)N(R 14 )2、-N(R 14 )C(O)R 14 、-N(R 14 )C(O)OR 14 、-N(R 14 )C(O)N(R 14 )2、-N(R 14 )S(O)2(R 14 ),-S(O)R 14 、-S(O)2R 14 、-S(O)2N(R 14 )2, -NO2, =S, =O and -CN. In some embodiments, A is an optionally substituted 3- to 6-membered heterocyclylene, wherein the optional substituents are independently selected from: halogen, -OR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 , -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 , -NO2 and -CN.

[0258] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), A is an optionally substituted 3- to 6-membered heterocyclylene, wherein the optional substituents are independently selected from: halogen, -OR 14 、-SR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 、-OC(O)R 14 、-OC(O)N(R 14 )2、-C(O)N(R 14 )2、-N(R 14 )C(O)R 14 、-N(R 14 )C(O)OR 14 、-N(R 14 )C(O)N(R 14 )2、-N(R 14 )S(O)2(R 14 ),-S(O)R 14 、-S(O)2R 14 、-S(O)2N(R 14 )2, -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 14 、-SR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 、-OC(O)R 14 、-OC(O)N(R 14 )2、-C(O)N(R 14 )2、-N(R 14 )C(O)R 14 、-N(R 14 )C(O)OR 14 、-N(R 14 )C(O)N(R 14 )2、-N(R 14 )S(O)2(R 14 ),-S(O)R 14 、-S(O)2R 14 、-S(O)2N(R 14 )2, -NO2, =S, =O and -CN. In some embodiments, A is an optionally substituted 3- to 6-membered heterocyclylene, wherein the optional substituents are independently selected from: halogen, -OR 14 、-N(R 14)2、-C(O)R 14 、-C(O)OR 14 , -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 , -NO2 and -CN; wherein when A is a 5-membered heteroaryl, the 5-membered heteroaryl contains one or more heteroatoms selected from O, S and N, and there are not more than two N atoms in the ring.

[0259] In some embodiments, for compounds or salts of Formula (I), (Ia), (Ib), (Ic), or (Id), A is an optionally substituted 6-membered heteroarylene, wherein the optional substituents are independently selected from: halogen, -OR 14 、-SR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 、-OC(O)R 14 、-OC(O)N(R 14 )2、-C(O)N(R 14 )2、-N(R 14 )C(O)R 14 、-N(R 14 )C(O)OR 14 、-N(R 14 )C(O)N(R 14 )2、-N(R 14 )S(O)2(R 14 ),-S(O)R 14 、-S(O)2R 14 、-S(O)2N(R 14 )2, -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 14 、-SR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 、-OC(O)R 14 、-OC(O)N(R 14 )2、-C(O)N(R 14 )2、-N(R 14 )C(O)R 14 、-N(R 14)C(O)OR 14 、-N(R 14 )C(O)N(R 14 )2、-N(R 14 )S(O)2(R 14 ),-S(O)R 14 、-S(O)2R 14 、-S(O)2N(R 14 )2, -NO2, =S, =O and -CN. In some embodiments, A is an optionally substituted 6-membered heteroarylene, wherein the optional substituents are independently selected from: halogen, -OR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 , -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 , -NO2 and -CN; wherein when A is a 5-membered heteroaryl, the 5-membered heteroaryl contains one or more heteroatoms selected from O, S and N, and there are not more than two N atoms in the ring.

[0260] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), A is optionally substituted pyridinylene, optionally substituted pyrimidinylene, and optionally substituted pyrazinylene, wherein the optional substituents are independently selected from: halogen, -OR 14 、-SR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 、-OC(O)R 14 、-OC(O)N(R 14 )2、-C(O)N(R 14 )2、-N(R 14 )C(O)R 14 、-N(R 14 )C(O)OR 14 、-N(R 14 )C(O)N(R 14 )2、-N(R 14 )S(O)2(R 14 ),-S(O)R 14 、-S(O)2R 14 、-S(O)2N(R 14)2, -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 14 、-SR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 、-OC(O)R 14 、-OC(O)N(R 14 )2、-C(O)N(R 14 )2、-N(R 14 )C(O)R 14 、-N(R 14 )C(O)OR 14 、-N(R 14 )C(O)N(R 14 )2、-N(R 14 )S(O)2(R 14 ),-S(O)R 14 、-S(O)2R 14 、-S(O)2N(R 14 )2, -NO2, =S, =O and -CN. In some embodiments, A is optionally substituted pyridinyl, optionally substituted pyrimidinyl and optionally substituted pyrazinyl, wherein the optional substituents are independently selected from: halogen, -OR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 , -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 , -NO2 and -CN; wherein when A is a 5-membered heteroaryl, the 5-membered heteroaryl contains one or more heteroatoms selected from O, S and N, and there are no more than two N atoms in the ring. In some embodiments, Selected from

[0261] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 1 is selected from C optionally substituted by one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 10 、-SR 10 、-N(R10 )2、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10 )C(O)R 10 、-N(R 10 )C(O)OR 10 、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R 10 、-S(O)2N(R 10 )2, -NO2, =S, =O and -CN; and Selected from

[0262] In some embodiments, for a compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), Selected from

[0263] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 1 is selected from C optionally substituted by one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10 )C(O)R 10 、-N(R 10 )C(O)OR 10 、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R10 、-S(O)2N(R 10 )2, -NO2, =S, =O and -CN; and Selected from

[0264] In some embodiments, for a compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), Selected from

[0265] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), A is selected from optionally substituted phenylene and optionally substituted 6-membered heteroarylene, wherein the optional substituents are independently selected from: halogen, -OR 14 、-SR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 、-OC(O)R 14 、-OC(O)N(R 14 )2、-C(O)N(R 14 )2、-N(R 14 )C(O)R 14 、-N(R 14 )C(O)OR 14 、-N(R 14 )C(O)N(R 14 )2、-N(R 14 )S(O)2(R 14 ),-S(O)R 14 、-S(O)2R 14 、-S(O)2N(R 14 )2, -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 14 、-SR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 、-OC(O)R 14 、-OC(O)N(R 14 )2、-C(O)N(R 14 )2、-N(R 14 )C(O)R 14 、-N(R 14 )C(O)OR 14、-N(R 14 )C(O)N(R 14 )2、-N(R 14 )S(O)2(R 14 ),-S(O)R 14 、-S(O)2R 14 、-S(O)2N(R 14 )2, -NO2, =S, =O and -CN. In some embodiments, A is selected from optionally substituted phenylene and optionally substituted 6-membered heteroarylene, wherein the optional substituents are independently selected from: halogen, -OR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 , -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 , -NO2 and -CN.

[0266] In some embodiments, for a compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), Selected from:

[0267] In some embodiments, for a compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), Selected from:

[0268] In some embodiments, for a compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), The optionally substituted 3- to 10-membered heterocyclylene is selected from the group consisting of an optionally substituted 3-membered heterocyclylene, an optionally substituted 4-membered heterocyclylene, an optionally substituted 5-membered heterocyclylene, an optionally substituted 6-membered heterocyclylene, an optionally substituted 7-membered heterocyclylene, an optionally substituted 8-membered heterocyclylene, an optionally substituted 9-membered heterocyclylene, and an optionally substituted 10-membered heterocyclylene. In some embodiments, is selected from the group consisting of an optionally substituted 3- to 4-membered heterocyclylene, an optionally substituted 3- to 5-membered heterocyclylene, an optionally substituted 3- to 6-membered heterocyclylene, an optionally substituted 3- to 7-membered heterocyclylene, an optionally substituted 3- to 8-membered heterocyclylene, and an optionally substituted 3- to 9-membered heterocyclylene. In some embodiments, is an optionally substituted 3- to 7-membered heterocyclylene. In some embodiments, is an optionally substituted 4- to 7-membered heterocyclylene. In some embodiments, is an optionally substituted 5- to 7-membered heterocyclylene group.

[0269] In some embodiments, for a compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), is selected from 4- to 7-membered heterocyclylene optionally substituted by one or more substituents independently selected from halogen, -OR 13 、-SR 13 、-N(R 13 )2、-C(O)R 13 、-C(O)OR 13 、-OC(O)R 13 、-OC(O)N(R 13 )2、-C(O)N(R 13 )2、-N(R 13 )C(O)R 13 、-N(R 13 )C(O)OR 13 、-N(R 13 )C(O)N(R 13 )2、-N(R 13 )S(O)2(R 13 ),-S(O)R 13 、-S(O)2R 13 、-S(O)2N(R 13 )2, -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 13 、-SR 13 、-N(R 13 )2、-C(O)R 13 、-C(O)OR 13 、-OC(O)R 13 、-OC(O)N(R 13 )2、-C(O)N(R 13 )2、-N(R 13 )C(O)R 13 、-N(R 13 )C(O)OR 13 、-N(R 13 )C(O)N(R 13 )2、-N(R 13 )S(O)2(R 13 ),-S(O)R 13、-S(O)2R 13 、-S(O)2N(R 13 )2, -NO2, =S, =O and -CN; and R 13 Selected from hydrogen, C 1-3 Alkyl and C 1-3 In some embodiments, is selected from 4- to 7-membered heterocyclylene optionally substituted by one or more substituents independently selected from halogen, -OR 13 、-N(R 13 )2、-C(O)R 13 、-C(O)OR 13 , -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 13 、-N(R 13 )2、-C(O)R 13 、-C(O)OR 13 , -NO2 and -CN; and R 13 Selected from hydrogen, C 1-3 Alkyl and C 1-3 Halogenated alkyl.

[0270] In some embodiments, for a compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), is selected from 4- to 7-membered heterocyclylene groups, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 13 、-N(R 13 )2、-C(O)R 13 、-C(O)OR 13 、-C(O)N(R 13 )2, -NO2, -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 13 、-N(R 13 )2、-C(O)R 13 、-C(O)OR 13 、-C(O)N(R 13 )2, -NO2, =S, =O and -CN; and R 13 Selected from hydrogen, C 1-3 Alkyl and C 1-3 Halogenated alkyl.

[0271] In some embodiments, for a compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), is selected from a 5- to 6-membered saturated heterocyclylene group optionally substituted by one or more substituents independently selected from halogen, -OR 13 、-SR 13 、-N(R 13 )2、-C(O)R 13 、-C(O)OR 13 、-OC(O)R 13 、-OC(O)N(R 13 )2、-C(O)N(R 13 )2、-N(R 13 )C(O)R 13 、-N(R 13 )C(O)OR 13 、-N(R 13 )C(O)N(R 13 )2、-N(R 13 )S(O)2(R 13 ),-S(O)R 13 、-S(O)2R 13 、-S(O)2N(R 13 )2, -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 13 、-SR 13 、-N(R 13 )2、-C(O)R 13 、-C(O)OR 13 、-OC(O)R 13 、-OC(O)N(R 13 )2、-C(O)N(R 13 )2、-N(R 13 )C(O)R 13 、-N(R 13 )C(O)OR 13 、-N(R 13 )C(O)N(R 13 )2、-N(R 13 )S(O)2(R 13 ),-S(O)R 13 、-S(O)2R 13 、-S(O)2N(R 13 )2, -NO2, =S, =O and -CN; and R 13 Selected from hydrogen, C 1-3 Alkyl and C 1-3 In some embodiments, is selected from a 5- to 6-membered saturated heterocyclylene group optionally substituted by one or more substituents independently selected from halogen, -OR 13 、-N(R 13 )2、-C(O)R 13 、-C(O)OR 13 , -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 13 、-N(R 13 )2、-C(O)R 13 、-C(O)OR 13 , -NO2 and -CN; and R 13 Selected from hydrogen, C 1-3 Alkyl and C 1-3 Halogenated alkyl.

[0272] In some embodiments, for a compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), is selected from a 5- to 6-membered saturated heterocyclylene group optionally substituted by one or more substituents independently selected from halogen, -OR 13 、-N(R 13 )2、-C(O)R 13 、-C(O)OR 13 、-C(O)N(R 13 )2, -NO2, -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 13 、-N(R 13 )2、-C(O)R 13 、-C(O)OR 13 、-C(O)N(R 13 )2, -NO2, =S, =O and -CN; and R 13 Selected from hydrogen, C 1-3 Alkyl and C 1-3 Halogenated alkyl.

[0273] In some embodiments, for a compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), selected from pyrrolidinylene, piperidinylene and piperazinylene, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 13 、-SR 13 、-N(R 13 )2、-C(O)R 13 、-C(O)OR 13 、-OC(O)R13 、-OC(O)N(R 13 )2、-C(O)N(R 13 )2、-N(R 13 )C(O)R 13 、-N(R 13 )C(O)OR 13 、-N(R 13 )C(O)N(R 13 )2、-N(R 13 )S(O)2(R 13 ),-S(O)R 13 、-S(O)2R 13 、-S(O)2N(R 13 )2, -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 13 、-SR 13 、-N(R 13 )2、-C(O)R 13 、-C(O)OR 13 、-OC(O)R 13 、-OC(O)N(R 13 )2、-C(O)N(R 13 )2、-N(R 13 )C(O)R 13 、-N(R 13 )C(O)OR 13 、-N(R 13 )C(O)N(R 13 )2、-N(R 13 )S(O)2(R 13 ),-S(O)R 13 、-S(O)2R 13 、-S(O)2N(R 13 )2, -NO2, =S, =O and -CN; and R 13 Selected from hydrogen, C 1-3 Alkyl and C 1-3 In some embodiments, selected from piperidinylene and piperazinylene, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 13 、-N(R 13 )2、-C(O)R 13 、-C(O)OR 13 , -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR13 、-N(R 13 )2、-C(O)R 13 、-C(O)OR 13 , -NO2 and -CN; and R 13 Selected from hydrogen, C 1-3 Alkyl and C 1-3 Halogenated alkyl.

[0274] In some embodiments, for a compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), selected from piperidinylene and piperazinylene, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 13 、-SR 13 、-N(R 13 )2、-C(O)R 13 、-C(O)OR 13 、-OC(O)R 13 、-OC(O)N(R 13 )2、-C(O)N(R 13 )2、-N(R 13 )C(O)R 13 、-N(R 13 )C(O)OR 13 、-N(R 13 )C(O)N(R 13 )2、-N(R 13 )S(O)2(R 13 ),-S(O)R 13 、-S(O)2R 13 、-S(O)2N(R 13 )2, -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 13 、-SR 13 、-N(R 13 )2、-C(O)R 13 、-C(O)OR 13 、-OC(O)R 13 、-OC(O)N(R 13 )2、-C(O)N(R 13 )2、-N(R 13 )C(O)R 13 、-N(R 13 )C(O)OR 13 、-N(R 13 )C(O)N(R 13 )2、-N(R 13)S(O)2(R 13 ),-S(O)R 13 、-S(O)2R 13 、-S(O)2N(R 13 )2, -NO2, =S, =O and -CN; and R 13 Selected from hydrogen, C 1-3 Alkyl and C 1-3 In some embodiments, selected from piperidinylene and piperazinylene, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 13 、-N(R 13 )2、-C(O)R 13 、-C(O)OR 13 , -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 13 、-N(R 13 )2、-C(O)R 13 、-C(O)OR 13 , -NO2 and -CN; and R 13 Selected from hydrogen, C 1-3 Alkyl and C 1-3 Halogenated alkyl.

[0275] In some embodiments, for a compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), selected from piperidinylene and piperazinylene, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 13 、-SR 13 、-N(R 13 )2、-C(O)R 13 、-C(O)OR 13 、-OC(O)R 13 、-OC(O)N(R 13 )2、-C(O)N(R 13 )2、-N(R 13 )C(O)R 13 、-N(R 13 )C(O)OR 13 、-N(R 13 )C(O)N(R 13 )2、-N(R 13 )S(O)2(R 13 ),-S(O)R 13 、-S(O)2R 13 、-S(O)2N(R13 )2, -NO2 and -CN; and R 13 Selected from hydrogen, C 1-3 Alkyl and C 1-3 In some embodiments, selected from piperidinylene and piperazinylene, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 13 、-N(R 13 )2、-C(O)R 13 、-C(O)OR 13 , -NO2 and -CN; and R 13 Selected from hydrogen, C 1-3 Alkyl and C 1-3 Halogenated alkyl.

[0276] In some embodiments, for a compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), is unsubstituted. In some embodiments, yes In some embodiments, yes

[0277] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 3 Selected from: halogen, -OR 12 、-SR 12 、-N(R 12 )2、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )2、-C(O)N(R 12 )2、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )2、-N(R 12 )S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 、-S(O)2N(R 12 )2, -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-3 Alkyl: halogen, -OR 12 、-SR12 、-N(R 12 )2、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )2、-C(O)N(R 12 )2、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )2、-N(R 12 )S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 、-S(O)2N(R 12 )2, -NO2, =S, =O and -CN. In some embodiments, R 3 Selected from halogen, -OR 12 、-SR 12 、-N(R 12 )2、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )2、-C(O)N(R 12 )2、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )2、-N(R 12 )S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 、-S(O)2N(R 12 )2, -NO2 and -CN. In some embodiments, R 3 Selected from halogen, -OR 12 、-N(R 12 )2、-C(O)R 12 、-C(O)OR 12 , -NO2 and -CN. In some embodiments, R 3 is selected from C optionally substituted by one or more substituents independently selected from 1-3 Alkyl: halogen, -OR 12、-SR 12 、-N(R 12 )2、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )2、-C(O)N(R 12 )2、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )2、-N(R 12 )S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 、-S(O)2N(R 12 )2, -NO2, =S, =O and -CN. In some embodiments, R 3 is selected from C optionally substituted by one or more substituents independently selected from 1-3 Alkyl: halogen, -OR 12 、-N(R 12 )2、-C(O)R 12 、-C(O)OR 12 , -NO2 and -CN. In some embodiments, R 3 Selected from halogen, -OR 12 、-N(R 12 )2、-C(O)R 12 、-C(O)OR 12 、-NO2、-CN、C 1-3 Alkyl and C 1-3 haloalkyl; and R 12 Selected from hydrogen, C 1-3 Alkyl and C 1-3 Halogenated alkyl.

[0278] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 10 In some embodiments, R 10 is selected from C optionally substituted by one or more substituents independently selected from 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein each C3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 10 is selected from C optionally substituted by one or more substituents independently selected from 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 10 is selected from C optionally substituted by one or more substituents independently selected from 1-6 Alkyl: C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN.

[0279] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 11 In some embodiments, R 11 is selected from C optionally substituted by one or more substituents independently selected from 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 11 is selected from C optionally substituted by one or more substituents independently selected from 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 11 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: C 3-10Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN.

[0280] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 12 In some embodiments, R 12 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 12 is selected from C optionally substituted by one or more substituents independently selected from 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 12 is selected from C optionally substituted by one or more substituents independently selected from 1-6 Alkyl: C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN.

[0281] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 13 In some embodiments, R 13 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 13 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 13 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN.

[0282] In some embodiments, for the compound or salt of Formula (I), (Ia), (Ib), (Ic), or (Id), R 14 In some embodiments, R 14 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 14 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 14 is selected from C optionally substituted with one or more substituents independently selected from 1-6Alkyl: C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN.

[0283] In some embodiments, the compound of formula (I) is:

[0284]

[0285] or a salt of any one thereof.

[0286] In some embodiments, the compound of formula (I) is:

[0287] or a salt of any one thereof.

[0288] A compound of formula (II).

[0289] In some aspects, the present disclosure provides a compound represented by the structure of Formula (II):

[0290]

[0291] or a pharmaceutically acceptable salt thereof, wherein:

[0292] X 1 Selected from N and C(R 8 );

[0293] R 4 is independently selected at each occurrence from (a), (b), and (c):

[0294] (a) Halogen, -OR 20 、-SR 20 、-N(R 20 )2、-C(O)R 20 、-C(O)OR 20 、-OC(O)R 20 、-OC(O)N(R 20 )2、-C(O)N(R 20 )2、-N(R 20 )C(O)R 20 、-N(R 20 )C(O)OR 20 、-N(R20 )C(O)N(R 20 )2、-N(R 20 )S(O)2(R 20 ),-S(O)R 20 、-S(O)2R 20 、-S(O)2N(R 20 )2, -NO2 and -CN;

[0295] (b) C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 20 、-SR 20 、-N(R 20 )2、-C(O)R 20 、-C(O)OR 20 、-OC(O)R 20 、-OC(O)N(R 20 )2、-C(O)N(R 20 )2、-N(R 20 )C(O)R 20 、-N(R 20 )C(O)OR 20 、-N(R 20 )C(O)N(R 20 )2、-N(R 20 )S(O)2(R 20 ),-S(O)R 20 、-S(O)2R 20 、-S(O)2N(R 20 )2, -NO2, =S, =O and -CN; and

[0296] (c)C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 20 、-SR 20 、-N(R 20 )2、-C(O)R 20 、-C(O)OR 20 、-OC(O)R 20 、-OC(O)N(R 20 )2、-C(O)N(R 20 )2、-N(R 20 )C(O)R 20 、-N(R 20 )C(O)OR 20 、-N(R 20 )C(O)N(R 20 )2、-N(R20 )S(O)2(R 20 ),-S(O)R 20 、-S(O)2R 20 、-S(O)2N(R 20 )2, -NO2, =S, =O and -CN;

[0297] R 5 is C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 21 、-SR 21 、-N(R 21 )2、-C(O)R 21 、-C(O)OR 21 、-OC(O)R 21 、-OC(O)N(R 21 )2、-C(O)N(R 21 )2、-N(R 21 )C(O)R 21 、-N(R 21 )C(O)OR 21 、-N(R 21 )C(O)N(R 21 )2、-N(R 21 )S(O)2(R 21 ),-S(O)R 21 、-S(O)2R 21 、-S(O)2N(R 21 )2, -NO2, =S, =O and -CN;

[0298] R 6 independently selected at each occurrence from:

[0299] Halogen, -OR 22 、-SR 22 、-N(R 22 )2、-C(O)R 22 、-C(O)OR 22 、-OC(O)R 22 、-OC(O)N(R 22 )2、-C(O)N(R 22 )2、-N(R 22 )C(O)R 22 、-N(R 22 )C(O)OR 22 、-N(R 22 )C(O)N(R 22 )2、-N(R 22 )S(O)2(R 22),-S(O)R 22 、-S(O)2R 22 、-S(O)2N(R 21 )2, -NO2, =S, =O and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: Halogen -OR 22 、-SR 22 、-N(R 22 )2、-C(O)R 22 、-C(O)OR 22 、-OC(O)R 22 、-OC(O)N(R 22 )2、-C(O)N(R 22 )2、-N(R 22 )C(O)R 22 、-N(R 22 )C(O)OR 22 、-N(R 22 )C(O)N(R 22 )2、-N(R 22 )S(O)2(R 22 ),-S(O)R 22 、-S(O)2R 22 、-S(O)2N(R 21 )2, -NO2, =S, =O and -CN;

[0300] Ring B is selected from C 3-10 Carbocyclylene and 3- to 10-membered heterocyclylene;

[0301] R 7 independently selected at each occurrence from:

[0302] Hydrogen, halogen, -OR 23 、-SR 23 、-N(R 23 )2、-C(O)R 23 、-OC(O)R 23 、-OC(O)N(R 23 )2、-C(O)N(R 23 )2、-N(R 23 )C(O)R 23 、-N(R 23 )C(O)OR 23 、-N(R 23 )C(O)N(R 23 )2、-N(R 12 )S(O)2(R 23 ),-S(O)R 23 、-S(O)2R23 、-S(O)2N(R 23 )2, -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 23 、-SR 23 、-N(R 23 )2、-C(O)R 23 、-C(O)OR 23 、-OC(O)R 23 、-OC(O)N(R 23 )2、-C(O)N(R 23 )2、-N(R 23 )C(O)R 23 、-N(R 23 )C(O)OR 23 、-N(R 23 )C(O)N(R 23 )2、-N(R 23 )S(O)2(R 23 ),-S(O)R 23 、-S(O)2R 23 、-S(O)2N(R 23 )2, -NO2, =S, =O and -CN;

[0303] R 8 、R 20 、R 21 、R 22 and R 23 is independently selected at each occurrence from (d), (e) and (f):

[0304] (d) hydrogen;

[0305] (e) C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, and -CN; and

[0306] (f) C optionally substituted with one or more substituents independently selected from the following 3-10Carbocyclic rings and 3- to 10-membered heterocyclic rings: halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN;

[0307] x is selected from 0, 1, 2, 3 and 4;

[0308] y is selected from 0, 1, 2, 3 and 4;

[0309] z is selected from 0, 1, 2, 3, 4, and 5; and

[0310] At least one of x or y is selected from 1, 2, 3 and 4.

[0311] In some embodiments, for the compound or salt of Formula (II), x is selected from 0, 1, 2, and 3. In some embodiments, x is selected from 0, 1, and 2. In some embodiments, x is selected from 1 and 2. In some embodiments, x is selected from 0 and 1. In some embodiments, x is 4. In some embodiments, x is 3. In some embodiments, x is 2. In some embodiments, x is 1. In some embodiments, x is 0.

[0312] In some embodiments, Formula (I) is represented by a structure selected from Formula (II-a), (II-b), (II-c), (II-d), and (II-e):

[0313]

[0314] In some embodiments, the compounds or salts of the present disclosure are represented by Formula (II-a) or a pharmaceutically acceptable salt thereof: where R 5 、R 6 、R 7 、X 1 , Ring B, y and z are as defined in formula (II).

[0315] In some embodiments, the compounds or salts of the present disclosure are represented by Formula (II-b) or a pharmaceutically acceptable salt thereof: where R 4 、R 5 、R 6 、R 7 、X 1 , Ring B, y and z are as defined in formula (II).

[0316] In some embodiments, the compounds or salts of the present disclosure are represented by Formula (II-c) or a pharmaceutically acceptable salt thereof: where R 4、R 5 、R 6 、R 7 、X 1 , Ring B, y and z are as defined in formula (II).

[0317] In some embodiments, the compounds or salts of the present disclosure are represented by Formula (II-d) or a pharmaceutically acceptable salt thereof: where R 4 、R 5 、R 6 、R 7 、X 1 , Ring B, y and z are as defined in formula (II).

[0318] In some embodiments, the compounds or salts of the present disclosure are represented by Formula (II-e) or a pharmaceutically acceptable salt thereof: where R 4 、R 5 、R 6 、R 7 、X 1 , Ring B, y and z are as defined in formula (II).

[0319] In some embodiments, the structure of Formula (II) is represented by the structure of Formula (II-a) or (II-b):

[0320]

[0321] In some embodiments, for a compound or salt of Formula (II), (II-b), (II-c), (II-d), or (II-e), R 4 Selected from halogen, -OR 20 、-SR 20 、-N(R 20 )2、-C(O)R 20 、-C(O)OR 20 、-OC(O)R 20 、-OC(O)N(R 20 )2、-C(O)N(R 20 )2、-N(R 20 )C(O)R 20 、-N(R 20 )C(O)OR 20 、-N(R 20 )C(O)N(R 20 )2、-N(R 20 )S(O)2(R 20 ),-S(O)R 20 、-S(O)2R20 、-S(O)2N(R 20 )2, -NO2 and -CN. In some embodiments, R 4 Selected from halogen, -OR 20 、-N(R 20 )2、-C(O)R 20 、-C(O)OR 20 , -NO2 and -CN.

[0322] In some embodiments, for a compound or salt of Formula (II), (II-b), (II-c), (II-d), or (II-e), R 4 is C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 20 、-SR 20 、-N(R 20 )2、-C(O)R 20 、-C(O)OR 20 、-OC(O)R 20 、-OC(O)N(R 20 )2、-C(O)N(R 20 )2、-N(R 20 )C(O)R 20 、-N(R 20 )C(O)OR 20 、-N(R 20 )C(O)N(R 20 )2、-N(R 20 )S(O)2(R 20 ),-S(O)R 20 、-S(O)2R 20 、-S(O)2N(R 20 )2, -NO2, =S, =O and -CN. In some embodiments, R 4 is C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 20 、-N(R 20 )2、-C(O)R 20 、-C(O)OR 20 , -NO2 and -CN.

[0323] In some embodiments, for a compound or salt of Formula (II), (II-b), (II-c), (II-d), or (II-e), R 4 Selected from C 3-10Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 20 、-SR 20 、-N(R 20 )2、-C(O)R 20 、-C(O)OR 20 、-OC(O)R 20 、-OC(O)N(R 20 )2、-C(O)N(R 20 )2、-N(R 20 )C(O)R 20 、-N(R 20 )C(O)OR 20 、-N(R 20 )C(O)N(R 20 )2、-N(R 20 )S(O)2(R 20 ),-S(O)R 20 、-S(O)2R 20 、-S(O)2N(R 20 )2, -NO2, =S, =O and -CN. In some embodiments, R 4 Selected from C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 20 、-N(R 20 )2、-C(O)R 20 、-C(O)OR 20 , -NO2 and -CN.

[0324] In some embodiments, for a compound or salt of Formula (II), (II-b), (II-c), (II-d), or (II-e), R 4 Selected from: halogen, -OR 20 、-N(R 20 )2、-C(O)R 20 , -NO2 and -CN; C 1-3 Alkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, any of which are optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 20 、-N(R 20 )2、-C(O)R 20 , -NO2 and -CN; and each R 20 are independently selected from hydrogen, C 1-4 Alkyl and C 1-4 In some embodiments, R 4Selected from: halogen, -OR 20 、-N(R 20 )2 and -CN; C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, any of which are optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 20 and -N(R 20 )2; and each R 20 are independently selected hydrogen, C 1-4 Alkyl and C 1-4 Halogenated alkyl.

[0325] In some embodiments, for a compound or salt of Formula (II), (II-b), (II-c), (II-d), or (II-e), R 4 Selected from: halogen, -OR 20 、-N(R 20 )2、-C(O)R 20 , -NO2 and -CN; C 1-3 Alkyl, C 3-6 saturated carbocyclic ring and 3- to 6-membered saturated heterocyclic ring, any of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 20 、-N(R 20 )2、-C(O)R 20 , -NO2 and -CN; and each R 20 are independently selected from hydrogen, C 1-4 Alkyl and C 1-4 In some embodiments, R 4 Selected from: halogen, -OR 20 、-N(R 20 )2 and -CN; C 3-6 saturated carbocyclic ring and 3- to 6-membered saturated heterocyclic ring, any of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 20 and -N(R 20 )2; and each R 20 are independently selected hydrogen, C 1-4 Alkyl and C 1-4 Halogenated alkyl.

[0326] In some embodiments, for a compound or salt of Formula (II), (II-b), (II-c), (II-d), or (II-e), R 4 Selected from: halogen, -OR 20 、-N(R 20 )2 and -CN; C 3-4 carbocyclic and 4- to 5-membered heterocyclic rings; and each R 20 independently selected from hydrogen and C 1-4In some embodiments, R 4 Selected from: fluoro, bromo, -OC 1-6 Alkyl, -N(CH3)2, -CN,

[0327] In some embodiments, for a compound or salt of Formula (II), (II-b), (II-c), (II-d), or (II-e), R 4 Selected from: halogen, -OR 20 、-N(R 20 )2 and -CN; C 3-4 saturated carbocyclic ring and 4- to 5-membered saturated heterocyclic ring; and each R 20 independently selected from hydrogen and C 1-4 In some embodiments, R 4 Selected from: fluoro, chloro, bromo, -OC 1-6 Alkyl, -N(CH3)2, -CN, In some embodiments, R 4 Selected from: fluoro, bromo, -OC 1-6 Alkyl, -N(CH3)2, -CN, In some embodiments, R 4 In some embodiments, R 4 Selected from: OC 1-6 In some embodiments, R 4 Selected from:

[0328] In some embodiments, for the compound or salt of Formula (II), (II-a), (II-b), (II-c), (II-d), or (II-e), y is selected from 0, 1, 2, and 3. In some embodiments, x is selected from 0, 1, and 2. In some embodiments, y is selected from 1 and 2. In some embodiments, y is selected from 0 and 1. In some embodiments, y is 4. In some embodiments, y is 3. In some embodiments, y is 2. In some embodiments, y is 1. In some embodiments, y is 0.

[0329] In some embodiments, for the compound or salt of Formula (II), (II-a), (II-b), (II-c), (II-d), or (II-e), x is selected from 1, 2, 3, and 4; and y is selected from 0, 1, 2, 3, and 4. In some embodiments, x is selected from 2, 3, and 4; and y is selected from 0, 1, 2, 3, and 4. In some embodiments, x is selected from 3 and 4; and y is selected from 0, 1, 2, 3, and 4. In some embodiments, x is selected from 4; and y is selected from 0, 1, 2, 3, and 4. In some embodiments, x is selected from 3; and y is selected from 0, 1, 2, 3, and 4. In some embodiments, x is selected from 2; and y is selected from 0, 1, 2, 3, and 4. In some embodiments, x is selected from 1; and y is selected from 0, 1, 2, 3, and 4.

[0330] In some embodiments, for the compound or salt of Formula (II), (II-a), (II-b), (II-c), (II-d), or (II-e), y is selected from 1, 2, 3, and 4; and x is selected from 0, 1, 2, 3, and 4. In some embodiments, y is selected from 2, 3, and 4; and x is selected from 0, 1, 2, 3, and 4. In some embodiments, y is selected from 3 and 4; and x is selected from 0, 1, 2, 3, and 4. In some embodiments, y is selected from 4; and x is selected from 0, 1, 2, 3, and 4. In some embodiments, y is selected from 3; and x is selected from 0, 1, 2, 3, and 4. In some embodiments, y is selected from 2; and x is selected from 0, 1, 2, 3, and 4. In some embodiments, y is selected from 1; and x is selected from 0, 1, 2, 3, and 4.

[0331] In some embodiments, for a compound or salt of Formula (II), (II-a), (II-b), (II-c), (II-d), or (II-e), R 6 At each occurrence is selected from: halogen, -OR 22 、-SR 22 、-N(R 22 )2、-C(O)R 22 、-C(O)OR 22 、-OC(O)R 22 、-OC(O)N(R 22 )2、-C(O)N(R 22 )2、-N(R 22 )C(O)R 22 、-N(R 22 )C(O)OR 22 、-N(R 22 )C(O)N(R 22 )2、-N(R 22 )S(O)2(R 22 ),-S(O)R22 、-S(O)2R 22 、-S(O)2N(R 21 )2, -NO2, =S, =O and -CN. In some embodiments, R 6 At each occurrence is selected from: halogen, -OR 22 、-N(R 22 )2、-C(O)R 22 、-C(O)OR 22 , -NO2, =S, =O and -CN. In some embodiments, R 6 is selected at each occurrence from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 22 、-SR 22 、-N(R 22 )2、-C(O)R 22 、-C(O)OR 22 、-OC(O)R 22 、-OC(O)N(R 22 )2、-C(O)N(R 22 )2、-N(R 22 )C(O)R 22 、-N(R 22 )C(O)OR 22 、-N(R 22 )C(O)N(R 22 )2、-N(R 22 )S(O)2(R 22 ),-S(O)R 22 、-S(O)2R 22 、-S(O)2N(R 21 )2, -NO2, =S, =O and -CN. In some embodiments, R 6 is selected at each occurrence from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 22 、-N(R 22 )2、-C(O)R 22 、-C(O)OR 22 , -NO2, =S, =O and -CN.

[0332] In some embodiments, for a compound or salt of Formula (II), (II-a), (II-b), (II-c), (II-d), or (II-e), R 6 is C optionally substituted by one or more substituents independently selected from the following 1-3 Alkyl: halogen, -OR 22、-N(R 22 )2、-C(O)R 22 , -NO2 and -CN; and R 22 Selected from hydrogen and C 1-3 In some embodiments, R 6 is unsubstituted C 1-3 In some embodiments, R 6 is selected from the group consisting of methyl, ethyl, propyl and isopropyl. 6 Selected from methyl and ethyl.

[0333] In some embodiments, for a compound or salt of Formula (II), (II-a), (II-b), (II-c), (II-d), or (II-e), X 1 It's nitrogen.

[0334] In some embodiments, for a compound or salt of Formula (II), (II-a), (II-b), (II-c), (II-d), or (II-e), X 1 It is C(R 8 ); and R 8 Selected from: hydrogen, C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, X 1 It is C(R 8 ); and R 8 Selected from: hydrogen, C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2 and -CN.

[0335] In some embodiments, for compounds or salts of Formula (II), (II-a), (II-b), (II-c), (II-d), or (II-e), Ring B is selected from C 3-6 In some embodiments, ring B is selected from C 3-6In some embodiments, ring B is selected from phenylene and 3- to 9-membered heterocyclylene. In some embodiments, ring B is selected from phenylene and 6-membered heteroarylene. In some embodiments, ring B is selected from phenylene, pyridinylene, and benzoxazolylene. In some embodiments, ring B is phenylene. In some embodiments, ring B is selected from pyridinylene and benzoxazolylene.

[0336] In some embodiments, for compounds or salts of Formula (II), (II-a), (II-b), (II-c), (II-d), or (II-e), Ring B is selected from C 3-10 In some embodiments, the C of Ring B is 3-10 The carbocyclylene group is selected from the group consisting of C3 carbocyclylene, C4 carbocyclylene, C5 carbocyclylene, C6 carbocyclylene, C7 carbocyclylene, C8 carbocyclylene, C9 carbocyclylene and C 10 In some embodiments, the C of Ring B is 3-10 The carbocyclylene group is selected from: C 3-4 Carbocyclylene, C 3-5 Carbocyclylene, C 3-6 Carbocyclylene, C 3-7 Carbocyclylene, C 3-8 Carbocyclylene and C 3-9 Carbocyclylene.

[0337] In some embodiments, for compounds or salts of Formula (II), (II-a), (II-b), (II-c), (II-d), or (II-e), Ring B is selected from a 3- to 10-membered heterocyclylene group. In some embodiments, the 3- to 10-membered heterocyclylene group of Ring B is selected from a 3- to 4-membered heterocyclylene group, a 5-membered heterocyclylene group, a 6-membered heterocyclylene group, a 7-membered heterocyclylene group, an 8-membered heterocyclylene group, a 9-membered heterocyclylene group, and a 10-membered heterocyclylene group. In some embodiments, the 3- to 10-membered heterocyclylene group of Ring B is selected from a 3- to 4-membered heterocyclylene group, a 3- to 5-membered heterocyclylene group, a 3- to 6-membered heterocyclylene group, a 3- to 7-membered heterocyclylene group, a 3- to 8-membered heterocyclylene group, and a 3- to 9-membered heterocyclylene group. In some embodiments, the 3- to 10-membered heterocyclylene group of Ring B is a 7- to 10-membered bicyclic heterocyclylene group. In some embodiments, Ring B is phenyl or pyridinyl. In some embodiments, Ring B is phenyl. In some embodiments, Ring B is pyridinyl.

[0338] In some embodiments, for the compound or salt of Formula (II), (II-a), (II-b), (II-c), (II-d), or (II-e), Ring B is selected from: In some embodiments, Ring B is In some embodiments, Ring B is In some embodiments, Ring B is In some embodiments, Ring B is

[0339] In some embodiments, for the compound or salt of Formula (II), (II-a), (II-b), (II-c), (II-d), or (II-e), Ring B is selected from: In some embodiments, Ring B is In some embodiments, Ring B is In some embodiments, Ring B is In some embodiments, Ring B is In some embodiments, Ring B is In some embodiments, Ring B is In some embodiments, Ring B is In some embodiments, Ring B is In some embodiments, Ring B is In some embodiments, Ring B is In some embodiments, Ring B is In some embodiments, Ring B is In some embodiments, Ring B is In some embodiments, Ring B is In some embodiments, Ring B is In some embodiments, Ring B is In some embodiments, Ring B is

[0340] In some embodiments, for the compound or salt of Formula (II), (II-a), (II-b), (II-c), (II-d), or (II-e), z is selected from 0, 1, 2, and 3. In some embodiments, z is selected from 0, 1, and 2. In some embodiments, z is selected from 0 and 1. In some embodiments, z is selected from 1, 2, 3, and 4. In some embodiments, z is selected from 2, 3, and 4. In some embodiments, z is selected from 3 and 4. In some embodiments, z is selected from 1 and 2. In some embodiments, z is 1 or 2. In some embodiments, z is 0. In some embodiments, z is 1. In some embodiments, z is 2. In some embodiments, z is 3. In some embodiments, z is 4.

[0341] In some embodiments, for a compound or salt of Formula (II), (II-a), (II-b), (II-c), (II-d), or (II-e), R 7 Selected from: hydrogen, halogen, -OR23 、-SR 23 、-N(R 23 )2、-C(O)R 23 、-OC(O)R 23 、-OC(O)N(R 23 )2、-C(O)N(R 23 )2、-N(R 23 )C(O)R 23 、-N(R 23 )C(O)OR 23 、-N(R 23 )C(O)N(R 23 )2、-N(R 12 )S(O)2(R 23 ),-S(O)R 23 、-S(O)2R 23 、-S(O)2N(R 23 )2, -NO2 and -CN. In some embodiments, R 7 Selected from: hydrogen, halogen, -OR 23 、-N(R 23 )2、-C(O)R 23 , -NO2 and -CN. In some embodiments, R 7 is selected from C optionally substituted by one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 23 、-SR 23 、-N(R 23 )2、-C(O)R 23 、-C(O)OR 23 、-OC(O)R 23 、-OC(O)N(R 23 )2、-C(O)N(R 23 )2、-N(R 23 )C(O)R 23 、-N(R 23 )C(O)OR 23 、-N(R 23 )C(O)N(R 23 )2、-N(R 23 )S(O)2(R 23 ),-S(O)R 23 、-S(O)2R 23 、-S(O)2N(R 23 )2, -NO2, =S, =O and -CN. In some embodiments, R 7 is selected from C optionally substituted by one or more substituents independently selected from 1-6Alkyl: halogen, -OR 23 、-N(R 23 )2、-C(O)R 23 、-C(O)OR 23 , -NO2, =S, =O and -CN.

[0342] In some embodiments, for a compound or salt of Formula (II), (II-a), (II-b), (II-c), (II-d), or (II-e), R 7 Selected from: hydrogen, halogen, -OR 23 、-N(R 23 )2、-C(O)R 23 , -NO2, -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 23 、-N(R 23 )2、-C(O)R 23 、-C(O)OR 23 , -NO2, =S, =O and -CN. In some embodiments, R 7 Selected from halogen, -OR 23 、-N(R 23 )2、-C(O)R 23 , -NO2, -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 23 、-N(R 23 )2、-C(O)R 23 , -NO2 and -CN; and R 23 Selected from hydrogen and C 1-3 In some embodiments, R 7 Select from -OR 23 and C 1-3 Halogenated alkyl.

[0343] In some embodiments, for a compound or salt of Formula (II), (II-a), (II-b), (II-c), (II-d), or (II-e), R 20 In some embodiments, R 20 is selected from C optionally substituted by one or more substituents independently selected from 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein each C 3-10The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 20 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 20 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN.

[0344] In some embodiments, for a compound or salt of Formula (II), (II-a), (II-b), (II-c), (II-d), or (II-e), R 21 In some embodiments, R 21 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 21 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 21 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: C 3-10Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN.

[0345] In some embodiments, for a compound or salt of Formula (II), (II-a), (II-b), (II-c), (II-d), or (II-e), R 22 In some embodiments, R 22 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 22 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 22 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN.

[0346] In some embodiments, for a compound or salt of Formula (II), (II-a), (II-b), (II-c), (II-d), or (II-e), R 23 In some embodiments, R 23 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 23 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 23 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN.

[0347] In another aspect, the present disclosure provides a compound or salt represented by the structure of formula (II), wherein:

[0348] X 1 Selected from N;

[0349] R 4 is independently selected at each occurrence from (a) and (b):

[0350] (a) Halogen, -OR 20 、-SR 20 、-N(R 20 )2、-C(O)R 20 、-C(O)OR 20 、-OC(O)R 20 、-OC(O)N(R 20 )2、-C(O)N(R 20 )2、-N(R 20 )C(O)R 20 、-N(R 20 )C(O)OR 20 、-N(R 20 )C(O)N(R 20 )2、-N(R 20 )S(O)2(R 20 ),-S(O)R20 、-S(O)2R 20 、-S(O)2N(R 20 )2, -NO2 and -CN; and

[0351] (b) C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 20 、-SR 20 、-N(R 20 )2、-C(O)R 20 、-C(O)OR 20 、-OC(O)R 20 、-OC(O)N(R 20 )2、-C(O)N(R 20 )2、-N(R 20 )C(O)R 20 、-N(R 20 )C(O)OR 20 、-N(R 20 )C(O)N(R 20 )2、-N(R 20 )S(O)2(R 20 ),-S(O)R 20 、-S(O)2R 20 、-S(O)2N(R 20 )2, -NO2, =S, =O and -CN;

[0352] For example, R 4 It is a halogen;

[0353] R 5 It is C 1-6 Alkyl or C 1-6 Haloalkyl; for example, R 5 It is a methyl group;

[0354] Ring B is a 3- to 10-membered heterocyclylene group; for example, Ring B is a 6-membered heterocyclylene group;

[0355] R 7 independently selected at each occurrence from:

[0356] Hydrogen, halogen, -OR 23 、-SR 23 、-N(R 23 )2、-C(O)R 23 、-OC(O)R 23 、-OC(O)N(R 23 )2、-C(O)N(R 23 )2、-N(R 23 )C(O)R 23、-N(R 23 )C(O)OR 23 、-N(R 23 )C(O)N(R 23 )2、-N(R 12 )S(O)2(R 23 ),-S(O)R 23 、-S(O)2R 23 、-S(O)2N(R 23 )2, -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 23 、-SR 23 、-N(R 23 )2、-C(O)R 23 、-C(O)OR 23 、-OC(O)R 23 、-OC(O)N(R 23 )2、-C(O)N(R 23 )2、-N(R 23 )C(O)R 23 、-N(R 23 )C(O)OR 23 、-N(R 23 )C(O)N(R 23 )2、-N(R 23 )S(O)2(R 23 ),-S(O)R 23 、-S(O)2R 23 、-S(O)2N(R 23 )2, -NO2, =S, =O and -CN; for example, R 7 Yes-OR 23 ;

[0357] R 20 and R 23 is independently selected at each occurrence from (d), (e) and (f):

[0358] (d) hydrogen;

[0359] (e) C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein each C 3-10The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, and -CN; and

[0360] (f) C optionally substituted with one or more substituents independently selected from the following 3-10 Carbocyclic rings and 3- to 10-membered heterocyclic rings: halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN;

[0361] x is selected from 1 or 2;

[0362] y is 0; and

[0363] z is selected from 0, 1 and 2.

[0364] In some embodiments, the compound of formula (II) is:

[0365] or a salt of any one thereof.

[0366] In some embodiments, the compound of formula (II) is:

[0367]

[0368] or a salt of any one thereof.

[0369] A compound of formula (III).

[0370] In some aspects, the present disclosure provides a compound represented by the structure of formula (III):

[0371]

[0372] or a pharmaceutically acceptable salt thereof, wherein:

[0373] X 1 Selected from N and C(R 35 );

[0374] R 31 is independently selected at each occurrence from (I), (II) and (III):

[0375] (I) halogen, -OR40 、-SR 40 、-N(R 40 )2、-C(O)R 40 、-C(O)OR 40 、-OC(O)R 40 、-OC(O)N(R 40 )2、-C(O)N(R 40 )2、-N(R 40 )C(O)R 40 、-N(R 40 )C(O)OR 40 、-N(R 40 )C(O)N(R 40 )2、-N(R 40 )S(O)2(R 40 ),-S(O)R 40 、-S(O)2R 40 、-S(O)2N(R 40 )2, -NO2 and -CN;

[0376] (II) C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 40 、-SR 40 、-N(R 40 )2、-C(O)R 40 、-C(O)OR 40 、-OC(O)R 40 、-OC(O)N(R 40 )2、-C(O)N(R 40 )2、-N(R 40 )C(O)R 40 、-N(R 40 )C(O)OR 40 、-N(R 40 )C(O)N(R 40 )2、-N(R 40 )S(O)2(R 40 ),-S(O)R 40 、-S(O)2R 40 、-S(O)2N(R 40 )2, -NO2, =S, =O and -CN; and

[0377] (III)C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 40 、-SR 40 、-N(R40 )2、-C(O)R 40 、-C(O)OR 40 、-OC(O)R 40 、-OC(O)N(R 40 )2、-C(O)N(R 40 )2、-N(R 40 )C(O)R 40 、-N(R 40 )C(O)OR 40 、-N(R 40 )C(O)N(R 40 )2、-N(R 40 )S(O)2(R 40 ),-S(O)R 40 、-S(O)2R 40 、-S(O)2N(R 40 )2, -NO2, =S, =O and -CN;

[0378] R 32 independently selected at each occurrence from:

[0379] Halogen, -OR 41 、-SR 41 、-N(R 41 )2、-C(O)R 41 、-C(O)OR 41 、-OC(O)R 41 、-OC(O)N(R 41 )2、-C(O)N(R 41 )2、-N(R 41 )C(O)R 41 、-N(R 41 )C(O)OR 41 、-N(R 41 )C(O)N(R 41 )2、-N(R 41 )S(O)2(R 41 ),-S(O)R 41 、-S(O)2R 41 、-S(O)2N(R 41 )2, -NO2, =S, =O and -CN; and

[0380] C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 41 、-SR 41 、-N(R 41 )2、-C(O)R 41 、-C(O)OR41 、-OC(O)R 41 、-OC(O)N(R 41 )2、-C(O)N(R 41 )2、-N(R 41 )C(O)R 41 、-N(R 41 )C(O)OR 41 、-N(R 41 )C(O)N(R 41 )2、-N(R 41 )S(O)2(R 41 ),-S(O)R 41 、-S(O)2R 41 、-S(O)2N(R 41 )2, -NO2, =S, =O and -CN; and

[0381] R 33 independently selected at each occurrence from:

[0382] Halogen, -OR 42 、-SR 42 、-N(R 42 )2、-C(O)OR 42 、-OC(O)R 42 、-OC(O)N(R 42 )2、-C(O)N(R 42 )2、-N(R 42 )C(O)R 42 、-N(R 42 )C(O)OR 42 、-N(R 42 )C(O)N(R 42 )2、-N(R 42 )S(O)2(R 42 ),-S(O)R 42 、-S(O)2R 42 and -S(O)2N(R 42 )2; and

[0383] C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 42 、-SR 42 、-N(R 42 )2、-C(O)R 42 、-C(O)OR 42 、-OC(O)R 42 、-OC(O)N(R 42 )2、-C(O)N(R 42)2、-N(R 42 )C(O)R 42 、-N(R 42 )C(O)OR 42 、-N(R 42 )C(O)N(R 42 )2、-N(R 42 )S(O)2(R 42 ),-S(O)R 42 、-S(O)2R 42 、-S(O)2N(R 42 )2, -NO2, =S and -CN;

[0384] When an R 33 is methyl, each additional R 33 Independently selected from (IV), (V) and (VI):

[0385] (IV) Halogen, -OR 42 、-SR 42 、-N(R 42 )2、-C(O)R 42 、-C(O)OR 42 、-OC(O)R 42 、-OC(O)N(R 42 )2、-C(O)N(R 42 )2、-N(R 42 )C(O)R 42 、-N(R 42 )C(O)OR 42 、-N(R 42 )C(O)N(R 42 )2、-N(R 42 )S(O)2(R 42 ),-S(O)R 42 、-S(O)2R 42 、-S(O)2N(R 42 )2, -NO2 and -CN;

[0386] (V) C1 alkyl substituted by one or more substituents independently selected from the group consisting of halogen, -OR 42 、-SR 42 、-N(R 42 )2、-C(O)R 42 、-C(O)OR 42 、-OC(O)R 42 、-OC(O)N(R 42 )2、-C(O)N(R 42 )2、-N(R 42 )C(O)R42 、-N(R 42 )C(O)OR 42 、-N(R 42 )C(O)N(R 42 )2、-N(R 42 )S(O)2(R 42 ),-S(O)R 42 、-S(O)2R 42 、-S(O)2N(R 42 )2, -NO2, =S, =O and -CN; and

[0387] (VI) C optionally substituted by one or more substituents independently selected from the following 2-6 Alkyl: halogen, -OR 42 、-SR 42 、-N(R 42 )2、-C(O)R 42 、-C(O)OR 42 、-OC(O)R 42 、-OC(O)N(R 42 )2、-C(O)N(R 42 )2、-N(R 42 )C(O)R 42 、-N(R 42 )C(O)OR 42 、-N(R 42 )C(O)N(R 42 )2、-N(R 42 )S(O)2(R 42 ),-S(O)R 42 、-S(O)2R 42 、-S(O)2N(R 42 )2, -NO2, =S, =O and -CN; or

[0388] Two R on adjacent atoms 33 Can form C together 3-8 a carbocyclic ring or a 3- to 8-membered heterocyclic ring, each of which is optionally substituted with one or more substituents independently selected from the following:

[0389] Halogen, -OR 42 、-SR 42 、-N(R 42 )2、-C(O)R 42 、-C(O)OR 42 、-OC(O)R 42 、-OC(O)N(R 42 )2、-C(O)N(R 42 )2、-N(R42 )C(O)R 42 、-N(R 42 )C(O)OR 42 、-N(R 42 )C(O)N(R 42 )2、-N(R 42 )S(O)2(R 42 ),-S(O)R 42 、-S(O)2R 42 、-S(O)2N(R 42 )2, -NO2, =O and -CN; and

[0390] C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 42 、-SR 42 、-N(R 42 )2、-C(O)R 42 、-C(O)OR 42 、-OC(O)R 42 、-OC(O)N(R 42 )2、-C(O)N(R 42 )2、-N(R 42 )C(O)R 42 、-N(R 42 )C(O)OR 42 、-N(R 42 )C(O)N(R 42 )2、-N(R 42 )S(O)2(R 42 ),-S(O)R 42 、-S(O)2R 42 、-S(O)2N(R 42 )2, -NO2, =S, =O and -CN;

[0391] R 34 Selected from C 1-6 Alkyl and C 2-6 alkenyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 43 、-SR 43 、-N(R 43 )2、-C(O)R 43 、-C(O)OR 43 、-OC(O)R 43 、-OC(O)N(R 43 )2、-C(O)N(R 43 )2、-N(R 43 )C(O)R43 、-N(R 43 )C(O)OR 43 、-N(R 43 )C(O)N(R 43 )2、-N(R 43 )S(O)2(R 43 ),-S(O)R 43 、-S(O)2R 43 、-S(O)2N(R 43 )2, -NO2, =S, =O and -CN;

[0392] Ring B is selected from C 3-6 Carbocyclylene and 4- to 6-membered heterocyclylene;

[0393] R 35 、R 40 、R 41 、R 42 and R 43 is independently selected at each occurrence from (VII), (VIII) and (IX):

[0394] (VII) hydrogen;

[0395] (VII) C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, and -CN; and

[0396] (IX) C optionally substituted by one or more substituents independently selected from the following 3-10 Carbocyclic rings and 3- to 10-membered heterocyclic rings: halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN;

[0397] x is selected from 0, 1, 2, 3 and 4;

[0398] y is selected from the group consisting of 0, 1, 2, 3, and 4; and

[0399] z is selected from 2, 3, 4 and 5.

[0400] In some embodiments, for the compound or salt of formula (III), X 1 It is C(R 35 In some embodiments, C(R 35 ) of R 35 is selected from hydrogen; and C optionally substituted by one or more substituents independently selected from 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, C(R 35 ) of R 35 is C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, C(R 35 ) of R 35 is selected from hydrogen, methyl, ethyl, propyl and isopropyl. In some embodiments, C(R 35 ) of R 35 is selected from the group consisting of methyl, ethyl, propyl and isopropyl. 35 ) of R 35 It's hydrogen.

[0401] In some embodiments, for the compound or salt of formula (III), R 35 In some embodiments, R 35 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R35 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 35 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN.

[0402] In some embodiments, for the compound or salt of formula (III), X 1 It's N.

[0403] In some embodiments, for the compound or salt of Formula (III), y is selected from 0, 1, 2, and 3. In some embodiments, y is selected from 0, 1, and 2. In some embodiments, y is selected from 0 and 1. In some embodiments, y is selected from 1, 2, 3, and 4. In some embodiments, y is selected from 2, 3, and 4. In some embodiments, y is selected from 3 and 4. In some embodiments, y is selected from 1 and 2. In some embodiments, y is 1 or 2. In some embodiments, y is 0. In some embodiments, y is 1. In some embodiments, y is 2. In some embodiments, y is 3. In some embodiments, y is 4.

[0404] In some embodiments, for the compound or salt of Formula (III), each R 32 Selected from halogen, -OR 41 、-SR 41 、-N(R 41 )2、-C(O)R 41 、-C(O)OR 41 、-OC(O)R 41 、-OC(O)N(R 41 )2、-C(O)N(R 41 )2、-N(R 41 )C(O)R 41 、-N(R 41 )C(O)OR 41 、-N(R 41 )C(O)N(R 41 )2、-N(R 41 )S(O)2(R 41),-S(O)R 41 、-S(O)2R 41 、-S(O)2N(R 41 )2, -NO2, =S, =O and -CN. In some embodiments, each R 32 Selected from halogen, -OR 41 、-N(R 41 )2、-C(O)R 41 、-C(O)OR 41 , -NO2, =S, =O and -CN.

[0405] In some embodiments, for the compound or salt of Formula (III), each R 32 is selected from C optionally substituted by one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 41 、-SR 41 、-N(R 41 )2、-C(O)R 41 、-C(O)OR 41 、-OC(O)R 41 、-OC(O)N(R 41 )2、-C(O)N(R 41 )2、-N(R 41 )C(O)R 41 、-N(R 41 )C(O)OR 41 、-N(R 41 )C(O)N(R 41 )2、-N(R 41 )S(O)2(R 41 ),-S(O)R 41 、-S(O)2R 41 、-S(O)2N(R 41 )2, -NO2, =S, =O and -CN. In some embodiments, each R 32 is selected from C optionally substituted by one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 41 、、-N(R 41 )2、-C(O)R 41 、-C(O)OR 41 , -NO2, =S, =O and -CN. In some embodiments, each R 32 is selected from C optionally substituted by one or more substituents independently selected from 1-3 Alkyl: halogen, -OR 41 、-N(R 41 )2、-C(O)R41 、-C(O)OR 41 , -NO2, =S, =O and -CN.

[0406] In some embodiments, for the compound or salt of Formula (III), x is selected from 0, 1, 2, and 3. In some embodiments, x is selected from 0, 1, and 2. In some embodiments, x is selected from 0 and 1. In some embodiments, x is selected from 1, 2, 3, and 4. In some embodiments, x is selected from 2, 3, and 4. In some embodiments, x is selected from 3 and 4. In some embodiments, x is selected from 1 and 2. In some embodiments, x is 1 or 2. In some embodiments, x is 0. In some embodiments, x is 1. In some embodiments, x is 2. In some embodiments, x is 3. In some embodiments, x is 4.

[0407] In some embodiments, for the compound or salt of formula (III), for the compound or salt of formula (III), each R 31 Selected from halogen, -OR 40 、-SR 40 、-N(R 40 )2、-C(O)R 40 、-C(O)OR 40 、-OC(O)R 40 、-OC(O)N(R 40 )2、-C(O)N(R 40 )2、-N(R 40 )C(O)R 40 、-N(R 40 )C(O)OR 40 、-N(R 40 )C(O)N(R 40 )2、-N(R 40 )S(O)2(R 40 ),-S(O)R 40 、-S(O)2R 40 、-S(O)2N(R 40 )2, -NO2 and -CN. In some embodiments, each R 31 Selected from halogen, -OR 40 、-N(R 40 )2、-C(O)R 40 、-C(O)OR 40 , -NO2 and -CN.

[0408] In some embodiments, for the compound or salt of Formula (III), each R 31 is selected from C optionally substituted by one or more substituents independently selected from 1-6Alkyl: halogen, -OR 40 、-SR 40 、-N(R 40 )2、-C(O)R 40 、-C(O)OR 40 、-OC(O)R 40 、-OC(O)N(R 40 )2、-C(O)N(R 40 )2、-N(R 40 )C(O)R 40 、-N(R 40 )C(O)OR 40 、-N(R 40 )C(O)N(R 40 )2、-N(R 40 )S(O)2(R 40 ),-S(O)R 40 、-S(O)2R 40 、-S(O)2N(R 40 )2, -NO2, =S, =O and -CN. In some embodiments, each R 31 is selected from C optionally substituted by one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 40 、-N(R 40 )2、-C(O)R 40 、-C(O)OR 40 , -NO2, =S, =O and -CN. In some embodiments, each R 31 is selected from C optionally substituted by one or more substituents independently selected from 1-3 Alkyl: halogen, -OR 40 、-N(R 40 )2、-C(O)R 40 、-C(O)OR 40 , -NO2, =S, =O and -CN.

[0409] In some embodiments, for the compound or salt of Formula (III), each R 31 Selected from C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 40 、-SR 40 、-N(R 40 )2、-C(O)R 40 、-C(O)OR 40 、-OC(O)R 40 、-OC(O)N(R 40)2、-C(O)N(R 40 )2、-N(R 40 )C(O)R 40 、-N(R 40 )C(O)OR 40 、-N(R 40 )C(O)N(R 40 )2、-N(R 40 )S(O)2(R 40 ),-S(O)R 40 、-S(O)2R 40 、-S(O)2N(R 40 )2, -NO2, =S, =O and -CN. In some embodiments, each R 31 Selected from C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 40 、-N(R 40 )2、-C(O)R 40 、-C(O)OR 40 , -NO2, =S, =O and -CN. In some embodiments, each R 31 Selected from C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, any of which are optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 40 、-N(R 40 )2、-C(O)R 40 、-C(O)OR 40 , -NO2, =S, =O and -CN.

[0410] In some embodiments, for the compound or salt of Formula (III), each R 31 independently selected from halogen, -OR 40 、-N(R 40 )2、-C(O)R 40 、-C(O)OR 40 , -NO2, -CN; and C 1-6 Alkyl, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 40 、-N(R 40 )2、-C(O)R 40 、-C(O)OR 40 , -NO2, =S, =O and -CN; and each R 40 independently selected from hydrogen, and optionally independently selected from halogen and -OC 1-3One or more substituents of the alkyl group substituted with C 1-3 alkyl.

[0411] In some embodiments, for the compound or salt of formula (III), R 34 is selected from C optionally substituted by one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 43 、-SR 43 、-N(R 43 )2、-C(O)R 43 、-C(O)OR 43 、-OC(O)R 43 、-OC(O)N(R 43 )2、-C(O)N(R 43 )2、-N(R 43 )C(O)R 43 、-N(R 43 )C(O)OR 43 、-N(R 43 )C(O)N(R 43 )2、-N(R 43 )S(O)2(R 43 ),-S(O)R 43 、-S(O)2R 43 、-S(O)2N(R 43 )2, -NO2, =S, =O and -CN. In some embodiments, R 34 is selected from C optionally substituted by one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 43 、-N(R 43 )2、-C(O)R 43 、-C(O)OR 43 , -NO2, =S, =O and -CN. In some embodiments, R 34 is selected from C optionally substituted by one or more substituents independently selected from 1-3 Alkyl: halogen, -OR 43 、-N(R 43 )2、-C(O)R 43 、-C(O)OR 43 , -NO2, =S, =O and -CN.

[0412] In some embodiments, for the compound or salt of formula (III), R 34 is selected from C optionally substituted by one or more substituents independently selected from 2-6 Alkenyl: halogen, -OR 43 、-SR43 、-N(R 43 )2、-C(O)R 43 、-C(O)OR 43 、-OC(O)R 43 、-OC(O)N(R 43 )2、-C(O)N(R 43 )2、-N(R 43 )C(O)R 43 、-N(R 43 )C(O)OR 43 、-N(R 43 )C(O)N(R 43 )2、-N(R 43 )S(O)2(R 43 ),-S(O)R 43 、-S(O)2R 43 、-S(O)2N(R 43 )2, -NO2, =S, =O and -CN. In some embodiments, R 34 is selected from C optionally substituted by one or more substituents independently selected from 2-6 Alkenyl: halogen, -OR 43 、-N(R 43 )2、-C(O)R 43 、-C(O)OR 43 , -NO2, =S, =O and -CN. In some embodiments, R 34 is selected from C optionally substituted by one or more substituents independently selected from 2-4 Alkenyl: halogen, -OR 43 、-N(R 43 )2、-C(O)R 43 、-C(O)OR 43 , -NO2, =S, =O and -CN.

[0413] In some embodiments, for the compound or salt of formula (III), R 34 Selected from C 1-4 Alkyl and C 2-4 alkenyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 43 、-N(R 43 )2、-C(O)R 43 and -CN, and each R 43 are independently selected from hydrogen, C 1-3 Alkyl and C 1-3 In some embodiments, R 34 Selected from methyl, ethyl, propyl, isopropyl and propenyl.

[0414] In some embodiments, for the compound or salt of Formula (III), z is selected from 2, 3, and 4. In some embodiments, z is selected from 3 and 4. In some embodiments, z is selected from 2 and 3. In some embodiments, z is selected from 3, 4, and 5. In some embodiments, z is selected from 4 and 5. In some embodiments, z is selected from 3 and 4. In some embodiments, z is 5. In some embodiments, z is 4. In some embodiments, z is 3. In some embodiments, z is 2.

[0415] In some embodiments, Formula (III) is represented by a structure selected from Formula (III-a), (III-b), (III-c), (III-d), and (III-e):

[0416]

[0417]

[0418] In some embodiments, the compounds or salts of the present disclosure are represented by Formula (III-a) or a pharmaceutically acceptable salt thereof: where R 31 、R 32 、R 33 、R 34 , Ring B, x, y and z are as defined in formula (III).

[0419] In some embodiments, the compounds or salts of the present disclosure are represented by Formula (III-b) or a pharmaceutically acceptable salt thereof: where R 31 、R 32 、R 33 、R 34 , Ring B, x and y are as defined in formula (III).

[0420] In some embodiments, the compounds or salts of the present disclosure are represented by Formula (III-c) or a pharmaceutically acceptable salt thereof: where R 31 、R 33 、R 34 , Ring B and x are as defined in formula (III).

[0421] In some embodiments, the compounds or salts of the present disclosure are represented by Formula (III-d) or a pharmaceutically acceptable salt thereof: where R 32 、R 33 、R 34, Ring B and y are as defined in formula (III).

[0422] In some embodiments, the compounds or salts of the present disclosure are represented by Formula (III-e) or a pharmaceutically acceptable salt thereof: where R 33 、R 34 and Ring B are as defined in formula (III).

[0423] In some embodiments, for compounds or salts of Formula (III), (III-a), (III-b), (III-c), (III-d), or (III-e), Ring B is selected from C 3-10 In some embodiments, the C of Ring B is 3-10 The carbocyclylene group is selected from the group consisting of C3 carbocyclylene, C4 carbocyclylene, C5 carbocyclylene, C6 carbocyclylene, C7 carbocyclylene, C8 carbocyclylene, C9 carbocyclylene and C 10 In some embodiments, Ring B is selected from: 3-4 Carbocyclylene, C 3-5 Carbocyclylene, C 3-6 Carbocyclylene, C 3-7 Carbocyclylene, C 3-8 Carbocyclylene and C 3-9 Carbocyclylene.

[0424] In some embodiments, for the compound or salt of Formula (III), (III-a), (III-b), (III-c), (III-d), or (III-e), Ring B is selected from a 3- to 10-membered heterocyclylene. In some embodiments, the 3- to 10-membered heterocyclylene of Ring B is selected from a 3-membered heterocyclylene, a 4-membered heterocyclylene, a 5-membered heterocyclylene, a 6-membered heterocyclylene, a 7-membered heterocyclylene, an 8-membered heterocyclylene, a 9-membered heterocyclylene, and a 10-membered heterocyclylene. In some embodiments, Ring B is selected from a 3- to 4-membered heterocyclylene, a 3- to 5-membered heterocyclylene, a 3- to 6-membered heterocyclylene, a 3- to 7-membered heterocyclylene, a 3- to 8-membered heterocyclylene, and a 3- to 9-membered heterocyclylene.

[0425] In some embodiments, for compounds or salts of Formula (III), (III-a), (III-b), (III-c), (III-d), or (III-e), Ring B is selected from C 3-6 In some embodiments, ring B is selected from phenylene and 6-membered heteroarylene. In some embodiments, ring B is selected from phenylene and pyridinylene.

[0426] In some embodiments, for compounds or salts of Formula (III), (III-a), (III-b), (III-c), (III-d), or (III-e), Ring B is selected from C 3-6 In some embodiments, ring B is selected from phenylene and pyridinylene, and z is 2.

[0427] In some embodiments, for the compound or salt of Formula (III) or (III-a), Ring B is selected from C 3-6 In some embodiments, ring B is selected from phenylene and pyridinylene, and z is 3.

[0428] In some embodiments, for the compound or salt of Formula (III) or (III-a), Ring B is selected from C 3-6 In some embodiments, ring B is selected from phenylene and pyridinylene, and z is 4.

[0429] In some embodiments, for a compound or salt of Formula (III), (III-a), (III-b), (III-c), (III-d), or (III-e), each R 33 Selected from halogen, -OR 42 、-SR 42 、-N(R 42 )2、-C(O)OR 42 、-OC(O)R 42 、-OC(O)N(R 42 )2、-C(O)N(R 42 )2、-N(R 42 )C(O)R 42 、-N(R 42 )C(O)OR 42 、-N(R 42 )C(O)N(R 42 )2、-N(R 42 )S(O)2(R 42 ),-S(O)R 42 、-S(O)2R 42 and -S(O)2N(R 42 )2. In some embodiments, each R 33 Selected from halogen, -OR 42 、-SR 42 、-N(R 42 )2、-C(O)OR 42 、-C(O)N(R 42 )2、-N(R42 )C(O)R 42 、-N(R 42 )S(O)2(R 42 ) and -S(O)2N(R 42 )2. In some embodiments, each R 33 Selected from halogen OR 42 、-N(R 42 )2 and -C(O)OR 42 .

[0430] In some embodiments, for a compound or salt of Formula (III), (III-a), (III-b), (III-c), (III-d), or (III-e), each R 33 is selected from C optionally substituted by one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 42 、-SR 42 、-N(R 42 )2、-C(O)R 42 、-C(O)OR 42 、-OC(O)R 42 、-OC(O)N(R 42 )2、-C(O)N(R 42 )2、-N(R 42 )C(O)R 42 、-N(R 42 )C(O)OR 42 、-N(R 42 )C(O)N(R 42 )2、-N(R 42 )S(O)2(R 42 ),-S(O)R 42 、-S(O)2R 42 、-S(O)2N(R 42 )2, -NO2, =S and -CN. In some embodiments, each R 33 is selected from C optionally substituted by one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 42 、-SR 42 、-N(R 42 )2、-C(O)OR 42 、-C(O)N(R 42 )2、-N(R 42 )C(O)R 42 、-N(R 42 )S(O)2(R 42 )、-S(O)2N(R 42)2, -NO2, =S and -CN. In some embodiments, each R 33 is selected from C optionally substituted by one or more substituents independently selected from 1-3 Alkyl: halogen, -OR 42 、-N(R 42 )2、-C(O)OR 42 , -NO2, =S and -CN.

[0431] In some embodiments, for a compound or salt of Formula (III), (III-a), (III-b), (III-c), (III-d), or (III-e), each R 33 Selected from halogen, -OR 42 、-SR 42 、-N(R 42 )2、-C(O)OR 42 、-OC(O)R 42 、-OC(O)N(R 42 )2、-C(O)N(R 42 )2、-N(R 42 )C(O)R 42 、-N(R 42 )C(O)OR 42 、-N(R 42 )C(O)N(R 42 )2、-N(R 42 )S(O)2(R 42 ),-S(O)R 42 、-S(O)2R 42 and -S(O)2N(R 42 )2; and each R 42 independently selected from hydrogen, and optionally independently selected from halogen and -OC 1-3 One or more substituents of the alkyl group substituted with C 1-3 In some embodiments, each R 33 Selected from halogen, -OR 42 、-SR 42 、-N(R 42 )2、-C(O)OR 42 、-C(O)N(R 42 )2、-N(R 42 )C(O)R 42 、-N(R 42 )S(O)2(R 42 ) and -S(O)2N(R 42 )2; and each R 42 independently selected from hydrogen, and optionally independently selected from halogen and -OC1-3 One or more substituents of the alkyl group substituted with C 1-3 In some embodiments, each R 33 Selected from halogen OR 42 、-N(R 42 )2 and -C(O)OR 42 ; and each R 42 independently selected from hydrogen, and optionally independently selected from halogen and -OC 1-3 One or more substituents of the alkyl group substituted with C 1-3 alkyl.

[0432] In some embodiments, for a compound or salt of Formula (III), (III-a), (III-b), (III-c), (III-d), or (III-e), each R 33 is selected from C optionally substituted by one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 42 、-SR 42 、-N(R 42 )2、-C(O)R 42 、-C(O)OR 42 、-OC(O)R 42 、-OC(O)N(R 42 )2、-C(O)N(R 42 )2、-N(R 42 )C(O)R 42 、-N(R 42 )C(O)OR 42 、-N(R 42 )C(O)N(R 42 )2、-N(R 42 )S(O)2(R 42 ),-S(O)R 42 、-S(O)2R 42 、-S(O)2N(R 42 )2, -NO2, =S and -CN; and each R 42 independently selected from hydrogen, and optionally independently selected from halogen and -OC 1-3 One or more substituents of the alkyl group substituted with C 1-3 In some embodiments, each R 33 is selected from C optionally substituted by one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 42 、-SR 42 、-N(R 42 )2、-C(O)OR 42、-C(O)N(R 42 )2、-N(R 42 )C(O)R 42 、-N(R 42 )S(O)2(R 42 )、-S(O)2N(R 42 )2, -NO2, =S and -CN; and each R 42 independently selected from hydrogen, and optionally independently selected from halogen and -OC 1-3 One or more substituents of the alkyl group substituted with C 1-3 In some embodiments, each R 33 is selected from C optionally substituted by one or more substituents independently selected from 1-3 Alkyl: halogen, -OR 42 、-N(R 42 )2、-C(O)OR 42 , -NO2, =S and -CN; and each R 42 independently selected from hydrogen, and optionally independently selected from halogen and -OC 1-3 One or more substituents of the alkyl group substituted with C 1-3 alkyl.

[0433] In some embodiments, for a compound or salt of Formula (III), (III-a), (III-b), (III-c), (III-d), or (III-e), each R 33 independently selected from halogen, -OR 42 、-SR 42 、-N(R 42 )2、-C(O)OR 42 、-C(O)N(R 42 )2、-N(R 42 )C(O)R 42 、-N(R 42 )S(O)2(R 42 )、-S(O)2N(R 42 )2; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 42 、-SR 42 、-N(R 42 )2、-C(O)OR 42 、-C(O)N(R 42 )2、-N(R 42 )C(O)R 42 、-N(R 42 )S(O)2(R 42 )、-S(O)2N(R42 )2, -NO2, =S and -CN; and each R 42 independently selected from hydrogen, and optionally independently selected from halogen and -OC 1-3 One or more substituents of the alkyl group substituted with C 1-3 alkyl.

[0434] In some embodiments, for a compound or salt of Formula (III), (III-a), (III-b), (III-c), (III-d), or (III-e), each R 33 Independently selected from: halogen, -OR 42 、-N(R 42 )2; and optionally independently selected from halogen, -OR 42 、-N(R 42 )2, -NO2 and -CN substituted with one or more substituents C 1-6 alkyl; and each R 42 independently selected from hydrogen, and optionally independently selected from halogen and -OC 1-3 One or more substituents of the alkyl group substituted with C 1-3 In some embodiments, each R 33 Independently selected from: halogen, -OR 42 and are optionally independently selected from halogen and -OR 42 One or more substituents substituted C 1-6 alkyl; and each R 42 independently selected from hydrogen, and optionally independently selected from halogen and -OC 1-3 One or more substituents of the alkyl group substituted with C 1-3 In some embodiments, each R 33 Independently selected from chloro, fluoro, bromo, methyl, -CF3, In some embodiments, each R 33 In some embodiments, each R 33 In some embodiments, each R 33 Independently selected from In some embodiments, each R 33 Independently selected from chloro, fluoro, bromo, In some embodiments, each R 33 independently selected from methyl, -CF3, In some embodiments, each R 33Independently selected from methyl, -CF3, chloro, fluoro and bromo.

[0435] In some embodiments, for a compound or salt of Formula (III), (III-a), (III-b), (III-c), (III-d), or (III-e), one R 33 is a methyl group, and each additional R 33 Selected from halogen, -OR 42 、-SR 42 、-N(R 42 )2、-C(O)R 42 、-C(O)OR 42 、-OC(O)R 42 、-OC(O)N(R 42 )2、-C(O)N(R 42 )2、-N(R 42 )C(O)R 42 、-N(R 42 )C(O)OR 42 、-N(R 42 )C(O)N(R 42 )2、-N(R 42 )S(O)2(R 42 ),-S(O)R 42 、-S(O)2R 42 、-S(O)2N(R 42 )2, -NO2 and -CN. In some embodiments, one R 33 is a methyl group, and each additional R 33 Selected from halogen, -OR 42 、-N(R 42 )2、-C(O)R 42 、-C(O)OR 42 , -NO2 and -CN.

[0436] In some embodiments, for a compound or salt of Formula (III), (III-a), (III-b), (III-c), (III-d), or (III-e), one R 33 is a methyl group, and each additional R 33 is selected from C1 alkyl substituted by one or more substituents independently selected from halogen, -OR 42 、-SR 42 、-N(R 42 )2、-C(O)R 42 、-C(O)OR 42 、-OC(O)R 42 、-OC(O)N(R 42)2、-C(O)N(R 42 )2、-N(R 42 )C(O)R 42 、-N(R 42 )C(O)OR 42 、-N(R 42 )C(O)N(R 42 )2、-N(R 42 )S(O)2(R 42 ),-S(O)R 42 、-S(O)2R 42 、-S(O)2N(R 42 )2, -NO2, =S, =O and -CN. In some embodiments, one R 33 is a methyl group, and each additional R 33 is selected from C1 alkyl substituted by one or more substituents independently selected from halogen, -OR 42 、-N(R 42 )2、-C(O)R 42 、-C(O)OR 42 , -NO2, =S, =O and -CN.

[0437] In some embodiments, for a compound or salt of Formula (III), (III-a), (III-b), (III-c), (III-d), or (III-e), one R 33 is a methyl group, and each additional R 33 is selected from C optionally substituted by one or more substituents independently selected from 2-6 Alkyl: halogen, -OR 42 、-SR 42 、-N(R 42 )2、-C(O)R 42 、-C(O)OR 42 、-OC(O)R 42 、-OC(O)N(R 42 )2、-C(O)N(R 42 )2、-N(R 42 )C(O)R 42 、-N(R 42 )C(O)OR 42 、-N(R 42 )C(O)N(R 42 )2、-N(R 42 )S(O)2(R 42 ),-S(O)R 42 、-S(O)2R 42 、-S(O)2N(R 42)2, -NO2, =S, =O and -CN. In some embodiments, one R 33 is a methyl group, and each additional R 33 is selected from C optionally substituted by one or more substituents independently selected from 2-6 Alkyl: halogen, -OR 42 、-N(R 42 )2、-C(O)R 42 、-C(O)OR 42 , -NO2, =S, =O and -CN.

[0438] In some embodiments, for a compound or salt of Formula (III), (III-a), (III-b), (III-c), (III-d), or (III-e), one R 33 is a methyl group, and each additional R 33 Selected from: halogen, -OR 42 、-N(R 42 )2、-C(O)R 42 、-C(O)OR 42 , -NO2, -CN; C1 alkyl substituted by one or more substituents independently selected from the following: halogen, -OR 42 、-N(R 42 )2、-C(O)R 42 、-C(O)OR 42 , -NO2, =S, =O and -CN; and C optionally substituted by one or more substituents independently selected from the following 2-6 Alkyl: halogen, -OR 42 、-N(R 42 )2、-C(O)R 42 、-C(O)OR 42 , -NO2, =S, =O and -CN. In some embodiments, one R 33 is a methyl group, and each additional R 33 Selected from halogen, -OR 42 、-N(R 42 )2、-C(O)R 42 、-C(O)OR 42 , -NO2, -CN; and C1 alkyl substituted with one or more substituents independently selected from the following: halogen, -OR 42 、-N(R 42 )2、-C(O)R 42 、-C(O)OR 42 , -NO2, =S, =O and -CN. In some embodiments, one R 33 is a methyl group, and each additional R 33Selected from halogen, -OR 42 、-N(R 42 )2、-C(O)R 42 、-C(O)OR 42 , -NO2, -CN; and C substituted by one or more substituents independently selected from the following 2-6 Alkyl: halogen, -OR 42 、-N(R 42 )2、-C(O)R 42 、-C(O)OR 42 , -NO2, =S, =O and -CN.

[0439] In some embodiments, for a compound or salt of Formula (III), (III-a), (III-b), (III-c), (III-d), or (III-e), Selected from:

[0440] In some embodiments, for a compound or salt of Formula (III), (III-a), (III-b), (III-c), (III-d), or (III-e), Selected from:

[0441] In some embodiments, for a compound or salt of Formula (III), (III-a), (III-b), (III-c), (III-d), or (III-e), Selected from:

[0442] In some embodiments, for a compound or salt of Formula (III), (III-a), (III-b), (III-c), (III-d), or (III-e), Selected from:

[0443] In some embodiments, for a compound or salt of Formula (III), (III-a), (III-b), (III-c), (III-d), or (III-e), Selected from:

[0444] In some embodiments, for a compound or salt of Formula (III), (III-a), (III-b), (III-c), (III-d), or (III-e), Selected from:

[0445] In some embodiments, for a compound or salt of Formula (III), (III-a), (III-b), (III-c), (III-d), or (III-e), two R 33 may together form C optionally substituted with one or more substituents independently selected from 3-8 Carbocyclic ring: halogen, -OR 42 、-SR 42 、-N(R 42 )2、-C(O)R 42 、-C(O)OR 42 、-OC(O)R 42 、-OC(O)N(R 42 )2、-C(O)N(R 42 )2、-N(R 42 )C(O)R 42 、-N(R 42 )C(O)OR 42 、-N(R 42 )C(O)N(R 42 )2、-N(R 42 )S(O)2(R 42 ),-S(O)R 42 、-S(O)2R 42 、-S(O)2N(R 42 )2, -NO2, =O and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 42 、-SR 42 、-N(R 42 )2、-C(O)R 42 、-C(O)OR 42 、-OC(O)R 42 、-OC(O)N(R 42 )2、-C(O)N(R 42 )2、-N(R 42 )C(O)R 42 、-N(R 42 )C(O)OR 42 、-N(R 42 )C(O)N(R 42 )2、-N(R42 )S(O)2(R 42 ),-S(O)R 42 、-S(O)2R 42 、-S(O)2N(R 42 )2, -NO2, =S, =O and -CN. In some embodiments, two R 33 may together form C optionally substituted with one or more substituents independently selected from 3-8 Carbocyclic ring: halogen, -OR 42 、-SR 42 、-N(R 42 )2、-C(O)R 42 、-C(O)OR 42 、-OC(O)R 42 、-OC(O)N(R 42 )2、-C(O)N(R 42 )2、-N(R 42 )C(O)R 42 、-N(R 42 )C(O)OR 42 、-N(R 42 )C(O)N(R 42 )2、-N(R 42 )S(O)2(R 42 ),-S(O)R 42 、-S(O)2R 42 、-S(O)2N(R 42 )2, -NO2, =O and -CN. In some embodiments, two R 33 can together form optionally one or more C 1-6 Alkyl substituted C 3-8 Carbon ring, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 42 、-SR 42 、-N(R 42 )2、-C(O)R 42 、-C(O)OR 42 、-OC(O)R 42 、-OC(O)N(R 42 )2、-C(O)N(R 42 )2、-N(R 42 )C(O)R 42 、-N(R 42 )C(O)OR 42 、-N(R 42 )C(O)N(R 42)2、-N(R 42 )S(O)2(R 42 ),-S(O)R 42 、-S(O)2R 42 、-S(O)2N(R 42 )2, -NO2, =S, =O and -CN.

[0446] In some embodiments, for a compound or salt of Formula (III), (III-a), (III-b), (III-c), (III-d), or (III-e), two R 33 may together form C optionally substituted with one or more substituents independently selected from 3-8 Carbocyclic ring: halogen, -OR 42 、-N(R 42 )2、-C(O)R 42 、-C(O)OR 42 , -NO2, =O and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 42 、-N(R 42 )2、-C(O)R 42 、-C(O)OR 42 , -NO2, =O and -CN. In some embodiments, two R 33 may together form C optionally substituted with one or more substituents independently selected from 3-8 Carbocyclic ring: halogen, -OR 42 、-N(R 42 )2、-C(O)R 42 、-C(O)OR 42 , -NO2, =O and -CN. In some embodiments, two R 33 can together form optionally one or more C 1-6 Alkyl substituted C 3-8 Carbon ring, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 42 、-N(R 42 )2、-C(O)R 42 、-C(O)OR 42 , -NO2, =O and -CN.

[0447] In some embodiments, for a compound or salt of Formula (III), (III-a), (III-b), (III-c), (III-d), or (III-e), two R33 Together they may form a 4- to 6-membered heterocyclic ring, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 42 、-N(R 42 )2、-C(O)R 42 , -NO2, -CN; and C optionally substituted by one or more substituents independently selected from the following 1-3 Alkyl: halogen, -OR 42 、-N(R 42 )2、-C(O)R 42 , -NO2 and -CN; and each R 42 are independently selected from hydrogen, C 1-3 Alkyl and C 1-3 Halogenated alkyl.

[0448] In some embodiments, for a compound or salt of Formula (III), (III-a), (III-b), (III-c), (III-d), or (III-e), two R 33 Can form C together 3-8 carbocyclic rings, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 42 、-N(R 42 )2、-C(O)R 42 , -NO2, -CN; and C optionally substituted by one or more substituents independently selected from the following 1-3 Alkyl: halogen, -OR 42 、-N(R 42 )2、-C(O)R 42 , -NO2 and -CN; and each R 42 are independently selected from hydrogen, C 1-3 Alkyl and C 1-3 Halogenated alkyl.

[0449] In some embodiments, for a compound or salt of Formula (III), (III-a), (III-b), (III-c), (III-d), or (III-e), two R 33 Together they may form a 3- to 8-membered heterocyclic ring, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 42 、-N(R 42 )2、-C(O)R 42 , -NO2, -CN; and C optionally substituted by one or more substituents independently selected from the following 1-3 Alkyl: halogen, -OR 42 、-N(R 42 )2、-C(O)R42 , -NO2 and -CN; and each R 42 are independently selected from hydrogen, C 1-3 Alkyl and C 1-3 Halogenated alkyl.

[0450] In some embodiments, for a compound or salt of Formula (III), (III-a), (III-b), (III-c), (III-d), or (III-e), selected from dihydrobenzofuranylene, benzofuranylene and benzobisoxazolylene, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 42 、-N(R 42 )2、-C(O)R 42 , -NO2, -CN; and C optionally substituted by one or more substituents independently selected from the following 1-3 Alkyl: halogen, -OR 42 、-N(R 42 )2、-C(O)R 42 , -NO2 and -CN; and each R 42 are independently selected from hydrogen, C 1-3 Alkyl and C 1-3 In some embodiments, is selected from dihydrobenzofuranyl, benzofuranyl and benzodioxolyl, each of which is optionally independently selected from halogen and unsubstituted C 1-3 In some embodiments, is selected from dihydrobenzofuranylene, benzofuranylene and benzodioxolylene, each of which is optionally substituted with one or more substituents independently selected from fluoro and methyl.

[0451] In some embodiments, for a compound or salt of Formula (III), (III-a), (III-b), (III-c), (III-d), or (III-e), Selected from In some embodiments, Selected from In some embodiments, Selected from

[0452] In some embodiments, for a compound or salt of Formula (III), (III-a), (III-b), (III-c), (III-d), or (III-e), selected from furopyridinyl, thienopyridinyl, indazolyl, pyrazolo[4,3-b]pyridinyl, imidazo[1,2-a]pyridinyl, imidazo[1,2-a]pyrazinyl and pyrazolo[1,5-a]pyridinyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 42 、-N(R 42 )2、-C(O)R 42 , -NO2, -CN; and C optionally substituted by one or more substituents independently selected from the following 1-3 Alkyl: halogen, -OR 42 、-N(R 42 )2、-C(O)R 42 , -NO2 and -CN; and each R 42 are independently selected from hydrogen, C 1-3 Alkyl and C 1-3 In some embodiments, is selected from furopyridinyl, thienopyridinyl, indazolyl, pyrazolo[4,3-b]pyridinyl, imidazo[1,2-a]pyridinyl, imidazo[1,2-a]pyrazinyl and pyrazolo[1,5-a]pyridinyl, each of which is optionally independently selected from halogen and unsubstituted C 1-3 In some embodiments, is selected from furopyridinyl, thienopyridinyl, indazolyl, pyrazolo[4,3-b]pyridinyl, imidazo[1,2-a]pyridinyl, imidazo[1,2-a]pyrazinyl and pyrazolo[1,5-a]pyridinyl, each of which is optionally substituted with one or more substituents independently selected from fluoro and methyl. In some embodiments, selected from furopyridinyl, thienopyridinyl, indazolyl, pyrazolo[4,3-b]pyridinyl, imidazo[1,2-a]pyridinyl, imidazo[1,2-a]pyrazinyl and pyrazolo[1,5-a]pyridinyl, each of which is optionally substituted with one substituent selected from methyl.

[0453] In some embodiments, for a compound or salt of Formula (III), (III-a), (III-b), (III-c), (III-d), or (III-e), Selected from

[0454] In some embodiments, for a compound or salt of Formula (III), (III-a), (III-b), (III-c), (III-d), or (III-e), R 40 In some embodiments, R 40is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 40 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 40 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN.

[0455] In some embodiments, for a compound or salt of Formula (III), (III-a), (III-b), (III-c), (III-d), or (III-e), R 41 In some embodiments, R 41 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 41 is selected from C optionally substituted with one or more substituents independently selected from 1-6Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 41 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN.

[0456] In some embodiments, for a compound or salt of Formula (III), (III-a), (III-b), (III-c), (III-d), or (III-e), R 42 In some embodiments, R 42 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 42 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 42 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN.

[0457] In some embodiments, for a compound or salt of Formula (III), (III-a), (III-b), (III-c), (III-d), or (III-e), R 43 In some embodiments, R 43 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 43 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 43 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN.

[0458] In some embodiments, the compound of formula (III) is

[0459]

[0460]

[0461]

[0462]

[0463]

[0464] Any salt thereof.

[0465] In some embodiments, the compound of formula (III) is

[0466]

[0467]

[0468]

[0469] or a salt of any one thereof.

[0470] A compound of formula (IV).

[0471] In some aspects, the present disclosure provides a compound represented by the structure of Formula (IV):

[0472]

[0473] or a pharmaceutically acceptable salt, wherein:

[0474] Each X 1 Selected from C(R 50 ) and N, and at least one X 1 It is N;

[0475] R 50 independently selected at each occurrence from:

[0476] Hydrogen, halogen, -OR 60 、-SR 60 、-N(R 60 )2、-C(O)R 60 、-C(O)OR 60 、-OC(O)R 60 、-OC(O)N(R 60 )2、-C(O)N(R 60 )2、-N(R 60 )C(O)R 60 、-N(R 60 )C(O)OR 60 、-N(R 60 )C(O)N(R 60 )2、-N(R 60 )S(O)2(R 60 ),-S(O)R 60 、-S(O)2R 60 、-S(O)2N(R 60 )2, -NO2 and -CN; and

[0477] C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR60 、-SR 60 、-N(R 60 )2、-C(O)R 60 、-C(O)OR 60 、-OC(O)R 60 、-OC(O)N(R 60 )2、-C(O)N(R 60 )2、-N(R 60 )C(O)R 60 、-N(R 60 )C(O)OR 60 、-N(R 60 )C(O)N(R 60 )2、-N(R 60 )S(O)2(R 60 ),-S(O)R 60 、-S(O)2R 60 、-S(O)2N(R 60 )2, -NO2, =S, =O and -CN;

[0478] R 51 Independently selected from:

[0479] C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 61 、-SR 61 、-N(R 61 )2、-C(O)R 61 、-C(O)OR 61 、-OC(O)R 61 、-OC(O)N(R 61 )2、-C(O)N(R 61 )2、-N(R 61 )C(O)R 61 、-N(R 61 )C(O)OR 61 、-N(R 61 )C(O)N(R 61 )2、-N(R 61 )S(O)2(R 61 ),-S(O)R 61 、-S(O)2R 61 、-S(O)2N(R 61 )2, -NO2, =S, =O and -CN; and

[0480] C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR61 、-SR 61 、-N(R 61 )2、-C(O)R 61 、-C(O)OR 61 、-OC(O)R 61 、-OC(O)N(R 61 )2、-C(O)N(R 61 )2、-N(R 61 )C(O)R 61 、-N(R 61 )C(O)OR 61 、-N(R 61 )C(O)N(R 61 )2、-N(R 61 )S(O)2(R 61 ),-S(O)R 61 、-S(O)2R 61 、-S(O)2N(R 61 )2, -NO2, =S, =O and -CN;

[0481] is a 3- to 12-membered heterocyclylene group optionally substituted with one or more substituents independently selected from:

[0482] Halogen, -OR 62 、-SR 62 、-N(R 62 )2、-C(O)R 62 、-C(O)OR 62 、-OC(O)R 62 、-OC(O)N(R 62 )2、-C(O)N(R 62 )2、-N(R 62 )C(O)R 62 、-N(R 62 )C(O)OR 62 、-N(R 62 )C(O)N(R 62 )2、-N(R 62 )S(O)2(R 62 ),-S(O)R 62 、-S(O)2R 62 、-S(O)2N(R 62 )2, -NO2 and -CN;

[0483] C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 62 、-SR 62、-N(R 62 )2、-C(O)R 62 、-C(O)OR 62 、-OC(O)R 62 、-OC(O)N(R 62 )2、-C(O)N(R 62 )2、-N(R 62 )C(O)R 62 、-N(R 62 )C(O)OR 62 、-N(R 62 )C(O)N(R 62 )2、-N(R 62 )S(O)2(R 62 ),-S(O)R 62 、-S(O)2R 62 、-S(O)2N(R 62 )2, -NO2, =S, =O and -CN; and

[0484] Ring B is selected from C 3-10 carbocyclic ring and 3- to 10-membered heterocyclic ring, any of which is optionally substituted with one or more substituents independently selected from:

[0485] Halogen, -OR 63 、-SR 63 、-N(R 63 )2、-C(O)R 63 、-C(O)OR 63 、-OC(O)R 63 、-OC(O)N(R 63 )2、-C(O)N(R 63 )2、-N(R 63 )C(O)R 63 、-N(R 63 )C(O)OR 63 、-N(R 63 )C(O)N(R 63 )2、-N(R 63 )S(O)2(R 63 ),-S(O)R 63 、-S(O)2R 63 、-S(O)2N(R 63 )2, -NO2 and -CN; and

[0486] C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 63 、-SR 63 、-N(R 63)2、-C(O)R 63 、-C(O)OR 63 、-OC(O)R 63 、-OC(O)N(R 63 )2、-C(O)N(R 63 )2、-N(R 63 )C(O)R 63 、-N(R 63 )C(O)OR 63 、-N(R 63 )C(O)N(R 63 )2、-N(R 63 )S(O)2(R 63 ),-S(O)R 63 、-S(O)2R 63 、-S(O)2N(R 63 )2, -NO2, =S, =O and -CN;

[0487] R 60 、R 61 、R 62 and R 63 independently selected at each occurrence from:

[0488] hydrogen;

[0489] C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, and -CN; and

[0490] C optionally substituted with one or more substituents independently selected from the following 3-10 Carbocyclic rings and 3- to 10-membered heterocyclic rings: halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN.

[0491] In some embodiments, for compounds of formula (IV), X 1 It is C(R 50 ), and R 50 Selected from hydrogen, halogen, -OR60 、-SR 60 、-N(R 60 )2、-C(O)R 60 、-C(O)OR 60 、-OC(O)R 60 、-OC(O)N(R 60 )2、-C(O)N(R 60 )2、-N(R 60 )C(O)R 60 、-N(R 60 )C(O)OR 60 、-N(R 60 )C(O)N(R 60 )2、-N(R 60 )S(O)2(R 60 ),-S(O)R 60 、-S(O)2R 60 、-S(O)2N(R 60 )2, -NO2 and -CN. In some embodiments, X 1 It is C(R 50 ), and R 50 Selected from hydrogen, halogen, -OR 60 、-SR 60 、-N(R 60 )2、-C(O)R 60 、-C(O)OR 60 -NO2 and -CN. In some embodiments, X 1 It is C(R 50 ), and R 50 It's hydrogen.

[0492] In some embodiments, Formula (IV) is represented by a structure selected from the group consisting of:

[0493]

[0494] In some embodiments, the compounds or salts of the present disclosure are represented by Formula (IV-a) or a pharmaceutically acceptable salt thereof: where R 50 、R 51 、 and Ring B are as defined in formula (IV).

[0495] In some embodiments, the compounds or salts of the present disclosure are represented by Formula (IV-b) or a pharmaceutically acceptable salt thereof: where R 50 、R 51 、 and Ring B are as defined in formula (IV).

[0496] In some embodiments, the compounds or salts of the present disclosure are represented by Formula (IV-c) or a pharmaceutically acceptable salt thereof: where R 50 、R 51 、 and Ring B are as defined in formula (IV).

[0497] In some embodiments, the compounds or salts of the present disclosure are represented by Formula (IV-d) or a pharmaceutically acceptable salt thereof: where R 50 、R 51 、 and Ring B are as defined in formula (IV).

[0498] In some embodiments, for a compound or salt of Formula (IV), (IV-a), (IV-b), (IV-c), or (IV-d), R 51 is selected from C optionally substituted by one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 61 、-SR 61 、-N(R 61 )2、-C(O)R 61 、-C(O)OR 61 、-OC(O)R 61 、-OC(O)N(R 61 )2、-C(O)N(R 61 )2、-N(R 61 )C(O)R 61 、-N(R 61 )C(O)OR 61 、-N(R 61 )C(O)N(R 61 )2、-N(R 61 )S(O)2(R 61 ),-S(O)R 61 、-S(O)2R 61 、-S(O)2N(R 61 )2, -NO2, =S, =O and -CN; and R 61 Selected from hydrogen and C 1-3 In some embodiments, R 51 is selected from C optionally substituted by one or more substituents independently selected from 1-6 Alkyl: halogen, -OR 61 、-SR 61 、-N(R61 )2、-C(O)R 61 、-C(O)OR 61 , -NO2, =S, =O and -CN; and R 61 Selected from hydrogen and C 1-3 In some embodiments, R 51 is C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 61 、-N(R 61 )2、-C(O)R 61 , -NO2, =S, =O and -CN; and R 61 Selected from hydrogen and C 1-3 In some embodiments, R 51 is unsubstituted C 1-3 alkyl.

[0499] In some embodiments, for a compound or salt of Formula (IV), (IV-a), (IV-b), (IV-c), or (IV-d), R 51 is selected from C optionally substituted by one or more substituents independently selected from 1-3 Alkyl: halogen, -OR 61 、-SR 61 、-N(R 61 )2、-C(O)R 61 、-C(O)OR 61 、-OC(O)R 61 、-OC(O)N(R 61 )2、-C(O)N(R 61 )2、-N(R 61 )C(O)R 61 、-N(R 61 )C(O)OR 61 、-N(R 61 )C(O)N(R 61 )2、-N(R 61 )S(O)2(R 61 ),-S(O)R 61 、-S(O)2R 61 、-S(O)2N(R 61 )2, -NO2, =S, =O and -CN; and R 61 Selected from hydrogen and C 1-3 In some embodiments, R 51 is selected from C optionally substituted by one or more substituents independently selected from 1-3 Alkyl: halogen, -OR 61 、-SR61 、-N(R 61 )2、-C(O)R 61 、-C(O)OR 61 , -NO2, =S, =O and -CN; and R 61 Selected from hydrogen and C 1-3 In some embodiments, R 51 is C optionally substituted by one or more substituents independently selected from the following 1-3 Alkyl: halogen, -OR 61 、-N(R 61 )2、-C(O)R 61 , -NO2, =S, =O and -CN; and R 61 Selected from hydrogen and C 1-3 alkyl.

[0500] In some embodiments, for a compound or salt of Formula (IV), (IV-a), (IV-b), (IV-c), or (IV-d), R 51 is selected from methyl, ethyl, propyl and isopropyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 61 、-SR 61 、-N(R 61 )2、-C(O)R 61 、-C(O)OR 61 、-OC(O)R 61 、-OC(O)N(R 61 )2、-C(O)N(R 61 )2、-N(R 61 )C(O)R 61 、-N(R 61 )C(O)OR 61 、-N(R 61 )C(O)N(R 61 )2、-N(R 61 )S(O)2(R 61 ),-S(O)R 61 、-S(O)2R 61 、-S(O)2N(R 61 )2, -NO2, =S, =O and -CN. In some embodiments, R 51 is selected from methyl, ethyl, propyl and isopropyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 61 、-SR 61 、-N(R 61 )2、-C(O)R 61 、-C(O)OR 61, -NO2, =S, =O and -CN; and R 61 Selected from hydrogen and C 1-3 alkyl.

[0501] In some embodiments, for a compound or salt of Formula (IV), (IV-a), (IV-b), (IV-c), or (IV-d), The optionally substituted 3- to 12-membered heterocyclylene is selected from an optionally substituted 3-membered heterocyclylene, an optionally substituted 4-membered heterocyclylene, an optionally substituted 5-membered heterocyclylene, an optionally substituted 6-membered heterocyclylene, an optionally substituted 7-membered heterocyclylene, an optionally substituted 8-membered heterocyclylene, an optionally substituted 9-membered heterocyclylene, an optionally substituted 10-membered heterocyclylene, an optionally substituted 11-membered heterocyclylene, and an optionally substituted 12-membered heterocyclylene. In some embodiments, The optionally substituted 3- to 12-membered heterocyclylene is selected from an optionally substituted 3- to 4-membered heterocyclylene, an optionally substituted 3- to 5-membered heterocyclylene, an optionally substituted 3- to 6-membered heterocyclylene, an optionally substituted 3- to 7-membered heterocyclylene, an optionally substituted 3- to 8-membered heterocyclylene, an optionally substituted 3- to 9-membered heterocyclylene, an optionally substituted 3- to 10-membered heterocyclylene, and an optionally substituted 3- to 11-membered heterocyclylene.

[0502] In some embodiments, for a compound or salt of Formula (IV), (IV-a), (IV-b), (IV-c), or (IV-d), is a 3- to 8-membered heterocyclylene group optionally substituted with one or more substituents independently selected from:

[0503] Halogen, -OR 62 、-SR 62 、-N(R 62 )2、-C(O)R 62 、-C(O)OR 62 、-OC(O)R 62 、-OC(O)N(R 62 )2、-C(O)N(R 62 )2、-N(R 62 )C(O)R 62 、-N(R 62 )C(O)OR 62 、-N(R 62 )C(O)N(R 62 )2、-N(R 62 )S(O)2(R 62 ),-S(O)R 62 、-S(O)2R 62 、-S(O)2N(R 62 )2, -NO2 and -CN;

[0504] C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 62 、-SR 62 、-N(R 62 )2、-C(O)R 62 、-C(O)OR 62 、-OC(O)R 62 、-OC(O)N(R 62 )2、-C(O)N(R 62 )2、-N(R 62 )C(O)R 62 、-N(R 62 )C(O)OR 62 、-N(R 62 )C(O)N(R 62 )2、-N(R 62 )S(O)2(R 62 ),-S(O)R 62 、-S(O)2R 62 、-S(O)2N(R 62 )2, -NO2, =S, =O and -CN.

[0505] In some embodiments, for a compound or salt of Formula (IV), (IV-a), (IV-b), (IV-c), or (IV-d), is a 5- to 6-membered heterocyclylene group optionally substituted with one or more substituents independently selected from:

[0506] Halogen, -OR 62 、-SR 62 、-N(R 62 )2、-C(O)R 62 、-C(O)OR 62 、-OC(O)R 62 、-OC(O)N(R 62 )2、-C(O)N(R 62 )2、-N(R 62 )C(O)R 62 、-N(R 62 )C(O)OR 62 、-N(R 62 )C(O)N(R 62 )2、-N(R 62 )S(O)2(R 62 ),-S(O)R 62 、-S(O)2R 62 、-S(O)2N(R62 )2, -NO2 and -CN;

[0507] C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 62 、-SR 62 、-N(R 62 )2、-C(O)R 62 、-C(O)OR 62 、-OC(O)R 62 、-OC(O)N(R 62 )2、-C(O)N(R 62 )2、-N(R 62 )C(O)R 62 、-N(R 62 )C(O)OR 62 、-N(R 62 )C(O)N(R 62 )2、-N(R 62 )S(O)2(R 62 ),-S(O)R 62 、-S(O)2R 62 、-S(O)2N(R 62 )2, -NO2, =S, =O and -CN.

[0508] In some embodiments, for a compound or salt of Formula (IV), (IV-a), (IV-b), (IV-c), or (IV-d), is a 5- to 6-membered saturated heterocyclylene group optionally substituted by one or more substituents independently selected from the following:

[0509] Halogen, -OR 62 、-SR 62 、-N(R 62 )2、-C(O)R 62 、-C(O)OR 62 、-OC(O)R 62 、-OC(O)N(R 62 )2、-C(O)N(R 62 )2、-N(R 62 )C(O)R 62 、-N(R 62 )C(O)OR 62 、-N(R 62 )C(O)N(R 62 )2、-N(R 62 )S(O)2(R 62 ),-S(O)R 62 、-S(O)2R62 、-S(O)2N(R 62 )2, -NO2 and -CN;

[0510] C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 62 、-SR 62 、-N(R 62 )2、-C(O)R 62 、-C(O)OR 62 、-OC(O)R 62 、-OC(O)N(R 62 )2、-C(O)N(R 62 )2、-N(R 62 )C(O)R 62 、-N(R 62 )C(O)OR 62 、-N(R 62 )C(O)N(R 62 )2、-N(R 62 )S(O)2(R 62 ),-S(O)R 62 、-S(O)2R 62 、-S(O)2N(R 62 )2, -NO2, =S, =O and -CN.

[0511] In some embodiments, for a compound or salt of Formula (IV), (IV-a), (IV-b), (IV-c), or (IV-d), is selected from piperidinylene and piperazinylene, each of which is optionally substituted with one or more substituents independently selected from:

[0512] Halogen, -OR 62 、-SR 62 、-N(R 62 )2、-C(O)R 62 、-C(O)OR 62 、-OC(O)R 62 、-OC(O)N(R 62 )2、-C(O)N(R 62 )2、-N(R 62 )C(O)R 62 、-N(R 62 )C(O)OR 62 、-N(R 62 )C(O)N(R 62 )2、-N(R 62 )S(O)2(R 62 ),-S(O)R62 、-S(O)2R 62 、-S(O)2N(R 62 )2, -NO2 and -CN;

[0513] C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 62 、-SR 62 、-N(R 62 )2、-C(O)R 62 、-C(O)OR 62 、-OC(O)R 62 、-OC(O)N(R 62 )2、-C(O)N(R 62 )2、-N(R 62 )C(O)R 62 、-N(R 62 )C(O)OR 62 、-N(R 62 )C(O)N(R 62 )2、-N(R 62 )S(O)2(R 62 ),-S(O)R 62 、-S(O)2R 62 、-S(O)2N(R 62 )2, -NO2, =S, =O and -CN.

[0514] In some embodiments, for a compound or salt of Formula (IV), (IV-a), (IV-b), (IV-c), or (IV-d), is selected from saturated 5- to 6-membered heterocyclylene groups, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 62 、-N(R 62 )2、-C(O)R 62 、-C(O)OR 62 、-C(O)N(R 62 )2, -NO2, -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 62 、-N(R 62 )2、-C(O)R 62 、-C(O)OR 62 、-C(O)N(R 62 )2, -NO2, =S, =O and -CN; and R 62 Selected from hydrogen and C 1-3 alkyl.

[0515] In some embodiments, for a compound or salt of Formula (IV), (IV-a), (IV-b), (IV-c), or (IV-d), selected from piperidinylene and piperazinylene, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 62 、-N(R 62 )2、-C(O)R 62 、-C(O)OR 62 、-C(O)N(R 62 )2, -NO2, -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 62 、-N(R 62 )2、-C(O)R 62 、-C(O)OR 62 、-C(O)N(R 62 )2, -NO2, =S, =O and -CN; and R 62 Selected from hydrogen and C 1-3 alkyl.

[0516] In some embodiments, for a compound or salt of Formula (IV), (IV-a), (IV-b), (IV-c), or (IV-d), yes In some embodiments, It is an unsubstituted piperazinylene.

[0517] In some embodiments, for compounds or salts of Formula (IV), (IV-a), (IV-b), (IV-c), or (IV-d), the optionally substituted C of Ring B is 3-10 The carbocycle is selected from an optionally substituted C3 carbocycle, an optionally substituted C4 carbocycle, an optionally substituted C5 carbocycle, an optionally substituted C6 carbocycle, an optionally substituted C7 carbocycle, an optionally substituted C8 carbocycle, an optionally substituted C9 carbocycle and an optionally substituted C 10 In some embodiments, the optionally substituted C 3-10 The carbocyclic ring is selected from optionally substituted C 3-4 Carbocyclic, optionally substituted C 3-5 Carbocyclic, optionally substituted C 3-6 Carbocyclic, optionally substituted C 3-7 Carbocyclic, optionally substituted C 3-8 Carbocyclic and optionally substituted C 3-9 Carbon ring.

[0518] In some embodiments, for the compound or salt of Formula (IV), (IV-a), (IV-b), (IV-c) or (IV-d), the optionally substituted 3- to 10-membered heterocyclic ring of Ring B is selected from an optionally substituted 3- to 4-membered heterocyclic ring, an optionally substituted 4-membered heterocyclic ring, an optionally substituted 5-membered heterocyclic ring, an optionally substituted 6-membered heterocyclic ring, an optionally substituted 7-membered heterocyclic ring, an optionally substituted 8-membered heterocyclic ring, an optionally substituted 9-membered heterocyclic ring, and an optionally substituted 10-membered heterocyclic ring. In some embodiments, the optionally substituted 3- to 10-membered heterocyclic ring of Ring B is selected from an optionally substituted 3- to 4-membered heterocyclic ring, an optionally substituted 3- to 5-membered heterocyclic ring, an optionally substituted 3- to 6-membered heterocyclic ring, an optionally substituted 3- to 7-membered heterocyclic ring, an optionally substituted 3- to 8-membered heterocyclic ring, and an optionally substituted 3- to 9-membered heterocyclic ring.

[0519] In some embodiments, for compounds or salts of Formula (IV), (IV-a), (IV-b), (IV-c), or (IV-d), Ring B is selected from C optionally substituted with one or more substituents independently selected from 3-10 Carbon ring:

[0520] Halogen, -OR 63 、-SR 63 、-N(R 63 )2、-C(O)R 63 、-C(O)OR 63 、-OC(O)R 63 、-OC(O)N(R 63 )2、-C(O)N(R 63 )2、-N(R 63 )C(O)R 63 、-N(R 63 )C(O)OR 63 、-N(R 63 )C(O)N(R 63 )2、-N(R 63 )S(O)2(R 63 ),-S(O)R 63 、-S(O)2R 63 、-S(O)2N(R 63 )2, -NO2 and -CN; and

[0521] C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 63 、-SR 63 、-N(R 63 )2、-C(O)R 63 、-C(O)OR 63 、-OC(O)R 63 、-OC(O)N(R63 )2、-C(O)N(R 63 )2、-N(R 63 )C(O)R 63 、-N(R 63 )C(O)OR 63 、-N(R 63 )C(O)N(R 63 )2、-N(R 63 )S(O)2(R 63 ),-S(O)R 63 、-S(O)2R 63 、-S(O)2N(R 63 )2, -NO2, =S, =O and -CN.

[0522] In some embodiments, for compounds or salts of Formula (IV), (IV-a), (IV-b), (IV-c), or (IV-d), Ring B is selected from C optionally substituted with one or more substituents independently selected from 3-6 Carbon ring:

[0523] Halogen, -OR 63 、-SR 63 、-N(R 63 )2、-C(O)R 63 、-C(O)OR 63 、-OC(O)R 63 、-OC(O)N(R 63 )2、-C(O)N(R 63 )2、-N(R 63 )C(O)R 63 、-N(R 63 )C(O)OR 63 、-N(R 63 )C(O)N(R 63 )2、-N(R 63 )S(O)2(R 63 ),-S(O)R 63 、-S(O)2R 63 、-S(O)2N(R 63 )2, -NO2 and -CN; and

[0524] C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 63 、-SR 63 、-N(R 63 )2、-C(O)R 63 、-C(O)OR 63 、-OC(O)R63 、-OC(O)N(R 63 )2、-C(O)N(R 63 )2、-N(R 63 )C(O)R 63 、-N(R 63 )C(O)OR 63 、-N(R 63 )C(O)N(R 63 )2、-N(R 63 )S(O)2(R 63 ),-S(O)R 63 、-S(O)2R 63 、-S(O)2N(R 63 )2, -NO2, =S, =O and -CN.

[0525] In some embodiments, for the compound or salt of Formula (IV), (IV-a), (IV-b), (IV-c), or (IV-d), Ring B is phenyl optionally substituted with one or more substituents independently selected from:

[0526] Halogen, -OR 63 、-SR 63 、-N(R 63 )2、-C(O)R 63 、-C(O)OR 63 、-OC(O)R 63 、-OC(O)N(R 63 )2、-C(O)N(R 63 )2、-N(R 63 )C(O)R 63 、-N(R 63 )C(O)OR 63 、-N(R 63 )C(O)N(R 63 )2、-N(R 63 )S(O)2(R 63 ),-S(O)R 63 、-S(O)2R 63 、-S(O)2N(R 63 )2, -NO2 and -CN; and

[0527] C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 63 、-SR 63 、-N(R 63 )2、-C(O)R 63 、-C(O)OR 63 、-OC(O)R63 、-OC(O)N(R 63 )2、-C(O)N(R 63 )2、-N(R 63 )C(O)R 63 、-N(R 63 )C(O)OR 63 、-N(R 63 )C(O)N(R 63 )2、-N(R 63 )S(O)2(R 63 ),-S(O)R 63 、-S(O)2R 63 、-S(O)2N(R 63 )2, -NO2, =S, =O and -CN.

[0528] In some embodiments, for compounds or salts of Formula (IV), (IV-a), (IV-b), (IV-c), or (IV-d), Ring B is phenyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 63 、-SR 63 、-N(R 63 )2、-C(O)R 63 、-C(O)OR 63 、-OC(O)R 63 、-OC(O)N(R 63 )2、-C(O)N(R 63 )2、-N(R 63 )C(O)R 63 、-N(R 63 )C(O)OR 63 、-N(R 63 )C(O)N(R 63 )2、-N(R 63 )S(O)2(R 63 ),-S(O)R 63 、-S(O)2R 63 、-S(O)2N(R 63 )2, -NO2 and -CN. In some embodiments, Ring B is phenyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 63 、-SR 63 、-N(R 63 )2、-C(O)R 63 、-C(O)OR 63 , -NO2 and -CN.

[0529] In some embodiments, for compounds or salts of Formula (IV), (IV-a), (IV-b), (IV-c), or (IV-d), Ring B is optionally independently selected from C 1-6 Phenyl substituted with one or more alkyl substituents, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 63 、-SR 63 、-N(R 63 )2、-C(O)R 63 、-C(O)OR 63 、-OC(O)R 63 、-OC(O)N(R 63 )2、-C(O)N(R 63 )2、-N(R 63 )C(O)R 63 、-N(R 63 )C(O)OR 63 、-N(R 63 )C(O)N(R 63 )2、-N(R 63 )S(O)2(R 63 ),-S(O)R 63 、-S(O)2R 63 、-S(O)2N(R 63 )2, -NO2, =S, =O and -CN. In some embodiments, Ring B is optionally independently selected from C 1-6 Phenyl substituted with one or more alkyl substituents, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 63 、-SR 63 、-N(R 63 )2、-C(O)R 63 、-C(O)OR 63 , -NO2, =S, =O and -CN. In some embodiments, Ring B is optionally independently selected from C 1-3 Phenyl substituted with one or more alkyl substituents, the C 1-3 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 63 、-SR 63 、-N(R 63 )2、-C(O)R 63 、-C(O)OR 63 , -NO2, =S, =O and -CN.

[0530] In some embodiments, for compounds or salts of Formula (IV), (IV-a), (IV-b), (IV-c), or (IV-d), Ring B is C optionally substituted with one or more substituents independently selected from the group consisting of: 3-6 Carbocyclic ring: halogen, -OR 63 、-N(R 63 )2、-C(O)R 63 , -NO2, -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 63 、-N(R 63 )2、-C(O)R 63 , -NO2 and -CN; and R 63 Selected from hydrogen and C 1-3 In some embodiments, Ring B is phenyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 63 、-N(R 63 )2、-C(O)R 63 , -NO2, -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 63 、-N(R 63 )2、-C(O)R 63 , -NO2 and -CN; and R 63 Selected from hydrogen and C 1-3 alkyl.

[0531] In some embodiments, for compounds or salts of Formula (IV), (IV-a), (IV-b), (IV-c), or (IV-d), Ring B is optionally independently selected from halogen and C 1-6 Phenyl substituted with one or more alkyl substituents, the C 1-6 Alkyl is optionally independently selected from halogen and -OR 63 substituted with one or more substituents; and R 63 Selected from hydrogen and C 1-3 In some embodiments, wherein Ring B is optionally independently selected from halogen and C 1-3 Phenyl substituted with one or more alkyl substituents, the C 1-3 Alkyl is optionally independently selected from halogen and -OR 63 substituted with one or more substituents; and R 63 Selected from hydrogen and C 1-3 In some embodiments, wherein Ring B is optionally independently selected from halogen, -OR 63 and C 1-3Phenyl substituted with one or more alkyl substituents, the C 1-3 Alkyl is optionally independently selected from halogen and -OR 63 substituted with one or more substituents; and each R 63 independently selected from hydrogen and C 1-3 alkyl.

[0532] In some embodiments, for the compound or salt of Formula (IV), (IV-a), (IV-b), (IV-c), or (IV-d), Ring B is selected from a 3- to 6-membered heterocyclic ring optionally substituted with one or more substituents independently selected from:

[0533] Halogen, -OR 63 、-SR 63 、-N(R 63 )2、-C(O)R 63 、-C(O)OR 63 、-OC(O)R 63 、-OC(O)N(R 63 )2、-C(O)N(R 63 )2、-N(R 63 )C(O)R 63 、-N(R 63 )C(O)OR 63 、-N(R 63 )C(O)N(R 63 )2、-N(R 63 )S(O)2(R 63 ),-S(O)R 63 、-S(O)2R 63 、-S(O)2N(R 63 )2, -NO2 and -CN; and

[0534] C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 63 、-SR 63 、-N(R 63 )2、-C(O)R 63 、-C(O)OR 63 、-OC(O)R 63 、-OC(O)N(R 63 )2、-C(O)N(R 63 )2、-N(R 63 )C(O)R 63 、-N(R 63 )C(O)OR 63 、-N(R 63 )C(O)N(R 63)2、-N(R 63 )S(O)2(R 63 ),-S(O)R 63 、-S(O)2R 63 、-S(O)2N(R 63 )2, -NO2, =S, =O and -CN.

[0535] In some embodiments, for the compound or salt of Formula (IV), (IV-a), (IV-b), (IV-c), or (IV-d), Ring B is pyridinyl optionally substituted with one or more substituents independently selected from:

[0536] Halogen, -OR 63 、-SR 63 、-N(R 63 )2、-C(O)R 63 、-C(O)OR 63 、-OC(O)R 63 、-OC(O)N(R 63 )2、-C(O)N(R 63 )2、-N(R 63 )C(O)R 63 、-N(R 63 )C(O)OR 63 、-N(R 63 )C(O)N(R 63 )2、-N(R 63 )S(O)2(R 63 ),-S(O)R 63 、-S(O)2R 63 、-S(O)2N(R 63 )2, -NO2 and -CN; and

[0537] C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 63 、-SR 63 、-N(R 63 )2、-C(O)R 63 、-C(O)OR 63 、-OC(O)R 63 、-OC(O)N(R 63 )2、-C(O)N(R 63 )2、-N(R 63 )C(O)R 63 、-N(R 63 )C(O)OR 63 、-N(R 63 )C(O)N(R63 )2、-N(R 63 )S(O)2(R 63 ),-S(O)R 63 、-S(O)2R 63 、-S(O)2N(R 63 )2, -NO2, =S, =O and -CN.

[0538] In some embodiments, for compounds or salts of Formula (IV), (IV-a), (IV-b), (IV-c), or (IV-d), Ring B is pyridinyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 63 、-SR 63 、-N(R 63 )2、-C(O)R 63 、-C(O)OR 63 、-OC(O)R 63 、-OC(O)N(R 63 )2、-C(O)N(R 63 )2、-N(R 63 )C(O)R 63 、-N(R 63 )C(O)OR 63 、-N(R 63 )C(O)N(R 63 )2、-N(R 63 )S(O)2(R 63 ),-S(O)R 63 、-S(O)2R 63 、-S(O)2N(R 63 )2, -NO2 and -CN. In some embodiments, Ring B is pyridinyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 63 、-SR 63 、-N(R 63 )2、-C(O)R 63 、-C(O)OR 63 , -NO2 and -CN.

[0539] In some embodiments, for compounds or salts of Formula (IV), (IV-a), (IV-b), (IV-c), or (IV-d), Ring B is optionally independently selected from C 1-6 The pyridyl group is substituted with one or more substituents of the alkyl group, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 63 、-SR 63 、-N(R 63)2、-C(O)R 63 、-C(O)OR 63 、-OC(O)R 63 、-OC(O)N(R 63 )2、-C(O)N(R 63 )2、-N(R 63 )C(O)R 63 、-N(R 63 )C(O)OR 63 、-N(R 63 )C(O)N(R 63 )2、-N(R 63 )S(O)2(R 63 ),-S(O)R 63 、-S(O)2R 63 、-S(O)2N(R 63 )2, -NO2, =S, =O and -CN. In some embodiments, Ring B is optionally independently selected from C 1-6 The pyridyl group is substituted with one or more substituents of the alkyl group, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 63 、-SR 63 、-N(R 63 )2、-C(O)R 63 、-C(O)OR 63 , -NO2, =S, =O and -CN. In some embodiments, Ring B is optionally independently selected from C 1-3 The pyridyl group is substituted with one or more substituents of the alkyl group, the C 1-3 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 63 、-SR 63 、-N(R 63 )2、-C(O)R 63 、-C(O)OR 63 , -NO2, =S, =O and -CN.

[0540] In some embodiments, for compounds or salts of Formula (IV), (IV-a), (IV-b), (IV-c), or (IV-d), Ring B is a 3- to 6-membered heterocyclic ring optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 63 、-N(R 63 )2、-C(O)R 63 , -NO2, -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 63、-N(R 63 )2、-C(O)R 63 , -NO2 and -CN; and R 63 Selected from hydrogen and C 1-3 In some embodiments, Ring B is pyridinyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 63 、-N(R 63 )2、-C(O)R 63 , -NO2, -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 63 、-N(R 63 )2、-C(O)R 63 , -NO2 and -CN; and R 63 Selected from hydrogen and C 1-3 alkyl.

[0541] In some embodiments, for compounds or salts of Formula (IV), (IV-a), (IV-b), (IV-c), or (IV-d), Ring B is optionally independently selected from halogen and C 1-6 The pyridyl group is substituted with one or more substituents of the alkyl group, the C 1-6 Alkyl is optionally independently selected from halogen and -OR 63 substituted with one or more substituents; and R 63 Selected from hydrogen and C 1-3 In some embodiments, wherein Ring B is optionally independently selected from halogen and C 1-3 The pyridyl group is substituted with one or more substituents of the alkyl group, the C 1-3 Alkyl is optionally independently selected from halogen and -OR 63 substituted with one or more substituents; and R 63 Selected from hydrogen and C 1-3 In some embodiments, wherein Ring B is optionally independently selected from halogen, -OR 63 and C 1-3 The pyridyl group is substituted with one or more substituents of the alkyl group, the C 1-3 Alkyl is optionally independently selected from halogen and -OR 63 substituted with one or more substituents; and each R 63 independently selected from hydrogen and C 1-3 alkyl.

[0542] In some embodiments, for compounds or salts of Formula (IV), (IV-a), (IV-b), (IV-c), or (IV-d), Ring B is selected from

[0543] In some embodiments, for compounds or salts of Formula (IV), (IV-a), (IV-b), (IV-c), or (IV-d), Ring B is selected from

[0544] In some embodiments, for compounds or salts of Formula (IV), (IV-a), (IV-b), (IV-c), or (IV-d), Ring B is selected from

[0545] In some embodiments, for compounds or salts of Formula (IV), (IV-a), (IV-b), (IV-c), or (IV-d), Ring B is selected from

[0546] In some embodiments, for a compound or salt of Formula (IV), (IV-a), (IV-b), (IV-c), or (IV-d), R 60 In some embodiments, R 60 is selected from C optionally substituted by one or more substituents independently selected from 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 60 is selected from C optionally substituted by one or more substituents independently selected from 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 60 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN.

[0547] In some embodiments, for a compound or salt of Formula (IV), (IV-a), (IV-b), (IV-c), or (IV-d), R 61 In some embodiments, R 61 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 61 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 61 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN.

[0548] In some embodiments, for a compound or salt of Formula (IV), (IV-a), (IV-b), (IV-c), or (IV-d), R 62 In some embodiments, R 62 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6In some embodiments, R 62 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 62 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN.

[0549] In some embodiments, for a compound or salt of Formula (IV), (IV-a), (IV-b), (IV-c), or (IV-d), R 63 In some embodiments, R 63 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 63 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 In some embodiments, R 63 is selected from C optionally substituted with one or more substituents independently selected from 1-6 Alkyl: C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6Haloalkyl, -NH2, -NO2, =O and -CN.

[0550] In some embodiments, the compound of formula (IV) is: or a salt of any one thereof.

[0551] In some embodiments, the compound of formula (IV) is:

[0552] or a salt of any one thereof.

[0553] A compound of formula (VI).

[0554] In some aspects, the present disclosure provides a compound represented by formula (VI):

[0555]

[0556] or a pharmaceutically acceptable salt, wherein:

[0557] Each X 1 Selected from C(R 100 ) and N;

[0558] X 2 Selected from C(R 104 ) and N;

[0559] R 100 independently selected at each occurrence from:

[0560] Hydrogen, halogen, -OR 102 、-SR 102 、-N(R 102 )2、-C(O)R 102 、-C(O)OR 102 、-OC(O)R 102 、-OC(O)N(R 102 )2、-C(O)N(R 102 )2、-N(R 102 )C(O)R 102 、-N(R 102 )C(O)OR 102 、-N(R 102 )C(O)N(R 102 )2、-N(R 102 )S(O)2(R 102 ),-S(O)R 102 、-S(O)2R102 、-S(O)2N(R 102 )2, -NO2 and -CN;

[0561] C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 102 、-SR 102 、-N(R 102 )2、-C(O)R 102 、-C(O)OR 102 、-OC(O)R 102 、-OC(O)N(R 102 )2、-C(O)N(R 102 )2、-N(R 102 )C(O)R 102 、-N(R 102 )C(O)OR 102 、-N(R 102 )C(O)N(R 102 )2、-N(R 102 )S(O)2(R 102 ),-S(O)R 102 、-S(O)2R 102 、-S(O)2N(R 102 )2, -NO2, =S, =O and -CN; and

[0562] C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 102 、-SR 102 、-N(R 102 )2、-C(O)R 102 、-C(O)OR 102 、-OC(O)R 102 、-OC(O)N(R 102 )2、-C(O)N(R 102 )2、-N(R 102 )C(O)R 102 、-N(R 102 )C(O)OR 102 、-N(R 102 )C(O)N(R 102 )2、-N(R 102 )S(O)2(R 102 ),-S(O)R 102 、-S(O)2R 102 、-S(O)2N(R 102)2, -NO2, =S, =O and -CN;

[0563] R 101 Independently selected from:

[0564] C 1-6 Alkyl and C 2-6 alkenyl, any of which is optionally substituted with one or more substituents independently selected from halogen, -OR 103 、-SR 103 、-N(R 103 )2、-C(O)R 103 、-C(O)OR 103 、-OC(O)R 103 、-OC(O)N(R 103 )2、-C(O)N(R 103 )2、-N(R 103 )C(O)R 103 、-N(R 103 )C(O)OR 103 、-N(R 103 )C(O)N(R 103 )2、-N(R 103 )S(O)2(R 103 ),-S(O)R 103 、-S(O)2R 103 、-S(O)2N(R 103 )2, -NO2, =S, =O and -CN; and

[0565] C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 103 、-SR 103 、-N(R 103 )2、-C(O)R 103 、-C(O)OR 103 、-OC(O)R 103 、-OC(O)N(R 103 )2、-C(O)N(R 103 )2、-N(R 103 )C(O)R 103 、-N(R 103 )C(O)OR 103 、-N(R 103 )C(O)N(R 103 )2、-N(R 103 )S(O)2(R 103 ),-S(O)R 103 、-S(O)2R 103、-S(O)2N(R 103 )2, -NO2, =S, =O and -CN;

[0566] Ring B is selected from phenyl, thienyl, imidazolyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, quinolinyl, benzimidazolyl, benzisoxazolyl, benzodioxolyl, benzofuranyl, dihydrobenzofuranyl, dihydrofuropyridinyl, furopyridinyl, any of which is optionally substituted with one or more substituents independently selected from the following:

[0567] Halogen, -OR 105 、-SR 105 、-N(R 105 )2、-C(O)R 105 、-C(O)OR 105 、-OC(O)R 105 、-OC(O)N(R 105 )2、-C(O)N(R 105 )2、-N(R 105 )C(O)R 105 、-N(R 105 )C(O)OR 105 、-N(R 105 )C(O)N(R 105 )2、-N(R 105 )S(O)2(R 105 ),-S(O)R 105 、-S(O)2R 105 、-S(O)2N(R 105 )2, -NO2 and -CN;

[0568] C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 105 、-SR 105 、-N(R 105 )2、-C(O)R 105 、-C(O)OR 105 、-OC(O)R 105 、-OC(O)N(R 105 )2、-C(O)N(R 105 )2、-N(R 105 )C(O)R 105 、-N(R 105 )C(O)OR 105 、-N(R 105 )C(O)N(R 105 )2、-N(R 105 )S(O)2(R 105),-S(O)R 105 、-S(O)2R 105 、-S(O)2N(R 105 )2, -NO2, =S, =O and -CN; and

[0569] C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 105 、-SR 105 、-N(R 105 )2、-C(O)R 105 、-C(O)OR 105 、-OC(O)R 105 、-OC(O)N(R 105 )2、-C(O)N(R 105 )2、-N(R 105 )C(O)R 105 、-N(R 105 )C(O)OR 105 、-N(R 105 )C(O)N(R 105 )2、-N(R 105 )S(O)2(R 105 ),-S(O)R 105 、-S(O)2R 105 、-S(O)2N(R 105 )2, -NO2, =S, =O and -CN;

[0570] R 104 Selected from hydrogen and C 1-3 alkyl;

[0571] R 102 、R 103 and R 105 independently selected at each occurrence from:

[0572] hydrogen;

[0573] C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6Haloalkyl, -NH2, -NO2, =O, and -CN; and

[0574] C optionally substituted with one or more substituents independently selected from the following 3-10 Carbocyclic rings and 3- to 10-membered heterocyclic rings: halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN,

[0575] Wherein the compound is not selected from:

[0576] 2-methyl-4-[(4-phenyl-1-piperidinyl)carbonyl]-1(2H)-phthalazinone,

[0577] 2-methyl-4-[(4-phenyl-1-piperazinyl)carbonyl]-1(2H)-phthalazinone,

[0578] 2-(1-methylethyl)-4-[(4-phenyl-1-piperidinyl)carbonyl]-1(2H)-phthalazinone,

[0579] 2-ethyl-4-[(4-phenyl-1-piperazinyl)carbonyl]-1(2H)-phthalazinone,

[0580] 2-(1-methylethyl)-4-[[4-(2-thienyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0581] 2-(2-methylpropyl)-4-[(4-phenyl-1-piperidinyl)carbonyl]-1(2H)-phthalazinone,

[0582] 2-methyl-4-[[4-(3-methylphenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0583] 2-(1-methylethyl)-4-[(4-phenyl-1-piperazinyl)carbonyl]-1(2H)-phthalazinone,

[0584] 4-[(4-phenyl-1-piperazinyl)carbonyl]-2-propyl-1(2H)-phthalazinone,

[0585] 2-(1-methylethyl)-4-[[4-(4-pyridinyl)-1-piperidinyl]carbonyl]-1(2H)-phthalazinone,

[0586] 2-(2-methylpropyl)-4-[(4-phenyl-1-piperazinyl)carbonyl]-1(2H)-phthalazinone,

[0587] 2-methyl-4-[[4-(2-pyridyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0588] 2-Butyl-4-[(4-phenyl-1-piperazinyl)carbonyl]-1(2H)-phthalazinone,

[0589] 2-(1-methylethyl)-4-[[4-(2-methylphenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0590] 2-(1-methylethyl)-4-[[4-(4-pyridyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0591] 2-(1-methylethyl)-4-[[4-(3-methylphenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0592] 4-[[4-(3-methylphenyl)-1-piperazinyl]carbonyl]-2-propyl-1(2H)-phthalazinone,

[0593] 2-ethyl-4-[[4-(2-pyridyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0594] 4-[[4-(4-Hydroxyphenyl)-1-piperazinyl]carbonyl]-2-(1-methylethyl)-1(2H)-phthalazinone,

[0595] 2-phenyl-4-[(4-phenyl-1-piperidinyl)carbonyl]-1(2H)-phthalazinone,

[0596] 2-methyl-4-[[4-(2-pyrazinyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0597] 2-methyl-4-[[4-(2-pyrimidinyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0598] 4-[[4-(2,3-dimethylphenyl)-1-piperazinyl]carbonyl]-2-methyl-1(2H)-phthalazinone,

[0599] 4-[[4-(4-methoxyphenyl)-1-piperazinyl]carbonyl]-2-methyl-1(2H)-phthalazinone,

[0600] 4-[[4-(3-hydroxyphenyl)-1-piperazinyl]carbonyl]-2-(1-methylethyl)-1(2H)-phthalazinone,

[0601] 2-(2-methylpropyl)-4-[[4-(4-pyridyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0602] 4-[[4-(2-hydroxyphenyl)-1-piperazinyl]carbonyl]-2-(1-methylethyl)-1(2H)-phthalazinone,

[0603] 2-ethyl-4-[[4-(2-pyrimidinyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0604] 2-pentyl-4-[(4-phenyl-1-piperazinyl)carbonyl]-1(2H)-phthalazinone,

[0605] 4-[[4-(2,3-dimethylphenyl)-1-piperazinyl]carbonyl]-2-ethyl-1(2H)-phthalazinone,

[0606] 2-ethyl-4-[[4-(4-methoxyphenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0607] 4-[[4-(2-Hydroxyphenyl)-1-piperazinyl]carbonyl]-2-propyl-1(2H)-phthalazinone,

[0608] 4-[[4-(2-methylphenyl)-1-piperazinyl]carbonyl]-2-(2-methylpropyl)-1(2H)-phthalazinone,

[0609] 4-[[4-(4-chlorophenyl)-1-piperazinyl]carbonyl]-2-methyl-1(2H)-phthalazinone,

[0610] 2-(1-methylethyl)-4-[[4-(2-pyridyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0611] 2-Hexyl-4-[(4-phenyl-1-piperazinyl)carbonyl]-1(2H)-phthalazinone,

[0612] 4-[[4-(2-methoxyphenyl)-1-piperazinyl]carbonyl]-2-methyl-1(2H)-phthalazinone,

[0613] 4-[[4-(3-methoxyphenyl)-1-piperazinyl]carbonyl]-2-methyl-1(2H)-phthalazinone,

[0614] 2-phenyl-4-[(4-phenyl-1-piperazinyl)carbonyl]-1(2H)-phthalazinone,

[0615] 2-propyl-4-[[4-(2-pyridyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0616] 4-[[4-(4-Fluorophenyl)-1-piperazinyl]carbonyl]-2-methyl-1(2H)-phthalazinone,

[0617] 2-(1-methylethyl)-4-[[4-(2-thiazolyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0618] 2-propyl-4-[[4-(2-thiazolyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0619] 2-(2-hydroxyethyl)-4-[[4-(2-pyridyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0620] 2-(1-methylethyl)-4-[[4-(3-pyridazinyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0621] 2-(1-methylethyl)-4-[[4-(4-methyl-3-pyridyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0622] 4-[[4-(4-Hydroxyphenyl)-1-piperazinyl]carbonyl]-2-(2-methylpropyl)-1(2H)-phthalazinone,

[0623] 2-ethyl-4-[[4-(2-methoxyphenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0624] 4-[[4-(4-acetylphenyl)-1-piperazinyl]carbonyl]-2-methyl-1(2H)-phthalazinone,

[0625] 2-ethyl-4-[[4-(3-methoxyphenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0626] 4-[[4-(3-chlorophenyl)-1-piperazinyl]carbonyl]-2-methyl-1(2H)-phthalazinone,

[0627] 4-[[4-(2-chlorophenyl)-1-piperazinyl]carbonyl]-2-methyl-1(2H)-phthalazinone,

[0628] 4-[[4-(2-Fluorophenyl)-1-piperazinyl]carbonyl]-2-methyl-1(2H)-phthalazinone,

[0629] 4-[[4-(4-Hydroxyphenyl)-1-piperidinyl]carbonyl]-2-pentyl-1(2H)-phthalazinone,

[0630] 4-[[4-(3-hydroxyphenyl)-1-piperazinyl]carbonyl]-2-(2-methylpropyl)-1(2H)-phthalazinone,

[0631] 4-[[4-(2-hydroxyphenyl)-1-piperazinyl]carbonyl]-2-(2-methylpropyl)-1(2H)-phthalazinone,

[0632] 2-ethyl-4-[[4-(4-fluorophenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0633] 4-[[4-(4-methoxyphenyl)-1-piperazinyl]carbonyl]-2-(1-methylethyl)-1(2H)-phthalazinone,

[0634] 2-(2-methylpropyl)-4-[[4-(2-pyridyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0635] 4-[[4-(2-ethoxyphenyl)-1-piperazinyl]carbonyl]-2-methyl-1(2H)-phthalazinone,

[0636] 4-[[4-(4-methoxyphenyl)-1-piperazinyl]carbonyl]-2-propyl-1(2H)-phthalazinone,

[0637] 2-butyl-4-[[4-(2-pyridyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0638] 4-[[4-(4-acetylphenyl)-1-piperazinyl]carbonyl]-2-ethyl-1(2H)-phthalazinone,

[0639] 2-(1-methylethyl)-4-[[4-(2-pyrazinyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0640] 4-[(4-phenyl-1-piperazinyl)carbonyl]-2-(4-pyridinyl)-1(2H)-phthalazinone,

[0641] 2-pentyl-4-[[4-(4-pyridyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0642] 4-[[4-(1H-imidazol-5-yl)-1-piperidinyl]carbonyl]-2-(1-methylethyl)-1(2H)-phthalazinone,

[0643] 4-[[4-(3-methylphenyl)-1-piperazinyl]carbonyl]-2-phenyl-1(2H)-phthalazinone,

[0644] 2-ethyl-4-[[4-(2-fluorophenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0645] 4-[[4-(2-chlorophenyl)-1-piperazinyl]carbonyl]-2-ethyl-1(2H)-phthalazinone,

[0646] 2-(1-methylethyl)-4-[[4-(2-pyrimidinyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0647] 2-propyl-4-[[4-(2-pyrimidinyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0648] 4-[[4-(2,3-dimethylphenyl)-1-piperazinyl]carbonyl]-2-(1-methylethyl)-1(2H)-phthalazinone,

[0649] 2-(1-methylethyl)-4-[[4-(4-methyl-2-pyridyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0650] 4-[[4-(4-methoxyphenyl)-1-piperazinyl]carbonyl]-2-(2-methylpropyl)-1(2H)-phthalazinone,

[0651] 4-[[4-(2-methylphenyl)-1-piperazinyl]carbonyl]-2-pentyl-1(2H)-phthalazinone,

[0652] 4-[[4-(4-Fluorophenyl)-1-piperazinyl]carbonyl]-2-(1-methylethyl)-1(2H)-phthalazinone,

[0653] 4-[[4-(3-methoxyphenyl)-1-piperazinyl]carbonyl]-2-(1-methylethyl)-1(2H)-phthalazinone,

[0654] 4-[[4-(2-methoxyphenyl)-1-piperazinyl]carbonyl]-2-propyl-1(2H)-phthalazinone,

[0655] 4-[[4-(2-methoxyphenyl)-1-piperazinyl]carbonyl]-2-(1-methylethyl)-1(2H)-phthalazinone,

[0656] 4-[[4-(3-methoxyphenyl)-1-piperazinyl]carbonyl]-2-propyl-1(2H)-phthalazinone,

[0657] 4-[[4-(2-ethoxyphenyl)-1-piperazinyl]carbonyl]-2-ethyl-1(2H)-phthalazinone,

[0658] 1-[(3,4-dihydro-3-methyl-4-oxo-1-phthalazinyl)carbonyl]-4-phenyl-4-piperidinic acid,

[0659] 4-[[4-(4-acetylphenyl)-1-piperazinyl]carbonyl]-2-propyl-1(2H)-phthalazinone,

[0660] 4-[[4-(2-Fluorophenyl)-1-piperazinyl]carbonyl]-2-propyl-1(2H)-phthalazinone,

[0661] 4-[[4-(3-chlorophenyl)-1-piperazinyl]carbonyl]-2-(1-methylethyl)-1(2H)-phthalazinone,

[0662] 4-[[4-(3-Hydroxyphenyl)-1-piperazinyl]carbonyl]-2-pentyl-1(2H)-phthalazinone,

[0663] 4-[[4-(2-Hydroxyphenyl)-1-piperazinyl]carbonyl]-2-pentyl-1(2H)-phthalazinone,

[0664] 2-methyl-4-[[4-(2-nitrophenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0665] 2-butyl-4-[[4-(4-methoxyphenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0666] 4-[[4-(2-Fluorophenyl)-1-piperazinyl]carbonyl]-2-(1-methylethyl)-1(2H)-phthalazinone,

[0667] 4-[[4-(4-acetylphenyl)-1-piperazinyl]carbonyl]-2-(1-methylethyl)-1(2H)-phthalazinone,

[0668] 4-[[4-(3-chlorophenyl)-1-piperazinyl]carbonyl]-2-propyl-1(2H)-phthalazinone,

[0669] 2-ethyl-4-[[4-(4-nitrophenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0670] 4-[[4-(2-Hydroxyphenyl)-1-piperazinyl]carbonyl]-2-phenyl-1(2H)-phthalazinone,

[0671] 2-phenyl-4-[[4-(2-pyridyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0672] 4-[[4-(4-methoxyphenyl)-1-piperidinyl]carbonyl]-2-phenyl-1(2H)-phthalazinone,

[0673] 2-Hexyl-4-[[4-(2-pyridyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0674] 4-[[4-(4-acetylphenyl)-1-piperazinyl]carbonyl]-2-(2-hydroxyethyl)-1(2H)-phthalazinone,

[0675] 4-[[4-(2,3-dimethylphenyl)-1-piperazinyl]carbonyl]-2-(2-methylpropyl)-1(2H)-phthalazinone,

[0676] 4-[[4-(3-methoxyphenyl)-1-piperazinyl]carbonyl]-2-(2-methylpropyl)-1(2H)-phthalazinone,

[0677] 2-butyl-4-[[4-(2-pyrazinyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0678] 4-[[4-(2-ethoxyphenyl)-1-piperazinyl]carbonyl]-2-propyl-1(2H)-phthalazinone,

[0679] 1-[(3-ethyl-3,4-dihydro-4-oxo-1-phthalazinyl)carbonyl]-4-phenyl-4-piperidinic acid,

[0680] 2-Butyl-4-[[4-(2,3-dimethylphenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0681] 2-pentyl-4-[[4-(2-pyridyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0682] 4-[[4-(2-methoxyphenyl)-1-piperazinyl]carbonyl]-2-(2-methylpropyl)-1(2H)-phthalazinone,

[0683] 2-butyl-4-[[4-(2-pyrimidinyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0684] 2-(1-methylethyl)-4-[[4-(1-methyl-1H-imidazol-2-yl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0685] 4-[[4-(5-chloro-2-methylphenyl)-1-piperazinyl]carbonyl]-2-methyl-1(2H)-phthalazinone,

[0686] 4-[[4-(3-methylphenyl)-1-piperazinyl]carbonyl]-2-(4-pyridyl)-1(2H)-phthalazinone,

[0687] 2-ethyl-4-[[4-(2-nitrophenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0688] 1-[[3,4-dihydro-3-(1-methylethyl)-4-oxo-1-phthalazinyl]carbonyl]-4-phenyl-4-piperidinic acid,

[0689] 1-[(3,4-dihydro-4-oxo-3-propyl-1-phthalazinyl)carbonyl]-4-phenyl-4-piperidinic acid,

[0690] 4-[[4-(4-nitrophenyl)-1-piperazinyl]carbonyl]-2-propyl-1(2H)-phthalazinone,

[0691] 2-butyl-4-[[4-(2-methoxyphenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0692] 2-butyl-4-[[4-(3-methoxyphenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0693] 4-[[4-(2,3-dimethylphenyl)-1-piperazinyl]carbonyl]-2-phenyl-1(2H)-phthalazinone,

[0694] 4-[[4-(4-acetylphenyl)-1-piperazinyl]carbonyl]-2-(2-methylpropyl)-1(2H)-phthalazinone,

[0695] 4-[[4-(4-acetylphenyl)-1-piperazinyl]carbonyl]-2-butyl-1(2H)-phthalazinone,

[0696] 4-[[4-(4-methoxyphenyl)-1-piperazinyl]carbonyl]-2-pentyl-1(2H)-phthalazinone,

[0697] 4-[[4-(2,3-dimethylphenyl)-1-piperazinyl]carbonyl]-2-pentyl-1(2H)-phthalazinone,

[0698] 2-(1-methylethyl)-4-[[4-(4-nitrophenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0699] 2-butyl-4-[[4-(4-fluorophenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0700] 4-[[4-(4-methoxyphenyl)-1-piperazinyl]carbonyl]-2-phenyl-1(2H)-phthalazinone,

[0701] 2-(4-methoxyphenyl)-4-[(4-phenyl-1-piperazinyl)carbonyl]-1(2H)-phthalazinone,

[0702] 4-[[4-(1H-indol-3-yl)-1-piperidinyl]carbonyl]-2-(2-methylpropyl)-1(2H)-phthalazinone,

[0703] 4-[[4-(3,4-dichlorophenyl)-1-piperazinyl]carbonyl]-2-methyl-1(2H)-phthalazinone,

[0704] 4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]carbonyl]-2-methyl-1(2H)-phthalazinone,

[0705] 4-[[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]carbonyl]-2-methyl-1(2H)-phthalazinone,

[0706] 4-[[4-(5-bromo-2-pyrimidinyl)-1-piperazinyl]carbonyl]-2-methyl-1(2H)-phthalazinone,

[0707] 4-[[4-(2-Benzoxazolyl)-1-piperidinyl]carbonyl]-2-methyl-1(2H)-phthalazinone,

[0708] 4-[[4-(3-methoxyphenyl)-1-piperazinyl]carbonyl]-2-phenyl-1(2H)-phthalazinone,

[0709] 4-[[4-(2-methoxyphenyl)-1-piperazinyl]carbonyl]-2-phenyl-1(2H)-phthalazinone,

[0710] 2-Hexyl-4-[[4-(2-pyrimidinyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0711] 2-pentyl-4-[[4-(2-pyrimidinyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0712] 2-(3-methoxyphenyl)-4-[(4-phenyl-1-piperazinyl)carbonyl]-1(2H)-phthalazinone,

[0713] 4-[[4-(4-acetylphenyl)-1-piperazinyl]carbonyl]-2-hexyl-1(2H)-phthalazinone,

[0714] 2-(4-pyridyl)-4-[[4-(2-pyridyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0715] 2-(2-methylpropyl)-4-[[4-(4-nitrophenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0716] 1-[[3,4-dihydro-3-(2-methylpropyl)-4-oxo-1-phthalazinyl]carbonyl]-4-phenyl-4-piperidinic acid,

[0717] 2-(1-methylethyl)-4-[[4-(2-nitrophenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0718] 4-[[4-(4-chlorophenyl)-1-piperazinyl]carbonyl]-2-pentyl-1(2H)-phthalazinone,

[0719] 4-[[4-(2-methoxyphenyl)-1-piperazinyl]carbonyl]-2-pentyl-1(2H)-phthalazinone,

[0720] 4-[[4-(3-methoxyphenyl)-1-piperazinyl]carbonyl]-2-pentyl-1(2H)-phthalazinone,

[0721] 4-[[4-(4-Fluorophenyl)-1-piperazinyl]carbonyl]-2-pentyl-1(2H)-phthalazinone,

[0722] 4-[[4-(4-acetylphenyl)-1-piperazinyl]carbonyl]-2-pentyl-1(2H)-phthalazinone,

[0723] 2-phenyl-4-[[4-(2-pyrimidinyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0724] 2-(4-ethoxyphenyl)-4-[(4-phenyl-1-piperazinyl)carbonyl]-1(2H)-phthalazinone,

[0725] 2-(2-methoxyphenyl)-4-[(4-phenyl-1-piperazinyl)carbonyl]-1(2H)-phthalazinone,

[0726] 4-[[4-(1H-indol-3-yl)-1-piperidinyl]carbonyl]-2-pentyl-1(2H)-phthalazinone,

[0727] 2-(4-chlorophenyl)-4-[(4-phenyl-1-piperazinyl)carbonyl]-1(2H)-phthalazinone,

[0728] 2-(4-pyridyl)-4-[[4-(2-pyrimidinyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0729] 4-[[4-(2,3-dimethylphenyl)-1-piperazinyl]carbonyl]-2-(4-pyridyl)-1(2H)-phthalazinone,

[0730] 4-[[4-(4-Fluorophenyl)-1-piperazinyl]carbonyl]-2-phenyl-1(2H)-phthalazinone,

[0731] 4-[[4-(2-Fluorophenyl)-1-piperazinyl]carbonyl]-2-pentyl-1(2H)-phthalazinone,

[0732] 4-[[4-(4-chlorophenyl)-1-piperazinyl]carbonyl]-2-phenyl-1(2H)-phthalazinone,

[0733] 4-[[4-(3-chlorophenyl)-1-piperazinyl]carbonyl]-2-pentyl-1(2H)-phthalazinone,

[0734] 4-[[4-(2-ethoxyphenyl)-1-piperazinyl]carbonyl]-2-phenyl-1(2H)-phthalazinone,

[0735] 1-[(3-butyl-3,4-dihydro-4-oxo-1-phthalazinyl)carbonyl]-4-phenyl-4-piperidinic acid,

[0736] 4-[[4-(3-chlorophenyl)-1-piperazinyl]carbonyl]-2-phenyl-1(2H)-phthalazinone,

[0737] 4-[[4-(2-Fluorophenyl)-1-piperazinyl]carbonyl]-2-phenyl-1(2H)-phthalazinone,

[0738] 2-butyl-4-[[4-(1H-indol-2-yl)-1-piperidinyl]carbonyl]-1(2H)-phthalazinone,

[0739] 4-[[4-(4-methoxyphenyl)-1-piperazinyl]carbonyl]-2-(4-pyridyl)-1(2H)-phthalazinone,

[0740] 2-(2-methylpropyl)-4-[[4-(2-nitrophenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0741] 2-[4-[(3-butyl-3,4-dihydro-4-oxo-1-phthalazinyl)carbonyl]-1-piperazinyl]-3-pyridinecarbonitrile,

[0742] 4-[[4-(2-ethoxyphenyl)-1-piperazinyl]carbonyl]-2-pentyl-1(2H)-phthalazinone,

[0743] 4-[[4-(4-nitrophenyl)-1-piperazinyl]carbonyl]-2-pentyl-1(2H)-phthalazinone,

[0744] 4-[[4-(4-nitrophenyl)-1-piperazinyl]carbonyl]-2-phenyl-1(2H)-phthalazinone,

[0745] 4-[[4-(4-acetylphenyl)-1-piperazinyl]carbonyl]-2-phenyl-1(2H)-phthalazinone,

[0746] 4-[[4-(2-methoxyphenyl)-1-piperazinyl]carbonyl]-2-(4-pyridyl)-1(2H)-phthalazinone,

[0747] 4-[[4-(3-nitrophenyl)-1-piperazinyl]carbonyl]-2-phenyl-1(2H)-phthalazinone,

[0748] 2-(4-chlorophenyl)-4-[[4-(4-methylphenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0749] 4-[[4-(2-Benzoxazolyl)-1-piperidinyl]carbonyl]-2-(2-hydroxyethyl)-1(2H)-phthalazinone,

[0750] 4-[[4-(2-Fluorophenyl)-1-piperazinyl]carbonyl]-2-(4-pyridyl)-1(2H)-phthalazinone,

[0751] 4-[[4-(4-Fluorophenyl)-1-piperazinyl]carbonyl]-2-(4-pyridyl)-1(2H)-phthalazinone,

[0752] 4-[[4-(3-chlorophenyl)-1-piperazinyl]carbonyl]-2-(4-pyridyl)-1(2H)-phthalazinone,

[0753] 4-[[4-(5-chloro-2-methylphenyl)-1-piperazinyl]carbonyl]-2-(2-methylpropyl)-1(2H)-phthalazinone,

[0754] 4-[[4-(2-nitrophenyl)-1-piperazinyl]carbonyl]-2-pentyl-1(2H)-phthalazinone,

[0755] 4-[[4-(5-chloro-2-pyridyl)-1-piperazinyl]carbonyl]-2-(2-methylpropyl)-1(2H)-phthalazinone,

[0756] 2-[4-[[3,4-dihydro-3-(1-methylethyl)-4-oxo-1-phthalazinyl]carbonyl]-1-piperazinyl]-6-fluorobenzonitrile,

[0757] 4-[[4-(1H-benzimidazol-2-yl)-1-piperidinyl]carbonyl]-2-(1-methylethyl)-1(2H)-phthalazinone,

[0758] 2-[4-[(3,4-dihydro-4-oxo-3-phenyl-1-phthalazinyl)carbonyl]-1-piperazinyl]-4-pyridinecarbonitrile,

[0759] 4-[[4-(2-Benzoxazolyl)-1-piperidinyl]carbonyl]-2-(1-methylethyl)-1(2H)-phthalazinone,

[0760] 6-[4-[(3,4-dihydro-4-oxo-3-phenyl-1-phthalazinyl)carbonyl]-1-piperazinyl]-3-pyridinecarbonitrile,

[0761] 4-[[4-(2-Benzothiazolyl)-1-piperidinyl]carbonyl]-2-propyl-1(2H)-phthalazinone,

[0762] 2-(4-methoxyphenyl)-4-[[4-(4-methoxyphenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0763] 2-(4-chlorophenyl)-4-[[4-(3-methylphenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0764] 2-(4-chlorophenyl)-4-[[4-(2-methylphenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0765] 4-[[4-(2-Benzothiazolyl)-1-piperidinyl]carbonyl]-2-(1-methylethyl)-1(2H)-phthalazinone,

[0766] 2-methyl-4-[[4-(8-nitro-5-isoquinolyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0767] 1-[(3,4-dihydro-4-oxo-3-phenyl-1-phthalazinyl)carbonyl]-4-phenyl-4-piperidinic acid,

[0768] 2-(3,5-dimethoxyphenyl)-4-[(4-phenyl-1-piperazinyl)carbonyl]-1(2H)-phthalazinone,

[0769] 1-[1-[(3,4-dihydro-4-oxo-3-phenyl-1-phthalazinyl)carbonyl]-4-piperidinyl]-1H-pyrrole-2-carboxylic acid,

[0770] 2-(2-methoxyphenyl)-4-[[4-(2-methoxyphenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0771] 2-[4-[[3,4-dihydro-3-(2-methylpropyl)-4-oxo-1-phthalazinyl]carbonyl]-1-piperazinyl]-6-fluorobenzonitrile,

[0772] 2-ethyl-4-[[4-(2-phenyl-4-pyrimidinyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0773] 4-[[4-(6-chloro-2-pyridyl)-1-piperazinyl]carbonyl]-2-(1-methylethyl)-1(2H)-phthalazinone,

[0774] 2-ethyl-4-[[4-(8-nitro-5-isoquinolyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone, 2-methyl-4-[[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0775] 2-(4-methoxyphenyl)-4-[[4-(2-methoxyphenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0776] 2-(3-methoxyphenyl)-4-[[4-(4-methoxyphenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0777] 2-(4-ethoxyphenyl)-4-[[4-(4-methoxyphenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0778] 2-(4-chlorophenyl)-4-[[4-(4-chlorophenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0779] 2-methyl-4-[[4-(1-methyl-1H-benzimidazol-2-yl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0780] 4-[[4-(5-chloro-2-pyridyl)-1-piperazinyl]carbonyl]-2-phenyl-1(2H)-phthalazinone,

[0781] 4-[[4-(5-chloro-2-pyridyl)-1-piperazinyl]carbonyl]-2-pentyl-1(2H)-phthalazinone,

[0782] 2-(4-ethoxyphenyl)-4-[[4-(2-pyridyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0783] 2-(2-methoxyphenyl)-4-[[4-(4-methoxyphenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0784] 2-(3-methoxyphenyl)-4-[[4-(2-methoxyphenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0785] 4-[[4-(5-chloro-1,6-dihydro-6-oxo-1-phenyl-4-pyridazinyl)-1-piperazinyl]carbonyl]-2-methyl-1(2H)-phthalazinone,

[0786] 2-(4-chlorophenyl)-4-[[4-(3-chlorophenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0787] 2-(4-chlorophenyl)-4-[[4-(2-chlorophenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0788] 4-[[4-(2,6-dimethyl-4-pyrimidinyl)-1-piperazinyl]carbonyl]-2-(2-methylpropyl)-1(2H)-phthalazinone,

[0789] 4-[4-[(3,4-dihydro-3-methyl-4-oxo-1-phthalazinyl)carbonyl]-3-methyl-1-piperazinyl]benzoic acid methyl ester,

[0790] 2-(4-chlorophenyl)-4-[[4-(2-fluorophenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0791] 2-(4-ethoxyphenyl)-4-[[4-(2-methoxyphenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0792] 4-[[4-(4-Acetyl-2-fluorophenyl)-1-piperazinyl]carbonyl]-2-ethyl-1(2H)-phthalazinone,

[0793] 4-[[4-(4-chloro-2-nitrophenyl)-1-piperazinyl]carbonyl]-2-methyl-1(2H)-phthalazinone,

[0794] 2-propyl-4-[[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0795] 4-[[4-(4-fluorophenyl)-1-piperazinyl]carbonyl]-2-(4-methoxyphenyl)-1(2H)-phthalazinone,

[0796] 2-(3,5-dimethoxyphenyl)-4-[[4-(4-methoxyphenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0797] 2-(2,4-dimethoxyphenyl)-4-[(4-phenyl-1-piperazinyl)carbonyl]-1(2H)-phthalazinone,

[0798] 4-[[4-(5-methoxy-1H-indol-3-yl)-1-piperidinyl]carbonyl]-2-(2-methylpropyl)-1(2H)-phthalazinone,

[0799] 4-[[4-(5-chloro-1,6-dihydro-6-oxo-1-phenyl-4-pyridazinyl)-1-piperazinyl]carbonyl]-2-ethyl-1(2H)-phthalazinone,

[0800] 4-[[4-(4-chloro-2-nitrophenyl)-1-piperazinyl]carbonyl]-2-ethyl-1(2H)-phthalazinone,

[0801] 4-[[4-(2,6-dimethyl-4-pyrimidinyl)-1-piperazinyl]carbonyl]-2-pentyl-1(2H)-phthalazinone,

[0802] 2-(1-methylethyl)-4-[[4-[6-methyl-2-(1-methylethyl)-4-pyrimidinyl]-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0803] 4-[[4-[6-methyl-2-(1-methylethyl)-4-pyrimidinyl]-1-piperazinyl]carbonyl]-2-propyl-1(2H)-phthalazinone,

[0804] 4-[[4-(3-chlorophenyl)-1-piperazinyl]carbonyl]-2-(4-methoxyphenyl)-1(2H)-phthalazinone,

[0805] 4-[[4-(2-fluorophenyl)-1-piperazinyl]carbonyl]-2-(4-methoxyphenyl)-1(2H)-phthalazinone,

[0806] 2-(3,5-dimethoxyphenyl)-4-[[4-(2-methoxyphenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0807] 4-[[4-(3-chlorophenyl)-1-piperazinyl]carbonyl]-2-(3-methoxyphenyl)-1(2H)-phthalazinone,

[0808] 4-[[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]carbonyl]-2-methyl-1(2H)-phthalazinone,

[0809] 4-[[4-(2,6-dimethyl-4-pyrimidinyl)-1-piperazinyl]carbonyl]-2-phenyl-1(2H)-phthalazinone,

[0810] 4-[[4-(6-chloro-2-pyridyl)-1-piperazinyl]carbonyl]-2-phenyl-1(2H)-phthalazinone,

[0811] 2-methyl-4-[[4-[5-(trifluoromethyl)-2-pyridyl]-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0812] 2-(4-chlorophenyl)-4-[[4-(2-methoxyphenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0813] 4-[[4-(2-fluorophenyl)-1-piperazinyl]carbonyl]-2-(2-methoxyphenyl)-1(2H)-phthalazinone,

[0814] 4-[[4-(4-Fluorophenyl)-1-piperazinyl]carbonyl]-2-(3-methoxyphenyl)-1(2H)-phthalazinone,

[0815] 4-[[4-(2-fluorophenyl)-1-piperazinyl]carbonyl]-2-(3-methoxyphenyl)-1(2H)-phthalazinone,

[0816] 2-(2-methylpropyl)-4-[[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0817] 4-[[4-(4-chloro-2-nitrophenyl)-1-piperazinyl]carbonyl]-2-(1-methylethyl)-1(2H)-phthalazinone,

[0818] 2-butyl-4-[[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0819] 2-ethyl-4-[[4-[5-(trifluoromethyl)-2-pyridyl]-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0820] 4-[[4-(4-chloro-2-nitrophenyl)-1-piperazinyl]carbonyl]-2-propyl-1(2H)-phthalazinone,

[0821] 4-[[4-(4-Fluorophenyl)-1-piperazinyl]carbonyl]-2-(2-methoxyphenyl)-1(2H)-phthalazinone,

[0822] 4-[[4-(3-chlorophenyl)-1-piperazinyl]carbonyl]-2-(2-methoxyphenyl)-1(2H)-phthalazinone,

[0823] 2-(2,4-dimethoxyphenyl)-4-[[4-(4-methoxyphenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0824] 2-(2,4-dimethoxyphenyl)-4-[[4-(2-methoxyphenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0825] 2-(4-ethoxyphenyl)-4-[[4-(4-fluorophenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0826] 4-[[4-(3,5-dichloro-2-pyridyl)-1-piperazinyl]carbonyl]-2-(2-methylpropyl)-1(2H)-phthalazinone,

[0827] 2-(4-ethoxyphenyl)-4-[[4-(2-fluorophenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0828] 6-[4-[(3-butyl-3,4-dihydro-4-oxo-1-phthalazinyl)carbonyl]-1-piperazinyl]-3-picolinic acid ethyl ester,

[0829] 4-[[4-(4-acetyl-2-fluorophenyl)-1-piperazinyl]carbonyl]-2-butyl-1(2H)-phthalazinone,

[0830] 2-propyl-4-[[4-[5-(trifluoromethyl)-2-pyridyl]-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0831] 2-(1-methylethyl)-4-[[4-[5-(trifluoromethyl)-2-pyridyl]-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0832] 2-pentyl-4-[[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0833] 4-[[4-(3-chlorophenyl)-1-piperazinyl]carbonyl]-2-(3,5-dimethoxyphenyl)-1(2H)-phthalazinone,

[0834] 4-[[4-(4-chloro-2-nitrophenyl)-1-piperazinyl]carbonyl]-2-phenyl-1(2H)-phthalazinone,

[0835] 2-phenyl-4-[[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0836] 2-(3,5-dimethoxyphenyl)-4-[[4-(4-fluorophenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0837] 2-(3,5-dimethoxyphenyl)-4-[[4-(2-fluorophenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0838] 2-(2,4-dimethoxyphenyl)-4-[[4-(2-pyridyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0839] 4-[[4-(4-chloro-2-nitrophenyl)-1-piperazinyl]carbonyl]-2-pentyl-1(2H)-phthalazinone,

[0840] 4-[[4-(4-Acetyl-2-fluorophenyl)-1-piperazinyl]carbonyl]-2-phenyl-1(2H)-phthalazinone,

[0841] 2-(2,4-dimethoxyphenyl)-4-[[4-(4-fluorophenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0842] 2-pentyl-4-[[4-[5-(trifluoromethyl)-2-pyridyl]-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0843] 2-(2,4-dimethoxyphenyl)-4-[[4-(2-fluorophenyl)-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0844] 2-phenyl-4-[[4-[5-(trifluoromethyl)-2-pyridyl]-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0845] 2-methyl-4-[[4-[2-nitro-4-(trifluoromethyl)phenyl]-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0846] 4-[[4-[3-chloro-5-(trifluoromethyl)-2-pyridyl]-1-piperazinyl]carbonyl]-2-ethyl-1(2H)-phthalazinone,

[0847] 4-[[4-[2-nitro-4-(trifluoromethyl)phenyl]-1-piperazinyl]carbonyl]-2-propyl-1(2H)-phthalazinone,

[0848] 4-[[4-[3-chloro-5-(trifluoromethyl)-2-pyridyl]-1-piperazinyl]carbonyl]-2-(2-hydroxyethyl)-1(2H)-phthalazinone,

[0849] 2-(1-methylethyl)-4-[[4-[2-nitro-4-(trifluoromethyl)phenyl]-1-piperazinyl]carbonyl]-1(2H)-phthalazinone,

[0850] 4-[[4-[3-chloro-5-(trifluoromethyl)-2-pyridyl]-1-piperazinyl]carbonyl]-2-(2-methylpropyl)-1(2H)-phthalazinone, and

[0851] 2-Hexyl-4-[[4-[2-nitro-4-(trifluoromethyl)phenyl]-1-piperazinyl]carbonyl]-1(2H)-phthalazinone.

[0852] In some aspects, the present disclosure provides a compound represented by the following structure:

[0853]

[0854]

[0855]

[0856] or a pharmaceutically acceptable salt of any one thereof.

[0857] In some aspects, the present disclosure provides a compound represented by the following structure:

[0858]

[0859]

[0860]

[0861] or a salt of any one thereof.

[0862] Treatment

[0863] The compounds described herein can be used to prepare a medicament for preventing or treating a disease or condition. In addition, a method for treating any of the diseases or conditions described herein in a subject in need of such treatment comprises administering to the subject a pharmaceutical composition comprising at least one compound described herein, or a pharmaceutically acceptable salt, pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof, in a therapeutically effective amount.

[0864] The compositions comprising one or more compounds described herein can be administered for prophylactic and / or therapeutic treatment. In therapeutic applications, the compositions are administered to a patient already suffering from a disease or condition in an amount sufficient to cure or at least partially arrest the symptoms of the disease or condition. Amounts effective for this use will depend on the severity and course of the disease or condition, previous therapy, the patient's health, weight, and response to drugs, and the judgment of the treating physician.

[0865] In prophylactic applications, compositions containing the compounds described herein are administered to a patient susceptible to or at risk of developing a particular disease, disorder, or condition. This amount is defined as a "prophylactically effective amount or dose." In this use, the exact amount also depends on the patient's health, weight, etc. When used in a patient, the amount effective for this use will depend on the severity and course of the disease, disorder, or condition, previous treatment, the patient's health and response to drugs, and the judgment of the treating physician.

[0866] In some aspects, the present disclosure provides methods of treating cancer comprising administering a compound or salt of the present disclosure to the cancer. In some embodiments, the cancer is melanoma. In some embodiments, the cancer is ovarian cancer.

[0867] In some aspects, the present disclosure provides methods of inhibiting A2058 cells comprising administering a compound or salt of the present disclosure.

[0868] In some aspects, the present disclosure provides methods of inhibiting PAl cells comprising administering a compound or salt of the present disclosure.

[0869] In some aspects, the present disclosure provides a method of killing cancer cells or inhibiting the proliferation of cancer cells.

[0870] In some aspects, the present disclosure provides methods of inhibiting A2058 cells, comprising administering a compound or salt of Formula (I), (II), (III), (IV), or (V) to the A2058 cells.

[0871] In some aspects, the present disclosure provides methods of inhibiting PAl cells comprising administering a compound or salt of Formula (I), (II), (III), (IV), or (V) to the PAl cells.

[0872] In some aspects, the present disclosure provides methods of treating cancer comprising administering a compound or salt of Formula (I), (II), (III), (IV), or (V) to the cancer. In some embodiments, the cancer is melanoma. In some embodiments, the cancer is ovarian cancer.

[0873] In some aspects, the present disclosure provides methods of inhibiting melanoma cells comprising administering to the melanoma cells a compound or salt of Formula (I), (II), (III), (IV), or (V).

[0874] In some aspects, the present disclosure provides methods of inhibiting ovarian cells comprising administering to the ovarian cells a compound or salt of Formula (I), (II), (III), (IV), or (V).

[0875] In some aspects, the present disclosure provides methods for treating ovarian cancer, comprising administering a compound or salt of Formula (I), (II), (III), (IV) or (V), or a pharmaceutical composition of any one thereof, to a subject in need thereof. In some embodiments, the method for treating ovarian cancer comprises administering a compound or salt of Formula (I), or a pharmaceutical composition thereof, to a subject in need thereof. In some embodiments, the method for treating ovarian cancer comprises administering a compound or salt of Formula (II), or a pharmaceutical composition thereof, to a subject in need thereof. In some embodiments, the method for treating ovarian cancer comprises administering a compound or salt of Formula (III), or a pharmaceutical composition thereof, to a subject in need thereof. In some embodiments, the method for treating ovarian cancer comprises administering a compound or salt of Formula (IV), or a pharmaceutical composition thereof, to a subject in need thereof. In some embodiments, the method for treating ovarian cancer comprises administering a compound or salt of Formula (V), or a pharmaceutical composition thereof, to a subject in need thereof.

[0876] In some aspects, the present disclosure provides methods of treating melanoma, comprising administering a compound or salt of Formula (I), (II), (III), (IV) or (V), or a pharmaceutical composition of any of them, to a subject in need thereof. In some embodiments, the method of treating melanoma comprises administering a compound or salt of Formula (I), or a pharmaceutical composition thereof, to a subject in need thereof. In some embodiments, the method of treating melanoma comprises administering a compound or salt of Formula (II), or a pharmaceutical composition thereof, to a subject in need thereof. In some embodiments, the method of treating melanoma comprises administering a compound or salt of Formula (III), or a pharmaceutical composition thereof, to a subject in need thereof. In some embodiments, the method of treating melanoma comprises administering a compound or salt of Formula (IV), or a pharmaceutical composition thereof, to a subject in need thereof. In some embodiments, the method of treating melanoma comprises administering a compound or salt of Formula (V), or a pharmaceutical composition thereof, to a subject in need thereof.

[0877] In some aspects, the present disc...

Claims

1. A compound represented by the structure of formula (I): or a pharmaceutically acceptable salt thereof, wherein: R 1 Selected from (i) and (ii): (i) C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10 )C(O)R 10 、-N(R 10 )C(O)OR 10 、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R 10 、-S(O)2N(R 10 )2, -NO2, =S, =O and -CN; and (ii) optionally substituted C 3-10 Saturated carbocyclic rings and optionally substituted 3- to 10-membered heterocyclic rings, wherein the optional substituents are independently selected from: Halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10 )C(O)R 10 、-N(R 10 )C(O)OR 10 、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R 10 、-S(O)2N(R 10 )2, -NO2, =S, =O and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 10 、-SR 10 、-N(R 10 )2、-C(O)R 10 、-C(O)OR 10 、-OC(O)R 10 、-OC(O)N(R 10 )2、-C(O)N(R 10 )2、-N(R 10 )C(O)R 10 、-N(R 10 )C(O)OR 10 、-N(R 10 )C(O)N(R 10 )2、-N(R 10 )S(O)2(R 10 ),-S(O)R 10 、-S(O)2R 10 、-S(O)2N(R 10 )2, -NO2, =S, =O and -CN; R 2 is selected from hydrogen, optionally substituted C 3-10 Saturated carbocyclic rings and optionally substituted 3- to 10-membered heterocyclic rings, wherein the optional substituents are independently selected from: Halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 、-OC(O)R 11 、-OC(O)N(R 11 )2、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 、-N(R 11 )C(O)OR 11 、-N(R 11 )C(O)N(R 11 )2、-N(R 11 )S(O)2(R 11 ),-S(O)R 11 、-S(O)2R 11 、-S(O)2N(R 11 )2, -NO2, =S, =O and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 11 、-SR 11 、-N(R 11 )2、-C(O)R 11 、-C(O)OR 11 、-OC(O)R 11 、-OC(O)N(R 11 )2、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 、-N(R 11 )C(O)OR 11 、-N(R 11 )C(O)N(R 11 )2、-N(R 11 )S(O)2(R 11 ),-S(O)R 11 、-S(O)2R 11 、-S(O)2N(R 11 )2, -NO2, =S, =O and -CN; where R 1 and R 2 At least one of the optionally substituted C 3-10 carbocyclic rings and optionally substituted 3- to 10-membered heterocyclic rings; R 3 independently selected at each occurrence from: Halogen, -OR 12 、-SR 12 、-N(R 12 )2、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )2、-C(O)N(R 12 )2、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )2、-N(R 12 )S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 、-S(O)2N(R 12 )2, -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 12 、-SR 12 、-N(R 12 )2、-C(O)R 12 、-C(O)OR 12 、-OC(O)R 12 、-OC(O)N(R 12 )2、-C(O)N(R 12 )2、-N(R 12 )C(O)R 12 、-N(R 12 )C(O)OR 12 、-N(R 12 )C(O)N(R 12 )2、-N(R 12 )S(O)2(R 12 ),-S(O)R 12 、-S(O)2R 12 、-S(O)2N(R 12 )2, -NO2, =S, =O and -CN; is a 3- to 10-membered heterocyclylene group optionally substituted with one or more substituents independently selected from: Halogen, -OR 13 、-SR 13 、-N(R 13 )2、-C(O)R 13 、-C(O)OR 13 、-OC(O)R 13 、-OC(O)N(R 13 )2、-C(O)N(R 13 )2、-N(R 13 )C(O)R 13 、-N(R 13 )C(O)OR 13 、-N(R 13 )C(O)N(R 13 )2、-N(R 13 )S(O)2(R 13 ),-S(O)R 13 、-S(O)2R 13 、-S(O)2N(R 13 )2, -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 13 、-SR 13 、-N(R 13 )2、-C(O)R 13 、-C(O)OR 13 、-OC(O)R 13 、-OC(O)N(R 13 )2、-C(O)N(R 13 )2、-N(R 13 )C(O)R 13 、-N(R 13 )C(O)OR 13 、-N(R 13 )C(O)N(R 13 )2、-N(R 13 )S(O)2(R 13 ),-S(O)R 13 、-S(O)2R 13 、-S(O)2N(R 13 )2, -NO2, =S, =O and -CN; A is selected from optionally substituted C 3-10 carbocyclylene and optionally substituted 3- to 10-membered heterocyclylene, wherein the optional substituents are independently selected from: Halogen, -OR 14 、-SR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 、-OC(O)R 14 、-OC(O)N(R 14 )2、-C(O)N(R 14 )2、-N(R 14 )C(O)R 14 、-N(R 14 )C(O)OR 14 、-N(R 14 )C(O)N(R 14 )2、-N(R 14 )S(O)2(R 14 ),-S(O)R 14 、-S(O)2R 14 、-S(O)2N(R 14 )2, -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 14 、-SR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 、-OC(O)R 14 、-OC(O)N(R 14 )2、-C(O)N(R 14 )2、-N(R 14 )C(O)R 14 、-N(R 14 )C(O)OR 14 、-N(R 14 )C(O)N(R 14 )2、-N(R 14 )S(O)2(R 14 ),-S(O)R 14 、-S(O)2R 14 、-S(O)2N(R 14 )2, -NO2, =S, =O and -CN; wherein when A is a 5-membered heteroaryl, the 5-membered heteroaryl contains one or more heteroatoms selected from O, S and N, and there are no more than two N atoms in the ring; R 10 、R 11 、R 12 、R 13 and R 14 is independently selected at each occurrence from (iii), (iv) and (v): (iii) hydrogen; (iv) C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, and -CN; and (v) C optionally substituted with one or more substituents independently selected from the following 3-10 Carbocyclic rings and 3- to 10-membered heterocyclic rings: halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 haloalkyl, -NH2, -NO2, =O, and -CN; and n is selected from 0, 1, 2, 3 and 4.

2. The compound or salt according to claim 1, wherein R 1 Selected from C 1-3 Alkyl, C 1-3 haloalkyl, optionally substituted saturated C 3-6 carbocyclic ring and optionally substituted 3- to 6-membered heterocyclic ring; and R 2 is selected from hydrogen, optionally substituted C 3-6 saturated carbocyclic and optionally substituted 3- to 6-membered heterocyclic rings; wherein R 1 and R 2 At least one of the following is selected from optionally substituted C 3-6 saturated carbocyclic rings and optionally substituted 3- to 6-membered heterocyclic rings.

3. The compound or salt according to claim 1 or 2, wherein R 1 is an optionally substituted saturated C 3-6 carbocyclic or optionally substituted saturated 3- to 6-membered heterocyclic ring; and R 2 is selected from hydrogen, optionally substituted C 3-6 saturated carbocyclic ring and optionally substituted saturated 3- to 6-membered heterocyclic ring.

4. The compound or salt according to claim 1 or 2, wherein R 1 is an optionally substituted saturated C 3-4 carbocyclic or optionally substituted saturated 3- to 4-membered heterocyclic ring; and R 2 selected from hydrogen, optionally substituted saturated C 3-6 carbocyclic rings and optionally substituted saturated 3- to 6-membered heterocyclic rings.

5. The compound or salt according to claim 4, wherein R 1 is an optionally substituted C 3-4 cycloalkyl or optionally substituted 3- to 4-membered heterocycloalkyl; and R 2 It's hydrogen.

6. The compound or salt according to claim 1 or claim 2, wherein R 2 is an optionally substituted C 3-6 saturated carbocyclic ring and optionally substituted 3- to 6-membered heterocyclic ring; and R 1 Selected from C 1-3 Alkyl, C 1-3 haloalkyl, optionally substituted saturated C 3-6 carbocyclic rings and optionally substituted 3- to 6-membered heterocyclic rings.

7. The compound or salt according to claim 6, wherein R 2 is an optionally substituted saturated C 3-4 carbocyclic or optionally substituted saturated 3- to 4-membered heterocyclic ring; and R 1 Selected from C 1-3 Alkyl, C 1-3 haloalkyl, optionally substituted saturated C 3-6 carbocyclic rings and optionally substituted 3- to 6-membered heterocyclic rings.

8. The compound or salt according to claim 1, 2, 6 or 7, wherein R 1 Selected from methyl and ethyl.

9. The compound or salt according to any one of claims 1 to 7, wherein R 1 Selected from 10. The compound or salt according to claim 1, 2, 6 or 7, wherein R 1 Selected from methyl, ethyl, 11. The compound or salt according to claim 1 or 2, wherein R 2 is hydrogen or 12. The compound or salt according to any one of claims 1-4, 6-8 or 10, wherein R 2 yes 13. The compound or salt according to any one of claims 1 to 12, wherein A is selected from optionally substituted phenylene and optionally substituted 6-membered heteroarylene, wherein the optional substituents are independently selected from: Halogen, -OR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 、-C(O)N(R 14 )2, -NO2, -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 14 、-N(R 14 )2、-C(O)R 14 、-C(O)OR 14 、-C(O)N(R 14 )2, -NO2, =S, =O and -CN; and R 14 Selected from hydrogen, C 1-3 Alkyl-OC 1-3 Alkyl, C 1-3 Alkyl and C 1-3 Halogenated alkyl.

14. The compound or salt according to any one of claims 1 to 12, wherein A is selected from phenylene and 6-membered heteroarylene, each of which is optionally substituted by one or more substituents independently selected from halogen, -OR 14 and are optionally independently selected from halogen and -OR 14 One or more substituents substituted C 1-3 alkyl; and R 14 Selected from hydrogen, C 1-3 Alkyl, C 1-3 Alkyl-OC 1-3 Alkyl and C 1-3 Halogenated alkyl.

15. The compound or salt according to any one of claims 1 to 12, wherein A is selected from phenylene, pyridinylene, pyrimidinylene and pyrazinylene, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 14 and are optionally independently selected from halogen and -OR 14 One or more substituents substituted C 1-3 alkyl; and R 14 Selected from hydrogen, C 1-3 Alkyl, C 1-3 Alkyl-OC 1-3 Alkyl and C 1-3 Halogenated alkyl.

16. The compound or salt according to claim 15, wherein Selected from:

17. The compound or salt according to claim 15, wherein Selected from:

18. A compound or salt according to any one of claims 1 to 17, wherein is selected from 4- to 7-membered heterocyclylene groups, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 13 、-N(R 13 )2、-C(O)R 13 、-C(O)OR 13 、-C(O)N(R 13 )2, -NO2, -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 13 、-N(R 13 )2、-C(O)R 13 、-C(O)OR 13 、-C(O)N(R 13 )2, -NO2, =S, =O and -CN; and R 13 Selected from hydrogen, C 1-3 Alkyl and C 1-3 Halogenated alkyl.

19. A compound or salt according to any one of claims 1 to 17, wherein is selected from saturated 4- to 7-membered heterocyclylene groups, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 13 、-N(R 13 )2、-C(O)R 13 、-C(O)OR 13 、-C(O)N(R 13 )2, -NO2, -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 13 、-N(R 13 )2、-C(O)R 13 、-C(O)OR 13 、-C(O)N(R 13 )2, -NO2, =S, =O and -CN; and R 13 Selected from hydrogen, C 1-3 Alkyl and C 1-3 Halogenated alkyl.

20. The compound or salt according to claim 19, wherein is selected from saturated 6-membered heterocyclylene, each of which is optionally substituted by one or more substituents independently selected from halogen, -OR 13 、-N(R 13 )2、-C(O)R 13 、-C(O)OR 13 、-C(O)N(R 13 )2, -NO2, -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 13 、-N(R 13 )2、-C(O)R 13 、-C(O)OR 13 、-C(O)N(R 13 )2, -NO2, =S, =O and -CN; and R 13 Selected from hydrogen, C 1-3 Alkyl and C 1-3 Halogenated alkyl.

21. The compound or salt according to claim 20, wherein selected from piperidinylene and piperazinylene, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 13 、-N(R 13 )2、-C(O)R 13 、-C(O)OR 13 、-C(O)N(R 13 )2, -NO2, -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 13 、-N(R 13 )2、-C(O)R 13 、-C(O)OR 13 、-C(O)N(R 13 )2, -NO2, =S, =O and -CN; and R 13 Selected from hydrogen, C 1-3 Alkyl and C 1-3 Halogenated alkyl.

22. The compound or salt according to claim 21, wherein Is unsubstituted.

23. The compound or salt according to claim 22, wherein yes 24. The compound or salt according to any one of claims 1 to 23, wherein n is selected from 0 and 1.

25. The compound or salt of claim 24, wherein n is 0.

26. The compound or salt of claim 24, wherein n is 1.

27. The compound or salt according to claim 26, wherein R 3 Selected from halogen, -OR 12 、-N(R 12 )2、-C(O)R 12 、-C(O)OR 12 、-NO2、-CN、C 1-3 Alkyl and C 1-3 haloalkyl; and R 12 Selected from hydrogen, C 1-3 Alkyl and C 1-3 Halogenated alkyl.

28. The compound or salt according to claim 27, wherein R 3 Selected from fluoro, chloro and bromo.

29. The compound or salt according to any one of claims 1 to 23, 26, 27 or 28, wherein the compound of formula (I) is selected from formula (Ia):

30. The compound according to claim 1, wherein the compound of formula (I) is: or a salt of any one thereof.

31. The compound of claim 1, wherein the compound of formula (I) is: or a salt of any one thereof.

32. A compound represented by the structure of formula (II): or a pharmaceutically acceptable salt thereof, wherein: X 1 Selected from N and C(R 8 ); R 4 is independently selected at each occurrence from (a), (b), and (c): (a) Halogen, -OR 20 , -SR 20 , -N(R 20 )2, -C(O)R 20 , -C(O)OR 20 , -OC(O)R 20 , -OC(O)N(R 20 )2, -C(O)N(R 20 )2, -N(R 20 )C(O)R 20 , -N(R 20 )C(O)OR 20 , -N(R 20 )C(O)N(R 20 )2, -N(R 20 )S(O)2(R 20 , -S(O)R 20 , -S(O)2R 20 , -S(O)2N(R 20 ), -NO2 and -CN; (b) C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 20 、-SR 20 、-N(R 20 )2、-C(O)R 20 、-C(O)OR 20 、-OC(O)R 20 、-OC(O)N(R 20 )2、-C(O)N(R 20 )2、-N(R 20 )C(O)R 20 、-N(R 20 )C(O)OR 20 、-N(R 20 )C(O)N(R 20 )2、-N(R 20 )S(O)2(R 20 ),-S(O)R 20 、-S(O)2R 20 、-S(O)2N(R 20 )2, -NO2, =S, =O and -CN; and (c)C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 20 、-SR 20 、-N(R 20 )2、-C(O)R 20 、-C(O)OR 20 、-OC(O)R 20 、-OC(O)N(R 20 )2、-C(O)N(R 20 )2、-N(R 20 )C(O)R 20 、-N(R 20 )C(O)OR 20 、-N(R 20 )C(O)N(R 20 )2、-N(R 20 )S(O)2(R 20 ),-S(O)R 20 、-S(O)2R 20 、-S(O)2N(R 20 )2, -NO2, =S, =O and -CN; R 5 is C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 21 、-SR 21 、-N(R 21 )2、-C(O)R 21 、-C(O)OR 21 、-OC(O)R 21 、-OC(O)N(R 21 )2、-C(O)N(R 21 )2、-N(R 21 )C(O)R 21 、-N(R 21 )C(O)OR 21 、-N(R 21 )C(O)N(R 21 )2、-N(R 21 )S(O)2(R 21 ),-S(O)R 21 、-S(O)2R 21 、-S(O)2N(R 21 )2, -NO2, =S, =O and -CN; R 6 independently selected at each occurrence from: Halogen, -OR 22 、-SR 22 、-N(R 22 )2、-C(O)R 22 、-C(O)OR 22 、-OC(O)R 22 、-OC(O)N(R 22 )2、-C(O)N(R 22 )2、-N(R 22 )C(O)R 22 、-N(R 22 )C(O)OR 22 、-N(R 22 )C(O)N(R 22 )2、-N(R 22 )S(O)2(R 22 ),-S(O)R 22 、-S(O)2R 22 、-S(O)2N(R 21 )2, -NO2, =S, =O and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 22 、-SR 22 、-N(R 22 )2、-C(O)R 22 、-C(O)OR 22 、-OC(O)R 22 、-OC(O)N(R 22 )2、-C(O)N(R 22 )2、-N(R 22 )C(O)R 22 、-N(R 22 )C(O)OR 22 、-N(R 22 )C(O)N(R 22 )2、-N(R 22 )S(O)2(R 22 ),-S(O)R 22 、-S(O)2R 22 、-S(O)2N(R 21 )2, -NO2, =S, =O and -CN; Ring B is selected from C 3-10 Carbocyclic rings and 3- to 10-membered heterocyclic rings; R 7 independently selected at each occurrence from: Hydrogen, halogen, -OR 23 、-SR 23 、-N(R 23 )2、-C(O)R 23 、-OC(O)R 23 、-OC(O)N(R 23 )2、-C(O)N(R 23 )2、-N(R 23 )C(O)R 23 、-N(R 23 )C(O)OR 23 、-N(R 23 )C(O)N(R 23 )2、-N(R 12 )S(O)2(R 23 ),-S(O)R 23 、-S(O)2R 23 、-S(O)2N(R 23 )2, -NO2 and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 23 、-SR 23 、-N(R 23 )2、-C(O)R 23 、-C(O)OR 23 、-OC(O)R 23 、-OC(O)N(R 23 )2、-C(O)N(R 23 )2、-N(R 23 )C(O)R 23 、-N(R 23 )C(O)OR 23 、-N(R 23 )C(O)N(R 23 )2、-N(R 23 )S(O)2(R 23 ),-S(O)R 23 、-S(O)2R 23 、-S(O)2N(R 23 )2, -NO2, =S, =O and -CN; R 8 、R 20 、R 21 、R 22 and R 23 is independently selected at each occurrence from (d), (e) and (f): (d) hydrogen; (e) C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, and -CN; and (f) C optionally substituted with one or more substituents independently selected from the following 3-10 Carbocyclic rings and 3- to 10-membered heterocyclic rings: halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN; x is selected from 0, 1, 2, 3 and 4; y is selected from 0, 1, 2, 3 and 4; z is selected from 0, 1, 2, 3, 4 and 5; and At least one of x or y is selected from 1, 2, 3 and 4.

33. The compound or salt of claim 32, wherein x is selected from 0 and 1.

34. The compound or salt of claim 33, wherein x is 0.

35. The compound or salt of claim 33, wherein x is 1.

36. The compound or salt according to claim 32 or 33, wherein the structure of formula (II) is represented by the structure of formula (II-a) or (II-b):

37. The compound or salt according to claim 35 or 36, wherein R 4 Selected from: Halogen, -OR 20 、-N(R 20 )2、-C(O)R 20 , -NO2 and -CN; C 1-3 Alkyl, C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, any of which are optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 20 、-N(R 20 )2、-C(O)R 20 , -NO2 and -CN; and Each R 20 are independently selected from hydrogen, C 1-4 Alkyl and C 1-4 Halogenated alkyl.

38. The compound or salt of claim 37, wherein R 4 Selected from: Halogen, -OR 20 、-N(R 20 )2 and -CN; C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, any of which are optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 20 and -N(R 20 )2; and Each R 20 are independently selected from hydrogen, C 1-4 Alkyl and C 1-4 Halogenated alkyl.

39. The compound or salt of claim 38, wherein R 4 Selected from: Halogen, -OR 20 、-N(R 20 )2 and -CN; C 3-4 carbocyclic rings and 4- to 5-membered heterocyclic rings; and Each R 20 independently selected from hydrogen and C 1-4 alkyl.

40. The compound or salt of claim 39, wherein R 4 Selected from: fluoro, bromo, -OC 1-6 Alkyl, -N(CH3)2, -CN, 41. The compound or salt of claim 39, wherein R 4 Selected from: fluoro, chloro, bromo, -OC 1-6 Alkyl, -N(CH3)2, -CN, 42. The compound or salt of any one of claims 32 to 40, wherein y is selected from 0 and 1.

43. The compound or salt of claim 42, wherein y is 0.

44. The compound or salt of claim 42, wherein y is 1.

45. The compound or salt of claim 44, wherein R 6 is C optionally substituted by one or more substituents independently selected from the following 1-3 Alkyl: halogen, -OR 22 、-N(R 22 )2、-C(O)R 22 , -NO2 and -CN; and R 22 Selected from hydrogen and C 1-3 alkyl.

46. The compound or salt of claim 45, wherein R 6 is unsubstituted C 1-3 alkyl.

47. The compound or salt according to claim 45 or 46, wherein R 6 Selected from methyl and ethyl.

48. A compound or salt according to any one of claims 32 to 47, wherein X 1 It's nitrogen.

49. A compound or salt according to any one of claims 32 to 48, wherein R 5 is C optionally substituted by one or more substituents independently selected from the following 1-3 Alkyl: halogen, -OR 21 、-N(R 21 )2、-C(O)R 21 , -NO2, =S, =O and -CN; and R 21 Selected from hydrogen and C 1-3 alkyl.

50. The compound or salt of claim 49, wherein R 5 is unsubstituted C 1-3 alkyl.

51. The compound or salt according to claim 49 or 50, wherein R 5 Selected from methyl and ethyl.

52. The compound or salt of any one of claims 32 to 51, wherein ring B is selected from phenylene, pyridylene, benzoxazolylene, and benzisoxazolylene.

53. The compound or salt of any one of claims 32 to 52, wherein z is selected from 0, 1 and 2.

54. The compound or salt of claim 53, wherein z is 0.

55. The compound or salt of claim 53, wherein z is selected from 1 and 2.

56. The compound or salt of claim 55, wherein R 7 Selected from halogen, -OR 23 、-N(R 23 )2、-C(O)R 23 , -NO2, -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 23 、-N(R 23 )2、-C(O)R 23 , -NO2 and -CN; and R 23 Selected from hydrogen and C 1-3 alkyl.

57. The compound or salt of claim 56, wherein R 7 Select from -OR 23 and C 1-3 Halogenated alkyl.

58. The compound or salt of claim 54 or claim 55, wherein Ring B is selected from:

59. The compound or salt of claim 54 or claim 55, wherein Ring B is selected from:

60. The compound of claim 32, wherein the compound of formula (II) is: or a salt of any one thereof.

61. The compound of claim 32, wherein the compound of formula (II) is: or a salt of any one thereof.

62. A compound represented by the structure of formula (III): or a pharmaceutically acceptable salt thereof, wherein: X 1 Selected from N and C(R 35 ); R 31 is independently selected at each occurrence from (I), (II) and (III): (I) Halogens, -OR 40 , -SR 40 , -N(R 40 )2, -C(O)R 40 , -C(O)OR 40 , -OC(O)R 40 , -OC(O)N(R 40 )2, -C(O)N(R 40 )2, -N(R 40 )C(O)R 40 , -N(R 40 )C(O)OR 40 , -N(R 40 )C(O)N(R 40 )2, -N(R 40 )S(O)2(R 40 , -S(O)R 40 , -S(O)2R 40 , -S(O)2N(R 40 )2, -NO2 and -CN; (II) C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 40 、-SR 40 、-N(R 40 )2、-C(O)R 40 、-C(O)OR 40 、-OC(O)R 40 、-OC(O)N(R 40 )2、-C(O)N(R 40 )2、-N(R 40 )C(O)R 40 、-N(R 40 )C(O)OR 40 、-N(R 40 )C(O)N(R 40 )2、-N(R 40 )S(O)2(R 40 ),-S(O)R 40 、-S(O)2R 40 、-S(O)2N(R 40 )2, -NO2, =S, =O and -CN; and (III)C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 40 、-SR 40 、-N(R 40 )2、-C(O)R 40 、-C(O)OR 40 、-OC(O)R 40 、-OC(O)N(R 40 )2、-C(O)N(R 40 )2、-N(R 40 )C(O)R 40 、-N(R 40 )C(O)OR 40 、-N(R 40 )C(O)N(R 40 )2、-N(R 40 )S(O)2(R 40 ),-S(O)R 40 、-S(O)2R 40 、-S(O)2N(R 40 )2, -NO2, =S, =O and -CN; R 32 independently selected at each occurrence from: Halogen, -OR 41 、-SR 41 、-N(R 41 )2、-C(O)R 41 、-C(O)OR 41 、-OC(O)R 41 、-OC(O)N(R 41 )2、-C(O)N(R 41 )2、-N(R 41 )C(O)R 41 、-N(R 41 )C(O)OR 41 、-N(R 41 )C(O)N(R 41 )2、-N(R 41 )S(O)2(R 41 ),-S(O)R 41 、-S(O)2R 41 、-S(O)2N(R 41 )2, -NO2, =S, =O and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 41 、-SR 41 、-N(R 41 )2、-C(O)R 41 、-C(O)OR 41 、-OC(O)R 41 、-OC(O)N(R 41 )2、-C(O)N(R 41 )2、-N(R 41 )C(O)R 41 、-N(R 41 )C(O)OR 41 、-N(R 41 )C(O)N(R 41 )2、-N(R 41 )S(O)2(R 41 ),-S(O)R 41 、-S(O)2R 41 、-S(O)2N(R 41 )2, -NO2, =S, =O and -CN; and R 33 independently selected at each occurrence from: Halogen, -OR 42 、-SR 42 、-N(R 42 )2、-C(O)OR 42 、-OC(O)R 42 、-OC(O)N(R 42 )2、-C(O)N(R 42 )2、-N(R 42 )C(O)R 42 、-N(R 42 )C(O)OR 42 、-N(R 42 )C(O)N(R 42 )2、-N(R 42 )S(O)2(R 42 ),-S(O)R 42 、-S(O)2R 42 and -S(O)2N(R 42 )2; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 42 、-SR 42 、-N(R 42 )2、-C(O)R 42 、-C(O)OR 42 、-OC(O)R 42 、-OC(O)N(R 42 )2、-C(O)N(R 42 )2、-N(R 42 )C(O)R 42 、-N(R 42 )C(O)OR 42 、-N(R 42 )C(O)N(R 42 )2、-N(R 42 )S(O)2(R 42 ),-S(O)R 42 、-S(O)2R 42 、-S(O)2N(R 42 )2, -NO2, =S and -CN; When an R 33 is methyl, each additional R 33 are all independently selected from (IV), (V) and (VI): (IV) Halogen, -OR 42 , -SR 42 , -N(R 42 )2, -C(O)R 42 , -C(O)OR 42 , -OC(O)R 42 , -OC(O)N(R 42 )2, -C(O)N(R 42 )2, -N(R 42 )C(O)R 42 , -N(R 42 )C(O)OR 42 , -N(R 42 )C(O)N(R 42 )2, -N(R 42 )S(O)2(R 42 , -S(O)R 42 , -S(O)2R 42 , -S(O)2N(R 42 )2, -NO2 and -CN; (V) C1 alkyl substituted by one or more substituents independently selected from the group consisting of halogen, -OR 42 、-SR 42 、-N(R 42 )2、-C(O)R 42 、-C(O)OR 42 、-OC(O)R 42 、-OC(O)N(R 42 )2、-C(O)N(R 42 )2、-N(R 42 )C(O)R 42 、-N(R 42 )C(O)OR 42 、-N(R 42 )C(O)N(R 42 )2、-N(R 42 )S(O)2(R 42 ),-S(O)R 42 、-S(O)2R 42 、-S(O)2N(R 42 )2, -NO2, =S, =O and -CN; and (VI) C optionally substituted by one or more substituents independently selected from the following 2-6 Alkyl: halogen, -OR 42 、-SR 42 、-N(R 42 )2、-C(O)R 42 、-C(O)OR 42 、-OC(O)R 42 、-OC(O)N(R 42 )2、-C(O)N(R 42 )2、-N(R 42 )C(O)R 42 、-N(R 42 )C(O)OR 42 、-N(R 42 )C(O)N(R 42 )2、-N(R 42 )S(O)2(R 42 ),-S(O)R 42 、-S(O)2R 42 、-S(O)2N(R 42 )2, -NO2, =S, =O and -CN; or Two R on adjacent atoms 33 Can form C together 3-8 a carbocyclic ring or a 3- to 8-membered heterocyclic ring, each of which is optionally substituted with one or more substituents independently selected from the following: Halogen, -OR 42 、-SR 42 、-N(R 42 )2、-C(O)R 42 、-C(O)OR 42 、-OC(O)R 42 、-OC(O)N(R 42 )2、-C(O)N(R 42 )2、-N(R 42 )C(O)R 42 、-N(R 42 )C(O)OR 42 、-N(R 42 )C(O)N(R 42 )2、-N(R 42 )S(O)2(R 42 ),-S(O)R 42 、-S(O)2R 42 、-S(O)2N(R 42 )2, -NO2, =O and -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 42 、-SR 42 、-N(R 42 )2、-C(O)R 42 、-C(O)OR 42 、-OC(O)R 42 、-OC(O)N(R 42 )2、-C(O)N(R 42 )2、-N(R 42 )C(O)R 42 、-N(R 42 )C(O)OR 42 、-N(R 42 )C(O)N(R 42 )2、-N(R 42 )S(O)2(R 42 ),-S(O)R 42 、-S(O)2R 42 、-S(O)2N(R 42 )2, -NO2, =S, =O and -CN; R 34 Selected from C 1-6 Alkyl and C 2-6 alkenyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 43 、-SR 43 、-N(R 43 )2、-C(O)R 43 、-C(O)OR 43 、-OC(O)R 43 、-OC(O)N(R 43 )2、-C(O)N(R 43 )2、-N(R 43 )C(O)R 43 、-N(R 43 )C(O)OR 43 、-N(R 43 )C(O)N(R 43 )2、-N(R 43 )S(O)2(R 43 ),-S(O)R 43 、-S(O)2R 43 、-S(O)2N(R 43 )2, -NO2, =S, =O and -CN; Ring B is selected from C 3-6 Carbocyclylene and 4- to 6-membered heterocyclylene; R 35 、R 40 、R 41 、R 42 and R 43 is independently selected at each occurrence from (VII), (VIII) and (IX): (VII) hydrogen; (VII) C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, and -CN; and (IX) C optionally substituted by one or more substituents independently selected from the following 3-10 Carbocyclic rings and 3- to 10-membered heterocyclic rings: halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN; x is selected from 0, 1, 2, 3 and 4; y is selected from the group consisting of 0, 1, 2, 3, and 4; and z is selected from 2, 3, 4 and 5.

63. The compound or salt of claim 62, wherein X 1 It's N.

64. The compound or salt of claim 62 or 63, wherein y is selected from 0 and 1.

65. The compound or salt of claim 64, wherein y is 0.

66. The compound or salt of claim 64, wherein y is 1.

67. The compound or salt of any one of claims 62 to 66, wherein x is selected from 0 and 1.

68. The compound or salt of claim 67, wherein x is 0.

69. The compound or salt of claim 67, wherein x is 1.

70. The compound or salt according to any one of claims 62 to 69, wherein ring B is selected from C 3-6 carbocyclylene and 5- to 6-membered heterocyclylene.

71. The compound or salt of claim 70, wherein Ring B is selected from phenylene and 6-membered heteroarylene.

72. The compound or salt of claim 71, wherein Ring B is selected from phenylene and pyridinylene.

73. The compound or salt of any one of claims 62 to 72, wherein z is 2 or 3.

74. The compound or salt of claim 73, wherein z is 3.

75. The compound or salt of claim 73, wherein z is 2.

76. The compound or salt of claim 73, wherein each R 33 Independently selected from: halogen, -OR 42 、-N(R 42 )2; and optionally independently selected from halogen, -OR 42 、-N(R 42 )2, -NO2 and -CN substituted with one or more substituents C 1-6 alkyl; and each R 42 independently selected from hydrogen, and optionally independently selected from halogen and -OC 1-3 One or more substituents of the alkyl group substituted with C 1-3 alkyl.

77. The compound or salt of claim 76, wherein each R 33 Independently selected from: halogen, -OR 42 and are optionally independently selected from halogen and -OR 42 One or more substituents substituted C 1-6 alkyl; and each R 42 independently selected from hydrogen, and optionally independently selected from halogen and -OC 1-3 One or more substituents of the alkyl group substituted with C 1-3 alkyl.

78. The compound or salt of claim 77, wherein each R 33 Independently selected from chloro, fluoro, bromo, methyl, -CF3, 79. A compound or salt according to any one of claims 62 to 78, wherein Selected from:

80. A compound or salt according to any one of claims 62 to 78, wherein Selected from:

81. according to the compound or salt described in any one of claim 62 to 75, wherein two R on adjacent atoms 33 Together they may form a 4- to 6-membered heterocyclic ring, each of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 42 、-N(R 42 )2、-C(O)R 42 , -NO2, -CN; and C optionally substituted by one or more substituents independently selected from the following 1-3 Alkyl: halogen, -OR 42 、-N(R 42 )2、-C(O)R 42 , -NO2 and -CN; and each R 42 are independently selected from hydrogen, C 1-3 Alkyl and C 1-3 Halogenated alkyl.

82. The compound or salt of claim 81, wherein is selected from dihydrobenzofuranyl, benzofuranyl and benzobisoxazolyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 42 、-N(R 42 )2、-C(O)R 42 , -NO2, -CN; and C optionally substituted by one or more substituents independently selected from the following 1-3 Alkyl: halogen, -OR 42 、-N(R 42 )2、-C(O)R 42 , -NO2 and -CN; and each R 42 are independently selected from hydrogen, C 1-3 Alkyl and C 1-3 Halogenated alkyl.

83. The compound or salt of claim 82, wherein is selected from dihydrobenzofuranyl, benzofuranyl and benzodioxolyl, each of which is optionally independently selected from halogen and unsubstituted C 1-3 The alkyl group is substituted with one or more substituents.

84. The compound or salt of claim 83, wherein Selected from 85. The compound or salt of claim 81, wherein selected from furopyridinyl, thienopyridinyl, indazolyl, pyrazolo[4,3-b]pyridinyl, imidazo[1,2-a]pyridinyl, imidazo[1,2-a]pyrazinyl and pyrazolo[1,5-a]pyridinyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 42 、-N(R 42 )2、-C(O)R 42 , -NO2, -CN; and C optionally substituted by one or more substituents independently selected from the following 1-3 Alkyl: halogen, -OR 42 、-N(R 42 )2、-C(O)R 42 , -NO2 and -CN; and each R 42 are independently selected from hydrogen, C 1-3 Alkyl and C 1-3 Halogenated alkyl.

86. The compound or salt of claim 85, wherein is selected from furopyridinyl, thienopyridinyl, indazolyl, pyrazolo[4,3-b]pyridinyl, imidazo[1,2-a]pyridinyl, imidazo[1,2-a]pyrazinyl and pyrazolo[1,5-a]pyridinyl, each of which is optionally independently selected from halogen and unsubstituted C 1-3 The alkyl group is substituted with one or more substituents.

87. The compound or salt of claim 86, wherein Selected from 88. A compound or salt according to any one of claims 62 to 84, wherein R 34 Selected from C 1-4 Alkyl and C 2-4 alkenyl, each of which is optionally independently selected from halogen, -OR 43 、-N(R 43 )2、-C(O)R 43 and -CN, and each R 43 are independently selected from hydrogen, C 1-3 Alkyl and C 1-3 Halogenated alkyl.

89. The compound or salt of claim 85, wherein R 34 Selected from methyl, ethyl, propyl, isopropyl and propenyl.

90. The compound of claim 62, wherein the compound of formula (III) is: or a salt of any one thereof.

91. The compound of claim 62, wherein the compound of formula (III) is: or a salt of any one thereof.

92. A compound represented by the structure of formula (IV): or a pharmaceutically acceptable salt, in: Each X 1 Selected from C(R 50 ) and N, and at least one X 1 It is N; R 50 independently selected at each occurrence from: Hydrogen, halogen, -OR 60 , -SR 60 , -N(R 60 )2, -C(O)R 60 , -C(O)OR 60 , -OC(O)R 60 , -OC(O)N(R 60 )2, -C(O)N(R 60 )2, -N(R 60 )C(O)R 60 , -N(R 60 )C(O)OR 60 , -N(R 60 )C(O)N(R 60 )2, -N(R 60 )S(O)2(R 60 , -S(O)R 60 , -S(O)2R 60 , -S(O)2N(R 60 ), -NO2 and -CN; and C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 60 、-SR 60 、-N(R 60 )2、-C(O)R 60 、-C(O)OR 60 、-OC(O)R 60 、-OC(O)N(R 60 )2、-C(O)N(R 60 )2、-N(R 60 )C(O)R 60 、-N(R 60 )C(O)OR 60 、-N(R 60 )C(O)N(R 60 )2、-N(R 60 )S(O)2(R 60 ),-S(O)R 60 、-S(O)2R 60 、-S(O)2N(R 60 )2, -NO2, =S, =O and -CN; R 51 Independently selected from: C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 61 、-SR 61 、-N(R 61 )2、-C(O)R 61 、-C(O)OR 61 、-OC(O)R 61 、-OC(O)N(R 61 )2、-C(O)N(R 61 )2、-N(R 61 )C(O)R 61 、-N(R 61 )C(O)OR 61 、-N(R 61 )C(O)N(R 61 )2、-N(R 61 )S(O)2(R 61 ),-S(O)R 61 、-S(O)2R 61 、-S(O)2N(R 61 )2, -NO2, =S, =O and -CN; and C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 61 、-SR 61 、-N(R 61 )2、-C(O)R 61 、-C(O)OR 61 、-OC(O)R 61 、-OC(O)N(R 61 )2、-C(O)N(R 61 )2、-N(R 61 )C(O)R 61 、-N(R 61 )C(O)OR 61 、-N(R 61 )C(O)N(R 61 )2、-N(R 61 )S(O)2(R 61 ),-S(O)R 61 、-S(O)2R 61 、-S(O)2N(R 61 )2, -NO2, =S, =O and -CN; is a 3- to 12-membered heterocyclylene group optionally substituted with one or more substituents independently selected from: halogen, -OR 62 , -SR 62 , -N(R 62 )2, -C(O)R 62 , -C(O)OR 62 , -OC(O)R 62 , -OC(O)N(R 62 )2, -C(O)N(R 62 )2, -N(R 62 )C(O)R 62 , -N(R 62 )C(O)OR 62 , -N(R 62 )C(O)N(R 62 )2, -N(R 62 )S(O)2(R 62 , -S(O)R 62 , -S(O)2R 62 , -S(O)2N(R 62 )2, -NO2 and -CN; C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 62 、-SR 62 、-N(R 62 )2、-C(O)R 62 、-C(O)OR 62 、-OC(O)R 62 、-OC(O)N(R 62 )2、-C(O)N(R 62 )2、-N(R 62 )C(O)R 62 、-N(R 62 )C(O)OR 62 、-N(R 62 )C(O)N(R 62 )2、-N(R 62 )S(O)2(R 62 ),-S(O)R 62 、-S(O)2R 62 、-S(O)2N(R 62 )2, -NO2, =S, =O and -CN; and Ring B is selected from C 3-10 carbocyclic ring and 3- to 10-membered heterocyclic ring, any of which is optionally substituted with one or more substituents independently selected from: halogen, -OR 63 , -SR 63 , -N(R 63 )2, -C(O)R 63 , -C(O)OR 63 , -OC(O)R 63 , -OC(O)N(R 63 )2, -C(O)N(R 63 )2, -N(R 63 )C(O)R 63 , -N(R 63 )C(O)OR 63 , -N(R 63 )C(O)N(R 63 )2, -N(R 63 )S(O)2(R 63 , -S(O)R 63 , -S(O)2R 63 , -S(O)2N(R 63 )2, -NO2 and -CN; and C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 63 、-SR 63 、-N(R 63 )2、-C(O)R 63 、-C(O)OR 63 、-OC(O)R 63 、-OC(O)N(R 63 )2、-C(O)N(R 63 )2、-N(R 63 )C(O)R 63 、-N(R 63 )C(O)OR 63 、-N(R 63 )C(O)N(R 63 )2、-N(R 63 )S(O)2(R 63 ),-S(O)R 63 、-S(O)2R 63 、-S(O)2N(R 63 )2, -NO2, =S, =O and -CN; R 60 、R 61 、R 62 and R 63 independently selected at each occurrence from: hydrogen; C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, and -CN; and C optionally substituted with one or more substituents independently selected from the following 3-10 Carbocyclic rings and 3- to 10-membered heterocyclic rings: halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN.

93. The compound or salt of claim 92, wherein the structure of formula (IV) is selected from:

94. The compound or salt of claim 92 or 93, wherein R 51 is C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 61 、-N(R 61 )2、-C(O)R 61 , -NO2, =S, =O and -CN; and R 61 Selected from hydrogen and C 1-3 alkyl.

95. The compound or salt of claim 94, wherein R 51 is unsubstituted C 1-3 alkyl.

96. A compound or salt according to any one of claims 92 to 95, wherein is selected from saturated 5- to 6-membered heterocyclylene groups, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 62 、-N(R 62 )2、-C(O)R 62 、-C(O)OR 62 、-C(O)N(R 62 )2, -NO2, -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 62 、-N(R 62 )2、-C(O)R 62 、-C(O)OR 62 、-C(O)N(R 62 )2, -NO2, =S, =O and -CN; and R 62 Selected from hydrogen and C 1-3 alkyl.

97. A compound or salt according to any one of claims 92 to 96, wherein selected from piperidinylene and piperazinylene, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 62 、-N(R 62 )2、-C(O)R 62 、-C(O)OR 62 、-C(O)N(R 62 )2, -NO2, -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 62 、-N(R 62 )2、-C(O)R 62 、-C(O)OR 62 、-C(O)N(R 62 )2, -NO2, =S, =O and -CN; and R 62 Selected from hydrogen and C 1-3 alkyl.

98. The compound or salt of claim 97, wherein yes 99. The compound or salt according to any one of claims 92 to 98, wherein ring B is C optionally substituted with one or more substituents independently selected from the group consisting of: 3-6 Carbocyclic ring: halogen, -OR 63 、-N(R 63 )2、-C(O)R 63 , -NO2, -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 63 、-N(R 63 )2、-C(O)R 63 , -NO2 and -CN; and R 63 Selected from hydrogen and C 1-3 alkyl.

100. The compound or salt of claim 99, wherein Ring B is phenyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 63 、-N(R 63 )2、-C(O)R 63 , -NO2, -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 63 、-N(R 63 )2、-C(O)R 63 , -NO2 and -CN; and R 63 Selected from hydrogen and C 1-3 alkyl.

101. The compound or salt of claim 100, wherein Ring B is phenyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 63 and are optionally independently selected from halogen and -OR 63 One or more substituents substituted C 1-6 alkyl; and R 63 independently selected from hydrogen and C 1-3 alkyl.

102. The compound or salt according to claim 101, wherein ring B is selected from 103. A compound or salt according to any one of claims 92 to 98, wherein ring B is C 3-6 carbocyclic or 3- to 6-membered heterocyclic rings, any of which is optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 63 、-N(R 63 )2、-C(O)R 63 , -NO2, -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 63 、-N(R 63 )2、-C(O)R 63 , -NO2 and -CN; and R 63 Selected from hydrogen and C 1-3 alkyl.

104. The compound or salt of claim 103, wherein Ring B is phenyl or pyridyl, either of which is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 63 、-N(R 63 )2、-C(O)R 63 , -NO2, -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 63 、-N(R 63 )2、-C(O)R 63 , -NO2 and -CN; and R 63 Selected from hydrogen and C 1-3 alkyl.

105. The compound or salt of claim 104, wherein Ring B is phenyl or pyridinyl, either of which is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 63 and are optionally independently selected from halogen and -OR 63 One or more substituents substituted C 1-6 alkyl; and R 63 independently selected from hydrogen and C 1-3 alkyl.

106. The compound or salt according to claim 105, wherein ring B is selected from 107. The compound of claim 92, wherein the compound of formula (IV) is: or a salt of any one thereof.

108. The compound of claim 92, wherein the compound of formula (IV) is: or a salt of any one thereof.

109. A pharmaceutical composition comprising a compound or salt according to claim 1, 32, 62 or 92 and a pharmaceutically acceptable excipient.

110. A method for killing cancer cells or inhibiting the proliferation of cancer cells, the method comprising contacting the cells with a compound represented by the structure of formula (V): or a pharmaceutically acceptable salt, wherein: Each X 1 Selected from C(R 100 ) and N; R 100 independently selected at each occurrence from: Hydrogen, halogen, -OR 102 , -SR 102 , -N(R 102 )2, -C(O)R 102 , -C(O)OR 102 , -OC(O)R 102 , -OC(O)N(R 102 )2, -C(O)N(R 102 )2, -N(R 102 )C(O)R 102 , -N(R 102 )C(O)OR 102 , -N(R 102 )C(O)N(R 102 )2, -N(R 102 )S(O)2(R 102 ), -S(O)R 102 , -S(O)2R 102 , -S(O)2N(R 102 )2, -NO2 and -CN; C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 102 、-SR 102 、-N(R 102 )2、-C(O)R 102 、-C(O)OR 102 、-OC(O)R 102 、-OC(O)N(R 102 )2、-C(O)N(R 102 )2、-N(R 102 )C(O)R 102 、-N(R 102 )C(O)OR 102 、-N(R 102 )C(O)N(R 102 )2、-N(R 102 )S(O)2(R 102 ),-S(O)R 102 、-S(O)2R 102 、-S(O)2N(R 102 )2, -NO2, =S, =O and -CN; and C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 102 、-SR 102 、-N(R 102 )2、-C(O)R 102 、-C(O)OR 102 、-OC(O)R 102 、-OC(O)N(R 102 )2、-C(O)N(R 102 )2、-N(R 102 )C(O)R 102 、-N(R 102 )C(O)OR 102 、-N(R 102 )C(O)N(R 102 )2、-N(R 102 )S(O)2(R 102 ),-S(O)R 102 、-S(O)2R 102 、-S(O)2N(R 102 )2, -NO2, =S, =O and -CN; R 101 Independently selected from: C 1-6 Alkyl and C 2-6 alkenyl, any of which is optionally substituted with one or more substituents independently selected from halogen, -OR 103 、-SR 103 、-N(R 103 )2、-C(O)R 103 、-C(O)OR 103 、-OC(O)R 103 、-OC(O)N(R 103 )2、-C(O)N(R 103 )2、-N(R 103 )C(O)R 103 、-N(R 103 )C(O)OR 103 、-N(R 103 )C(O)N(R 103 )2、-N(R 103 )S(O)2(R 103 ),-S(O)R 103 、-S(O)2R 103 、-S(O)2N(R 103 )2, -NO2, =S, =O and -CN; and C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 103 、-SR 103 、-N(R 103 )2、-C(O)R 103 、-C(O)OR 103 、-OC(O)R 103 、-OC(O)N(R 103 )2、-C(O)N(R 103 )2、-N(R 103 )C(O)R 103 、-N(R 103 )C(O)OR 103 、-N(R 103 )C(O)N(R 103 )2、-N(R 103 )S(O)2(R 103 ),-S(O)R 103 、-S(O)2R 103 、-S(O)2N(R 103 )2, -NO2, =S, =O and -CN; is a 3- to 12-membered heterocyclylene group optionally substituted with one or more substituents independently selected from: halogen, -OR 104 , -SR 104 , -N(R 104 )2, -C(O)R 104 , -C(O)OR 104 , -OC(O)R 104 , -OC(O)N(R 104 )2, -C(O)N(R 104 )2, -N(R 104 )C(O)R 104 , -N(R 104 )C(O)OR 104 , -N(R 104 )C(O)N(R 104 )2, -N(R 104 )S(O)2(R 104 ), -S(O)R 104 , -S(O)2R 104 , -S(O)2N(R 104 )2, -NO2 and -CN; C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 104 、-SR 104 、-N(R 104 )2、-C(O)R 104 、-C(O)OR 104 、-OC(O)R 104 、-OC(O)N(R 104 )2、-C(O)N(R 104 )2、-N(R 104 )C(O)R 104 、-N(R 104 )C(O)OR 104 、-N(R 104 )C(O)N(R 104 )2、-N(R 104 )S(O)2(R 104 ),-S(O)R 104 、-S(O)2R 104 、-S(O)2N(R 104 )2, -NO2, =S, =O and -CN; and C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 104 、-SR 104 、-N(R 104 )2、-C(O)R 104 、-C(O)OR 104 、-OC(O)R 104 、-OC(O)N(R 104 )2、-C(O)N(R 104 )2、-N(R 104 )C(O)R 104 、-N(R 104 )C(O)OR 104 、-N(R 104 )C(O)N(R 104 )2、-N(R 104 )S(O)2(R 104 ),-S(O)R 104 、-S(O)2R 104 、-S(O)2N(R 104 )2, -NO2, =S, =O and -CN; Ring B is selected from C 3-12 carbocyclic ring and 3- to 12-membered heterocyclic ring, any of which is optionally substituted with one or more substituents independently selected from: halogen, -OR 105 , -SR 105 , -N(R 105 )2, -C(O)R 105 , -C(O)OR 105 , -OC(O)R 105 , -OC(O)N(R 105 )2, -C(O)N(R 105 )2, -N(R 105 )C(O)R 105 , -N(R 105 )C(O)OR 105 , -N(R 105 )C(O)N(R 105 )2, -N(R 105 )S(O)2(R 105 , -S(O)R 105 , -S(O)2R 105 , -S(O)2N(R 105 )2, -NO2 and -CN; C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 105 、-SR 105 、-N(R 105 )2、-C(O)R 105 、-C(O)OR 105 、-OC(O)R 105 、-OC(O)N(R 105 )2、-C(O)N(R 105 )2、-N(R 105 )C(O)R 105 、-N(R 105 )C(O)OR 105 、-N(R 105 )C(O)N(R 105 )2、-N(R 105 )S(O)2(R 105 ),-S(O)R 105 、-S(O)2R 105 、-S(O)2N(R 105 )2, -NO2, =S, =O and -CN; and C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 105 、-SR 105 、-N(R 105 )2、-C(O)R 105 、-C(O)OR 105 、-OC(O)R 105 、-OC(O)N(R 105 )2、-C(O)N(R 105 )2、-N(R 105 )C(O)R 105 、-N(R 105 )C(O)OR 105 、-N(R 105 )C(O)N(R 105 )2、-N(R 105 )S(O)2(R 105 ),-S(O)R 105 、-S(O)2R 105 、-S(O)2N(R 105 )2, -NO2, =S, =O and -CN; R 102 、R 103 、R 104 and R 105 independently selected at each occurrence from: hydrogen; C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, and -CN; and C optionally substituted with one or more substituents independently selected from the following 3-10 Carbocyclic rings and 3- to 10-membered heterocyclic rings: halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN.

111. The method of claim 110, wherein the structure of formula (V) is selected from the group consisting of:

112. The method of claim 111, wherein the structure of Formula (V) is selected from Formula (Vb), Formula (Vc), Formula (Vd), and Formula (Ve).

113. The method of claim 112, wherein each R 100 Independently selected from: Hydrogen, halogen, -OR 102 、-N(R 102 )2、-C(O)R 102 , -NO2 and -CN; C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 102 、-N(R 102 )2、-C(O)R 102 , -NO2 and -CN; and C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 102 、-N(R 102 )2、-C(O)R 102 , -NO2 and -CN.

114. The method of claim 113, wherein each R 100 are independently selected from hydrogen, halogen, -OR 102 、-N(R 102 )2、-C(O)R 102 , -NO2 and -CN; and R 102 Selected from hydrogen and C 1-3 alkyl.

115. The method of claim 114, wherein each R 100 are independently hydrogen.

116. The method according to any one of claims 112 to 115, wherein R 101 is C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 103 、-N(R 103 )2、-C(O)R 103 , -NO2, =S, =O and -CN; and R 103 Selected from hydrogen and C 1-3 alkyl.

117. The method of claim 116, wherein R 101 is unsubstituted C 1-3 alkyl.

118. The method according to any one of claims 112 to 117, wherein is selected from saturated 5- to 6-membered heterocyclylene groups, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 104 、-N(R 104 )2、-C(O)R 104 、-C(O)OR 104 、-C(O)N(R 104 )2, -NO2, -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 104 、-N(R 104 )2、-C(O)R 104 、-C(O)OR 104 、-C(O)N(R 104 )2-NO2, =S, =O and -CN; and R 104 Selected from hydrogen and C 1-3 alkyl.

119. The method of claim 118, wherein selected from piperidinylene and piperazinylene, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 104 、-N(R 104 )2、-C(O)R 104 、-C(O)OR 104 、-C(O)N(R 104 )2, -NO2, -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 104 、-N(R 104 )2、-C(O)R 104 、-C(O)OR 104 、-C(O)N(R 104 )2-NO2, =S, =O and -CN; and R 104 Selected from hydrogen and C 1-3 alkyl.

120. The method of claim 119, wherein yes 121. The method according to any one of claims 112 to 120, wherein Ring B is C optionally substituted with one or more substituents independently selected from the group consisting of: 3-6 Carbocyclic ring: halogen, -OR 105 、-N(R 105 )2、-C(O)R 105 , -NO2, -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 105 、-N(R 105 )2、-C(O)R 105 , -NO2 and -CN; and R 105 Selected from hydrogen and C 1-3 alkyl.

122. The method of claim 121, wherein Ring B is phenyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 105 、-N(R 105 )2、-C(O)R 105 , -NO2, -CN; and C optionally substituted by one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 105 、-N(R 105 )2、-C(O)R 105 , -NO2 and -CN; and R 105 Selected from hydrogen and C 1-3 alkyl.

123. The method of claim 122, wherein Ring B is phenyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OC 1-3 alkyl and optionally independently selected from halogen and -OC 1-3 One or more substituents of the alkyl group substituted with C 1-6 alkyl.

124. The method according to claim 123, wherein Ring B is selected from 125. The method of claim 123, wherein Ring B is selected from 126. The method of claim 111, wherein the structure of formula (V) is represented by the structure of formula (Va).

127. The method of claim 126, wherein each R 100 Independently selected from: Hydrogen, halogen, -OR 102 、-N(R 102 )2、-C(O)R 102 , -NO2 and -CN; C optionally substituted with one or more substituents independently selected from the following 1-3 Alkyl: halogen, -OR 102 、-N(R 102 )2、-C(O)R 102 , -NO2 and -CN; and C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, any of which are optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 102 、-N(R 102 )2、-C(O)R 102 , -NO2 and -CN.

128. The method of claim 127, wherein each R 100 Selected from hydrogen, halogen, -OR 102 、-N(R 102 )2、-C(O)R 102 、-NO2、-CN、C 1-3 Alkyl and C 1-3 haloalkyl; and R 102 Selected from hydrogen and C 1-3 alkyl.

129. The method of claim 128, wherein each R 100 are independently selected from hydrogen, fluoro, bromo, -OC 1-3 Alkyl, -N(CH3)2, -CN, -CH2CHF2 and -CH2CF3.

130. The method of claim 129, wherein each R 100 are independently hydrogen.

131. The method of claim 127, wherein each R 100 Independently selected from: hydrogen; and C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, each of which is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 102 、-N(R 102 )2、-C(O)R 102 , -NO2 and -CN; and R 102 Selected from hydrogen and C 1-3 alkyl.

132. The method of claim 131, wherein each R 100 Selected from: hydrogen; and Cyclopropyl and pyrrolidinyl, each optionally substituted with one or more substituents independently selected from halogen, -OR 102 、-N(R 102 )2、-C(O)R 102 , -NO2 and -CN; and R 102 Selected from hydrogen and C 1-3 alkyl.

133. The method of claim 132, wherein each R 100 Selected from: hydrogen, 134. The method of any one of claims 126 to 133, wherein R 101 Selected from: C 1-3 Alkyl and C 2-4 alkenyl, any of which is optionally substituted with one or more substituents independently selected from halogen, -OR 103 、-SR 103 、-N(R 103 )2、-C(O)R 103 、-C(O)OR 103 、-OC(O)R 103 、-OC(O)N(R 103 )2、-C(O)N(R 103 )2、-N(R 103 )C(O)R 103 、-N(R 103 )C(O)OR 103 、-N(R 103 )C(O)N(R 103 )2、-N(R 103 )S(O)2(R 103 ),-S(O)R 103 、-S(O)2R 103 、-S(O)2N(R 103 )2, -NO2, =S, =O and -CN; and C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, any of which are optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 103 、-SR 103 、-N(R 103 )2、-C(O)R 103 、-C(O)OR 103 、-OC(O)R 103 、-OC(O)N(R 103 )2、-C(O)N(R 103 )2、-N(R 103 )C(O)R 103 、-N(R 103 )C(O)OR 103 、-N(R 103 )C(O)N(R 103 )2、-N(R 103 )S(O)2(R 103 ),-S(O)R 103 、-S(O)2R 103 、-S(O)2N(R 103 )2, -NO2, =S, =O and -CN.

135. The method of claim 134, wherein R 101 Selected from C 1-3 Alkyl and C 2-6 alkenyl, any of which is optionally substituted with one or more substituents independently selected from halogen, -OR 103 、-SR 103 、-N(R 103 )2、-C(O)R 103 、-C(O)OR 103 、-OC(O)R 103 、-OC(O)N(R 103 )2、-C(O)N(R 103 )2、-N(R 103 )C(O)R 103 、-N(R 103 )C(O)OR 103 、-N(R 103 )C(O)N(R 103 )2、-N(R 103 )S(O)2(R 103 ),-S(O)R 103 、-S(O)2R 103 、-S(O)2N(R 103 )2, -NO2, =S, =O and -CN; and R 103 Selected from hydrogen and C 1-3 alkyl.

136. The method of claim 135, wherein R 101 is selected from methyl, ethyl, propyl, isopropyl and propenyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 103 、-SR 103 、-N(R 103 )2、-C(O)R 103 、-C(O)OR 103 、-OC(O)R 103 、-OC(O)N(R 103 )2、-C(O)N(R 103 )2、-N(R 103 )C(O)R 103 、-N(R 103 )C(O)OR 103 、-N(R 103 )C(O)N(R 103 )2、-N(R 103 )S(O)2(R 103 ),-S(O)R 103 、-S(O)2R 103 、-S(O)2N(R 103 )2, -NO2, =S, =O and -CN; and R 103 Selected from hydrogen and C 1-3 alkyl.

137. The method of claim 136, wherein R 101 Selected from methyl, ethyl, propyl, isopropyl and propenyl.

138. The method of claim 134, wherein R 101 Selected from C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, any of which are optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 103 、-SR 103 、-N(R 103 )2、-C(O)R 103 、-C(O)OR 103 、-OC(O)R 103 、-OC(O)N(R 103 )2、-C(O)N(R 103 )2、-N(R 103 )C(O)R 103 、-N(R 103 )C(O)OR 103 、-N(R 103 )C(O)N(R 103 )2、-N(R 103 )S(O)2(R 103 ),-S(O)R 103 、-S(O)2R 103 、-S(O)2N(R 103 )2, -NO2, =S, =O and -CN; and R 103 Selected from hydrogen and C 1-3 alkyl.

139. The method of claim 138, wherein R 101 Selected from saturated C 3-4 Carbocyclic and saturated 3- to 4-membered heterocyclic rings, each optionally substituted with one or more substituents independently selected from halogen, -OR 103 、-N(R 103 )2、-C(O)R 103 , -NO2, =S, =O and -CN; and R 103 Selected from hydrogen and C 1-3 alkyl.

140. The method of claim 139, wherein R 101 is selected from cyclopropyl and oxetanyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 103 、-N(R 103 )2、-C(O)R 103 , -NO2, =S, =O and -CN; and R 103 Selected from hydrogen and C 1-3 alkyl.

141. The method of claim 140, wherein R 101 Selected from 142. The method of any one of claims 126 to 141, wherein is selected from 4- to 9-membered heterocyclylene groups, each of which is optionally substituted with one or more substituents independently selected from: Halogen, -OR 104 、-N(R 104 )2、-C(O)R 104 、-C(O)OR 104 、-C(O)N(R 104 )2-NO2, -CN; and C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 104 、-N(R 104 )2、-C(O)R 104 、-C(O)OR 104 、-C(O)N(R 104 )2, -NO2, =S, =O and -CN.

143. The method of claim 142, wherein is selected from saturated 4- to 6-membered heterocyclylene groups, each of which is optionally substituted with one or more substituents independently selected from: Halogen, -OR 104 、-N(R 104 )2、-C(O)R 104 、-C(O)OR 104 、-C(O)N(R 104 )2-NO2, -CN; and C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 104 、-N(R 104 )2、-C(O)R 104 、-C(O)OR 104 、-C(O)N(R 104 )2, -NO2, =S, =O and -CN; and R 104 Selected from hydrogen and C 1-3 alkyl.

144. The method of claim 143, wherein is selected from piperidinylene and piperazinylene, each of which is optionally substituted with one or more substituents independently selected from: Halogen, -OR 104 、-N(R 104 )2、-C(O)R 104 、-C(O)OR 104 、-C(O)N(R 104 )2-NO2, -CN; and C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 104 、-N(R 104 )2、-C(O)R 104 、-C(O)OR 104 、-C(O)N(R 104 )2, -NO2; =S, =O and -CN; and R 104 Selected from hydrogen and C 1-3 alkyl.

145. The method of claim 144, wherein Selected from 146. The method according to any one of claims 126 to 145, wherein Ring B is C optionally substituted with one or more substituents independently selected from the group consisting of: 3-10 Carbon ring: halogen, -OR 105 , -SR 105 , -N(R 105 )2, -C(O)R 105 , -C(O)OR 105 , -OC(O)R 105 , -OC(O)N(R 105 )2, -C(O)N(R 105 )2, -N(R 105 )C(O)R 105 , -N(R 105 )C(O)OR 105 , -N(R 105 )C(O)N(R 105 )2, -N(R 105 )S(O)2(R 105 , -S(O)R 105 , -S(O)2R 105 , -S(O)2N(R 105 )2, -NO2 and -CN; C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 105 、-SR 105 、-N(R 105 )2、-C(O)R 105 、-C(O)OR 105 、-OC(O)R 105 、-OC(O)N(R 105 )2、-C(O)N(R 105 )2、-N(R 105 )C(O)R 105 、-N(R 105 )C(O)OR 105 、-N(R 105 )C(O)N(R 105 )2、-N(R 105 )S(O)2(R 105 ),-S(O)R 105 、-S(O)2R 105 、-S(O)2N(R 105 )2, -NO2, =S, =O and -CN; and C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 105 、-SR 105 、-N(R 105 )2、-C(O)R 105 、-C(O)OR 105 、-OC(O)R 105 、-OC(O)N(R 105 )2、-C(O)N(R 105 )2、-N(R 105 )C(O)R 105 、-N(R 105 )C(O)OR 105 、-N(R 105 )C(O)N(R 105 )2、-N(R 105 )S(O)2(R 105 ),-S(O)R 105 、-S(O)2R 105 、-S(O)2N(R 105 )2, -NO2, =S, =O and -CN.

147. The method of claim 146, wherein Ring B is C optionally substituted with one or more substituents independently selected from the group consisting of 3-6 Carbon ring: halogen, -OR 105 , -SR 105 , -N(R 105 )2, -C(O)R 105 , -C(O)OR 105 , -OC(O)R 105 , -OC(O)N(R 105 )2, -C(O)N(R 105 )2, -N(R 105 )C(O)R 105 , -N(R 105 )C(O)OR 105 , -N(R 105 )C(O)N(R 105 )2, -N(R 105 )S(O)2(R 105 , -S(O)R 105 , -S(O)2R 105 , -S(O)2N(R 105 )2, -NO2 and -CN; C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 105 、-SR 105 、-N(R 105 )2、-C(O)R 105 、-C(O)OR 105 、-OC(O)R 105 、-OC(O)N(R 105 )2、-C(O)N(R 105 )2、-N(R 105 )C(O)R 105 、-N(R 105 )C(O)OR 105 、-N(R 105 )C(O)N(R 105 )2、-N(R 105 )S(O)2(R 105 ),-S(O)R 105 、-S(O)2R 105 、-S(O)2N(R 105 )2, -NO2, =S, =O and -CN; and C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 105 、-SR 105 、-N(R 105 )2、-C(O)R 105 、-C(O)OR 105 、-OC(O)R 105 、-OC(O)N(R 105 )2、-C(O)N(R 105 )2、-N(R 105 )C(O)R 105 、-N(R 105 )C(O)OR 105 、-N(R 105 )C(O)N(R 105 )2、-N(R 105 )S(O)2(R 105 ),-S(O)R 105 、-S(O)2R 105 、-S(O)2N(R 105 )2, -NO2, =S, =O and -CN.

148. The method of claim 147, wherein Ring B is phenyl optionally substituted with one or more substituents independently selected from: halogen, -OR 105 , -SR 105 , -N(R 105 )2, -C(O)R 105 , -C(O)OR 105 , -OC(O)R 105 , -OC(O)N(R 105 )2, -C(O)N(R 105 )2, -N(R 105 )C(O)R 105 , -N(R 105 )C(O)OR 105 , -N(R 105 )C(O)N(R 105 )2, -N(R 105 )S(O)2(R 105 , -S(O)R 105 , -S(O)2R 105 , -S(O)2N(R 105 ), -NO2 and -CN; C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 105 、-SR 105 、-N(R 105 )2、-C(O)R 105 、-C(O)OR 105 、-OC(O)R 105 、-OC(O)N(R 105 )2、-C(O)N(R 105 )2、-N(R 105 )C(O)R 105 、-N(R 105 )C(O)OR 105 、-N(R 105 )C(O)N(R 105 )2、-N(R 105 )S(O)2(R 105 ),-S(O)R 105 、-S(O)2R 105 、-S(O)2N(R 105 )2, -NO2, =S, =O and -CN; and C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 105 、-SR 105 、-N(R 105 )2、-C(O)R 105 、-C(O)OR 105 、-OC(O)R 105 、-OC(O)N(R 105 )2、-C(O)N(R 105 )2、-N(R 105 )C(O)R 105 、-N(R 105 )C(O)OR 105 、-N(R 105 )C(O)N(R 105 )2、-N(R 105 )S(O)2(R 105 ),-S(O)R 105 、-S(O)2R 105 、-S(O)2N(R 105 )2, -NO2, =S, =O and -CN.

149. The method of claim 148, wherein Ring B is phenyl optionally substituted with one or more substituents independently selected from: halogen, -OR 105 , -N(R 105 )2, -C(O)R 105 , -C(O)OR 105 , -C(O)N(R 105 )2, -N(R 105 )C(O)R 105 , -NO2 and -CN; C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 105 、-N(R 105 )2、-C(O)R 105 、-C(O)OR 105 、-C(O)N(R 105 )2、-N(R 105 )C(O)R 105 , -NO2, =S, =O and -CN; C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, any of which are optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 105 、-N(R 105 )2、-C(O)R 105 、-C(O)OR 105 、-C(O)N(R 105 )2、-N(R 105 )C(O)R 105 , -NO2, =S, =O and -CN; and R 105 Selected from hydrogen, C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 3-6 saturated carbocyclic rings and 3- to 6-membered saturated heterocyclic rings.

150. The method of claim 149, wherein Ring B is selected from:

151. The method of claim 149, wherein Ring B is selected from:

152. The method of any one of claims 126 to 145, wherein Ring B is a 3- to 10-membered heterocyclic ring optionally substituted with one or more substituents independently selected from: halogen, -OR 105 , -SR 105 , -N(R 105 )2, -C(O)R 105 , -C(O)OR 105 , -OC(O)R 105 , -OC(O)N(R 105 )2, -C(O)N(R 105 )2, -N(R 105 )C(O)R 105 , -N(R 105 )C(O)OR 105 , -N(R 105 )C(O)N(R 105 )2, -N(R 105 )S(O)2(R 105 , -S(O)R 105 , -S(O)2R 105 , -S(O)2N(R 105 )2, -NO2 and -CN; C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 105 、-SR 105 、-N(R 105 )2、-C(O)R 105 、-C(O)OR 105 、-OC(O)R 105 、-OC(O)N(R 105 )2、-C(O)N(R 105 )2、-N(R 105 )C(O)R 105 、-N(R 105 )C(O)OR 105 、-N(R 105 )C(O)N(R 105 )2、-N(R 105 )S(O)2(R 105 ),-S(O)R 105 、-S(O)2R 105 、-S(O)2N(R 105 )2, -NO2, =S, =O and -CN; and C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 105 、-SR 105 、-N(R 105 )2、-C(O)R 105 、-C(O)OR 105 、-OC(O)R 105 、-OC(O)N(R 105 )2、-C(O)N(R 105 )2、-N(R 105 )C(O)R 105 、-N(R 105 )C(O)OR 105 、-N(R 105 )C(O)N(R 105 )2、-N(R 105 )S(O)2(R 105 ),-S(O)R 105 、-S(O)2R 105 、-S(O)2N(R 105 )2, -NO2, =S, =O and -CN.

153. The method of claim 152, wherein Ring B is selected from a 3- to 6-membered monocyclic heterocycle and a 6- to 10-membered bicyclic heterocycle, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OR 105 , -SR 105 , -N(R 105 )2, -C(O)R 105 , -C(O)OR 105 , -OC(O)R 105 , -OC(O)N(R 105 )2, -C(O)N(R 105 )2, -N(R 105 )C(O)R 105 , -N(R 105 )C(O)OR 105 , -N(R 105 )C(O)N(R 105 )2, -N(R 105 )S(O)2(R 105 , -S(O)R 105 , -S(O)2R 105 , -S(O)2N(R 105 )2, -NO2 and -CN; C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 105 、-SR 105 、-N(R 105 )2、-C(O)R 105 、-C(O)OR 105 、-OC(O)R 105 、-OC(O)N(R 105 )2、-C(O)N(R 105 )2、-N(R 105 )C(O)R 105 、-N(R 105 )C(O)OR 105 、-N(R 105 )C(O)N(R 105 )2、-N(R 105 )S(O)2(R 105 ),-S(O)R 105 、-S(O)2R 105 、-S(O)2N(R 105 )2, -NO2, =S, =O and -CN; and C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 105 、-SR 105 、-N(R 105 )2、-C(O)R 105 、-C(O)OR 105 、-OC(O)R 105 、-OC(O)N(R 105 )2、-C(O)N(R 105 )2、-N(R 105 )C(O)R 105 、-N(R 105 )C(O)OR 105 、-N(R 105 )C(O)N(R 105 )2、-N(R 105 )S(O)2(R 105 ),-S(O)R 105 、-S(O)2R 105 、-S(O)2N(R 105 )2, -NO2, =S, =O and -CN.

154. The method of claim 153, wherein Ring B is selected from the group consisting of imidazolyl, thienyl, pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, benzodioxolyl, dihydrobenzofuranyl, benzofuranyl, benzimidazolyl, benzisoxazolyl, dihydrofuropyridinyl, furopyridinyl, and quinolinyl, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OR 105 , -SR 105 , -N(R 105 )2, -C(O)R 105 , -C(O)OR 105 , -OC(O)R 105 , -OC(O)N(R 105 )2, -C(O)N(R 105 )2, -N(R 105 )C(O)R 105 , -N(R 105 )C(O)OR 105 , -N(R 105 )C(O)N(R 105 )2, -N(R 105 )S(O)2(R 105 , -S(O)R 105 , -S(O)2R 105 , -S(O)2N(R 105 )2, -NO2 and -CN; C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 105 、-SR 105 、-N(R 105 )2、-C(O)R 105 、-C(O)OR 105 、-OC(O)R 105 、-OC(O)N(R 105 )2、-C(O)N(R 105 )2、-N(R 105 )C(O)R 105 、-N(R 105 )C(O)OR 105 、-N(R 105 )C(O)N(R 105 )2、-N(R 105 )S(O)2(R 105 ),-S(O)R 105 、-S(O)2R 105 、-S(O)2N(R 105 )2, -NO2, =S, =O and -CN; and C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, any of which are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 105 、-SR 105 、-N(R 105 )2、-C(O)R 105 、-C(O)OR 105 、-OC(O)R 105 、-OC(O)N(R 105 )2、-C(O)N(R 105 )2、-N(R 105 )C(O)R 105 、-N(R 105 )C(O)OR 105 、-N(R 105 )C(O)N(R 105 )2、-N(R 105 )S(O)2(R 105 ),-S(O)R 105 、-S(O)2R 105 、-S(O)2N(R 105 )2, -NO2, =S, =O and -CN.

155. The method of claim 154, wherein Ring B is selected from the group consisting of imidazolyl, thienyl, pyridazinonyl, pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, benzodioxolyl, dihydrobenzofuranyl, benzofuranyl, benzimidazolyl, benzisoxazolyl, dihydrofuropyridinyl, furopyridinyl, and quinolinyl, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OR 105 , -N(R 105 )2, -C(O)R 105 , -C(O)OR 105 , -C(O)N(R 105 )2, -N(R 105 )C(O)R 105 , -NO2 and -CN; C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 105 、-N(R 105 )2、-C(O)R 105 、-C(O)OR 105 、-C(O)N(R 105 )2、-N(R 105 )C(O)R 105 , -NO2, =S, =O and -CN; C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, any of which are optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 105 、-N(R 105 )2、-C(O)R 105 、-C(O)OR 105 、-C(O)N(R 105 )2、-N(R 105 )C(O)R 105 , -NO2, =S, =O and -CN; and R 105 Selected from hydrogen, C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 3-6 saturated carbocyclic rings and 3- to 6-membered saturated heterocyclic rings.

156. The method of claim 155, wherein Ring B is selected from:

157. The method of claim 153, wherein Ring B is selected from the group consisting of imidazolyl, thienyl, pyridazinonyl, pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, benzodioxolyl, dihydrobenzofuranyl, benzofuranyl, benzimidazolyl, benzisoxazolyl, dihydrofuropyridinyl, furopyridinyl, thienopyridinyl, indazolyl, pyrazolo[4,3-b]pyridinyl, imidazo[1,2-a]pyridinyl, imidazo[1,2-a]pyrazinyl, pyrazolo[1,5-a]pyridinyl, and quinolinyl, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OR 105 , -N(R 105 )2, -C(O)R 105 , -C(O)OR 105 , -C(O)N(R 105 )2, -N(R 105 )C(O)R 105 , -NO2 and -CN; C optionally substituted with one or more substituents independently selected from the following 1-6 Alkyl: halogen, -OR 105 、-N(R 105 )2、-C(O)R 105 、-C(O)OR 105 、-C(O)N(R 105 )2、-N(R 105 )C(O)R 105 , -NO2, =S, =O and -CN; C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, any of which are optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 105 、-N(R 105 )2、-C(O)R 105 、-C(O)OR 105 、-C(O)N(R 105 )2、-N(R 105 )C(O)R 105 , -NO2, =S, =O and -CN; and R 105 Selected from hydrogen, C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 3-6 saturated carbocyclic rings and 3- to 6-membered saturated heterocyclic rings.

158. The method of claim 157, wherein Ring B is selected from:

159. The method of any one of claims 110 to 158, wherein the cancer cell is an A2058 cell or a PA1 cell.

160. The method of any one of claims 110 to 158, wherein the cancer cell is an ovarian cancer cell or a melanoma cell.

161. A method of treating ovarian cancer, comprising administering to a subject in need thereof a compound or salt according to claim 1, 32, 62, or 92, or a pharmaceutical composition according to claim 109.

162. A method of treating melanoma comprising administering to a subject in need thereof a compound or salt according to claim 1, 32, 62, or 92, or a pharmaceutical composition according to claim 109.

Images